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Abstract 
 
Erythrocyte concentrates (ECs) are the major labile blood product being transfused worldwide, 
aiming at curing anemia of diverse origins. In Switzerland, ECs are stored at 4 °C up to 42 days in 
saline-adenine-glucose-mannitol (SAGM). Such storage induces cellular lesions, altering red 
blood cells (RBCs) metabolism, protein content and rheological properties. A hot debate exists 
regarding the impact of the storage lesions, thus the age of ECs on transfusion-related clinical 
adverse outcomes. Several studies tend to show that poorer outcomes occur in patients 
receiving older blood products. However, no clear association was demonstrated up to date. 
While metabolism and early rheological changes are reversible through transfusion of the blood 
units, oxidized proteins cannot be repaired, and it is likely such irreversible damages would 
affect the quality of the blood product and the efficiency of the transfusion. In vivo, RBCs are 
constantly exposed to oxygen fluxes, and are thus well equipped to deal with oxidative 
challenges. Moreover, functional 20S proteasome complexes allow for recognition and 
proteolysis of fairly oxidized protein, and some proteins can be eliminated from RBCs by the 
release of microvesicles. 
The present PhD thesis is involved in a global research project which goal is to characterize the 
effect of processing and storage on the quality of ECs.  Assessing protein oxidative damages 
during RBC storage is of major importance to understand the mechanisms of aging of stored 
RBCs. To this purpose, redox proteomic-based investigations were conducted here. In a first 
part, cysteine oxidation and protein carbonylation were addressed via 2D-DIGE and 
derivatization-driven immunodetection approaches, respectively. Then, the oxidized sub-
proteomes were characterized through LC-MS/MS identification of proteins in spots of interest 
(cysteine oxidation) or affinity-purified carbonylated proteins. Gene ontology annotation 
allowed classifying targets of oxidation according to their molecular functions. In a third part, 
the P20S activity was evaluated throughout the storage period of ECs, and its susceptibility to 
highly oxidized environment was investigated. The potential defensive role of microvesiculation 
was also addressed through the quantification of eliminated carbonylated proteins.  
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We highlighted distinct protein groups differentially affected by cysteine oxidation, either 
reversibly or irreversibly. In addition, soluble extracts showed a decrease in carbonylation at the 
beginning of the storage and membrane extracts revealed increasing carbonylation after 4 
weeks of storage. Engaged molecular functions revealed that antioxidant (AO) are rather 
reversibly oxidized at their cysteine residue(s), but are irreversibly oxidized through 
carbonylation. In the meantime, the 20S proteasome activity is decreased by around 40 % at the 
end of the storage period. Incubation of fresh RBCs extracts with exogenous oxidized proteins 
showed a dose-dependent and protein-dependent inhibitory effect. Finally, we proved that the 
release of microvesicles allows the elimination of increasing quantities of carbonylated proteins. 
Taken together, these results revealed an oxidative pathway model of RBCs storage, on which 
further investigation towards improved storage conditions will be based.  
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Résumé 
 
Les concentrés érythrocytaires (CE) sont le produit sanguin le plus délivré au monde, 
permettant de traiter différentes formes d’anémies. En Suisse, les CE sont stocké à 4 °C pendant 
42 jours dans une solution saline d’adénine, glucose et mannitol (SAGM). Une telle conservation 
induit des lésions de stockage qui altèrent le métabolisme, les protéines et les propriétés 
rhéologique du globule rouge (GR). Un débat important concerne l’impact du temps de 
stockage des CE sur les risques de réaction transfusionnelles, certaines études tentant de 
démontrer que des transfusions de sang vieux réduiraient l’espérance de vie des patients. 
Cependant, aucune association concrète n’a été prouvée à ce jour. Alors que les modifications 
du métabolisme et changement précoces des propriétés rhéologiques sont réversibles suite à la 
transfusion du CE, les protéines oxydées ne peuvent être réparées, et il est probable que de 
telles lésions affectent la qualité et l’efficacité des produits sanguins. In vivo, les GR sont 
constamment exposés à l’oxygène, et sont donc bien équipés pour résister aux lésions 
oxydatives. De plus, les complexes fonctionnels de proteasome 20S reconnaissent et dégradent 
les protéines modérément oxydées, et certaines protéines peuvent être éliminées par les 
microparticules. 
Cette thèse de doctorat est imbriquée dans un projet de recherche global ayant pour objectif la 
caractérisation  des effets de la préparation et du stockage sur la qualité des GR. Evaluer les 
dommages oxydatifs du GR pendant le stockage est primordial pour comprendre les 
mécanismes de vieillissement des produits sanguin. Dans ce but, des recherches orientées 
redoxomique ont été conduites. Dans une première partie, l’oxydation des cystéines et la 
carbonylation des protéines sont évaluées par électrophorèse bidimensionnelle différentielle et 
par immunodétection de protéines dérivatisées. Ensuite, les protéines d’intérêt ainsi que les 
protéines carbonylées, purifiées par affinité, sont identifiées par spectrométrie de masse en 
tandem. Les protéines cibles de l’oxydation sont classées selon leur fonction moléculaire. Dans 
une troisième partie, l’activité protéolytique du protéasome 20S est suivie durant la période de 
stockage. L’impact du stress oxydant sur cette activité a été évalué en utilisant des protéines 
exogènes oxydées in vitro. Le potentiel rôle défensif de la microvesiculation a également été 
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étudié par la quantification des protéines carbonylées éliminées. 
Dans ce travail, nous avons observé que différents groupes de protéines sont affectés par 
l’oxydation réversible ou irréversible de leurs cystéines. De plus, une diminution de la 
carbonylation en début de stockage dans les extraits solubles et une augmentation de la 
carbonylation après 4 semaines dans les extraits membranaires ont été montrées. Les fonctions 
moléculaires engagées par les protéines altérées montrent que les défenses antioxydantes sont 
oxydées de façon réversible sur leurs résidus cystéines, mais sont également irréversiblement 
carbonylées. Pendant ce temps, l’activité protéolytique du protéasome 20S décroit de 40 % en 
fin de stockage. L’incubation d’extraits de GR en début de stockage avec des protéines oxydées 
exogènes montre un effet inhibiteur « dose-dépendant » et « protéine-dépendant ». Enfin, les 
microvésicules s’avèrent éliminer des quantités croissantes de protéines carbonylées. 
La synthèse de ces résultats permet de modéliser une voie oxydative du stockage des GRs, à 
partir de laquelle de futures recherches seront menées avec pour but l’amélioration des 
conditions de stockage.  
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The history of blood transfusion 
 
First observations and attempts 
The story of blood transfusion really began with the discovery of the mechanics of blood flow in 
the human body by the English physician William Harvey, described in the “Exercitatio 
Anatomica de Motu Cordis et Sanguinis in Animalibus” in 1628. From this highly important 
improvement in human physiology knowledge and the vision of blood as the “river of life”, it 
became possible to consider blood transfer as the way to cure pathological states, ranging from 
febrile state to mental disorders. In 1656, experimenting the feasibility of conveying liquid 
poison into a dog bloodstream, the English architect and scientist Christopher Wren designed 
an injection device that will be used for the first trials of blood transfusion. First blood 
transfusions are imputed to Richard Lower, British physician, in 1665, performing both animal-
to-animal and animal-to-human transfusions. The latter being published 4 years later, the first 
published animal-to-human blood transfusion was thus attributed to the French physician Jean-
Baptiste Denis, successfully curing a 16-year-old boy suffering from fever, thanks to sheep 
blood in 1667. However, further unsuccessful attempts led the transfusion of blood being 
restricted to animal experiments and 
prohibited in humans in France by the 1675 
edict of Châtelet. Meanwhile, the high 
quality of microscope lens fashioned by 
Antoni van Leeuwenhoek, a Dutch scientist 
precursor of cellular biology and 
microbiology, allowed him to observe, 
among others, animal and human blood in 
1674, and to describe it as composed of 
red corpuscles swimming into a clear 
liquid, thanks to an innovative and 
incomparable microscope for its time (see 
Figure 1). 
Figure 1: The microscope of Leeuwenhoek and some drawings 
of its observations. 
 Part 1 - Introduction 
5 
Approximatively one and a half century later, the English obstetrician James Blundell realized 
the first successful human-to-human blood transfusion in 1829. He further documented several 
successful transfusions but also had some failures. Moreover, he contributed to the 
development of instruments for blood transfusion. In the second half of the XIXth century, two 
authors described the phenomenon of agglutination of the red cells of blood. In 1869, the 
German physician Adolf Creite, upon injection of serum from different mammals into rabbits, 
observed bloody urines free of intact red cells, as others previously noted while injecting whole 
blood. Creite concluded to chemical properties from some serum constituents, able to dissolve 
red cells. However, injection of protein-depleted serum did not induce blood-stained urines, 
attributing the dissolving role to serum proteins. Trying to support the role of such chemical 
agents in serum, other experiments in which sera from different mammals (except rabbit) were 
added to fresh rabbit blood allowed him to report for the first time the phenomenon of red 
cells agglutination, which he termed “accumulation”. Half a decade later, in 1875, the German 
physiologist Leonard Landois extended Creite’s experimentations, observing both the 
dissolution of transfused red cells and a “ball formation” of red cells in contact with sera from 
other animals. He noted differences in these activities, depending on the origins of 
blood/serum. When dissolution was not immediate, he was able to observe a change in red 
cells shape, in particular the formation of spikes and then a tendency to become spherical. 
Depending on the number of red cells added, he also remarked a tendency to accumulation 
rather than dissolution. He hypothesized that red cells were acquiring the ability to stick 
together while changing of shape, and that the dissolution capacity was due to an unknown 
ratio of the serum constituent parts. These observations from Creite and Landois led the 
community to progressively abandon animal-to-human transfusion because of the systematic 
lethal agglutination phenomenon. In the early 1900’s, Karl Landsteiner, an Austrian biologist 
and physician, processed to interactions between blood serum and red corpuscles of different 
human individuals. In a first study (1900), he footnoted that  
“the sera of healthy individuals […] have an agglutinating effect […] on human red cells from 
different individuals”
1. 
                                                             
1 The translations from original German texts were reproduced from ref [1]. 
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He thus associated agglutinogens to red cells and agglutinins to blood serum, but had doubts 
regarding a hypothetical disease-origin of serum agglutinins, as thought by others. One year 
later, he discovered the existence of 3 groups of blood, describing that  
 
“In many cases sera of group A react with red cells of another group, B, but not with group A; on 
the other hand, A red cells are affected in the same way by serum B. The sera of the third group 
(C) agglutinates red cells A and B, but C red cells are not affected by sera from A and B. 
Naturally the red cells must be considered insensitive to the agglutinins which are present in the 
same serum”
1(page 5) 
 
Human-to-human blood incompatibilities were thus demonstrated by these studies which can 
be considered as the premises of the discovery of blood groups and transfusion compatibility 
rules, Landsteiner suggesting the existence of 2 agglutinins as an explanation of the 3 groups he 
observed. In 1902, Decastrello and Sturli, Austrian physicians, discovered the fourth blood 
group. In particular, the publication of the American physician and hematologist Reuben 
Ottenberg in 1911 [2] describes very well the isoagglutination issues from each possible 
combination of red cells and serum, as shown in Figure 2. 
 
 
Figure 2: Discovery of the 4 blood groups. Table of cross-reactivity between serum agglutinins and red blood cells from the 4 
discovered blood groups, as reported by Ottenberg in 1911. Reproduced from ref [2]. 
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World Wars as the battlefields of developments and experimentations 
The next steps towards current blood transfusion are related with World War I and the need to 
dissociate the blood donor from the recipient. Blood transfusion was a surgical act involving the 
dissection of veins or arteries from the donor and the recipient. The Carrel’s suture and the 
Crile’s cannula methods were the two techniques commonly used for end-to-end anastomosis 
of blood vessels (see Figure 3). Until then, transfusions were thus performed arm-to-arm, 
which was problematic in war times, meaning that donors of blood had to be present next to 
patients. In the early 1890’s, citrate was shown to interfere with the clotting process [3] 
through calcium binding [4]. Wright even declared that citrated blood appeared more suitable 
for transfusion [5]. However, blood clotting was then a minor issue in comparison with the not 
yet understood group incompatibility-related agglutination. Moreover, sodium citrate was 
considered highly toxic thus unsuitable for human transfusion. 
 
 
Figure 3: Schemes of stages of blood vessels anastomosis as performed by the end of the XIX
th
 century. Left panel: Carrel’s 
suture method; right panel: Crile’s cannula method. Schemes were reproduced from ref [6]. 
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Technical development of transfusion devices allowed puncturing blood from the donor and 
further injecting it in the recipient, but blood clotting often prevent success of such approaches. 
Blood clotting thus became a main issue in transfusion, and sodium citrate was reconsidered in 
1914 by Albert Hustin, a Belgian physician, to prevent blood from coagulation. Independently, 
Hustin, Agote and Lewisohn performed the first transfusions of citrated blood to human in 
1914-1915. This discovery allowing the spatial dissociation of recipient from the blood donor 
will however not be used until the end of the war. The first direct blood transfusion (arm-to-
arm) of World War I was performed by the French physician Émile Jeanbrau in 1914. This 
transfusion was luckily successful though bloods of donor and recipient were not cross-
matched to ensure their group compatibility, as suggested by Hektoen in 1907. And so were 
done most transfusions during the war. Indeed, the watchword was to take the risk of blood 
incompatibility issues rather than watching people dying from massive hemorrhage. 
If sodium citrate was proven to keep blood liquid up to a few days, it did not make blood 
uncoagulable, and blood storage was not really feasible. The first success in erythrocyte 
conservation was achieved in 1916 by Rous and Turner who were able to store rabbit red blood 
cells in ice box for up to 4 weeks in a solution composed of sodium citrate and glucose, with 
reasonably low hemolysis [7, 8]. However, the transfusion of such stored RBCs back to rabbit 
was shown efficient only with cells stored for up to 2 weeks [8], which already highlighted the 
problem of storage-related aging of RBCs (see the section RBCs storage lesions, page 24). 
Thanks to this method, Oswald Robertson reported in 1918 the efficient storage, transport and 
transfusion of 22 “units” of human RBCs stored for up to 26 days, during rush periods at 
casualty clearing stations [9]. What Robertson described here can be considered as the world’s 
first blood bank. He also developed a specific bottle equipped with a negative or positive 
pressure pump device for blood collection in citrate solution or infusion of the citrated blood to 
the recipient (see Figure 4) [10]. 
World War I, through its duration and the number of involved countries, is considered as the 
theater of high developments and experimentations in blood transfusion. From isolated 
attempts to rejuvenate life, blood transfusion became a routine medical care for soldiers 
suffering from hemorrhage. After W.W.I, the main developments in transfusion consisted in 
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one hand in the implementation of developed techniques into general practice, and in the 
other hand in the identification and organization of potential donors for peace times.  
 
 
Figure 4: Robertson’s bottle for citrated blood transfusion. Elements A and B are the puncture line for blood collection and 
the transfusion line to the recipient, respectively. The pumping device (C) allows applying negative or positive pressure to 
the bottle content for either collection or transfusion. Marks (D) indicate the volume of citrate solution (lower mark) and 
different volumes of blood collection (3 upper marks). The drawing is a reproduction from ref [10]. 
After war, technical development for transfusion was limited. Direct and indirect transfusion 
co-existed. Arm-to-arm transfusion was improved regarding the control of transfused blood 
volumes thanks the apparatus of Tzanck (1925) or the pump of Bakey (1935) for instance. 
Existing devices for indirect transfusion (for instance syringe, paraffin-coated tube or temporary 
storage bottle) were still in use in the 1930’s, the real improvement being the effective use of 
sodium citrate. What especially marked the modern transfusion field between wars is the fact 
that this medical treatment was applied for routine care. From blood donation between 
soldiers, one had to begin recruiting donors from the civil population, calling for people 
solidarity (see Box 1). 
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Box 1: The selfless nature of blood donation 
 
Wars allowed a lot of technical and scientific development. The high solidarity existing between comrades in arms, to fight for 
liberty against their enemies, and against death, allowed the experimentation of blood transfusion. During the First World War, 
several records of people altruism and solidarity demonstrated the beauty of blood donation, the gift of self, and the recognition 
of transfused peoples towards their benefactors, as illustrated by the first direct arm-to-arm transfusion presented in Figure 5. 
After W.W.I, the main application for blood transfusion became women birth-related hemorrhages. It is really symbolic that 
modern transfusion, developed to prevent death of victims from such a man-ascribed tragedy, became the insurance of 
happiness and life. The motivation for blood donation then appeared not so evident in comparison with war times. 
 
Figure 5: First direct transfusion during the World War I. The text in A is a clipping from the French newspaper “l’ouest-Éclair” published in 1914, 
relating the first direct blood transfusion of W.W.I. The picture in B was taken during the transfusion process, realized by anastomosis of an artery 
from the donor with a vein of the recipient, as schematized in C. Henri Legrain, the recipient (on the right in picture D) was very thankful to his 
new “blood-brother”, Isidore Colas, the donor (on the left in picture D). 
The donation of blood is not an insignificant act. Blood as long been considered as the symbol of vitality and it is not so easy to 
say oneself “well, I am healthy so I will give part of my vitality to help other people”. However, humans are, by nature, selfless 
and humanistic. Thanks to the development of blood storage, a big wave of solidarity took place during W.W.II. In France, the 
first transfusion center at the hospital Saint-Antoine in Paris (Dr. Arnault Tzank, 1923) organized the collection of citrated blood 
from the rear to supply the battle front, the only watchword being “no one injured would die for lack of blood”. This awareness 
campaign was a resounding success among the population.    
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Box 1: The selfless nature of blood donation (continued) 
 
In most countries, the donation of blood is a voluntary non-remunerated act. In 2005, Misje et al. conducted a questionnaire-
based study of motivational characteristics of active blood donors at the blood bank of Oslo, Norway [11]. The questionnaire 
investigated four factors of motivation, labeled “value” for altruistic and empathic reasons for volunteering, “social” for the 
normative influence of friends, family, or a social group, “esteem” for the better feeling about oneself and “understanding” for 
the positive experiences associated with volunteering. 
The study demonstrated that long-term donors were mostly motivated by altruism and empathic reasons (e.g. “it’s important to 
help other people”, “I feel compassion towards the receivers of blood products” or “blood donation is a cause that is important 
to me”), whereas donors presenting a short donation record appeared to be more supportive of self-esteem motives (e.g. 
“donating blood makes me feel needed”, “makes me feel important” or “makes me feel better about myself”). 
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The spread of the blood transfusion practice required more blood donations, and a better 
organization. Thus, the 1920’s were witnesses of the creation of the first centers for blood 
transfusion, followed in the late 1930’s by the establishment of blood banks. Spain gave birth in 
1936 to the world’s first blood bank during its civil war, rapidly followed by the United States of 
America as well as other European countries, coinciding with the beginning of World War II. 
Meanwhile, in 1940, Karl Landsteiner, Nobel Prize of physiology-medicine in 1930 for his 
discovery on human blood groups, highlighted the existence of the Rhesus factor with his 
colleague Alexander Wiener. In 1939, Levine reported a case of group O patient of which serum 
presented iso-agglutination (intragroup erythrocyte agglutination) with 80 % of tested group O 
bloods [12]. One year later, Landsteiner and Wiener showed that rabbit serum immunized with 
Rhesus monkeys (Macaca mulatta) blood was reactive to around 85 % of Caucasian humans’ 
blood, in an ABO blood group-independent manner [13]. Landsteiner further confirmed that 
the majority of ABO-compatible transfusion reactions were caused by this antigen [14]. Since 
then, the process of blood transfusion (without regarding transfusion-related disease 
transmission) became a really secured procedure for recipients. The year 1940 also corresponds 
to the beginnings of plasma fractionation into its different protein constituents. In particular, 
Edwin Cohn brought the bases of plasma fractionation with 2 papers introducing the separation 
of equine or bovine serum upon equilibration across membranes using ammonium sulfate or 
ethanol dilutions of controlled pH, ionic strength, and temperature [15, 16]. The second paper 
also presented a detailed procedure to obtain 50 g of albumin from 2 L of plasma [16]. Cohn’s 
method allowed producing therapeutic dried albumin units successfully used during W.W. II. 
In 1943, a great advancement occurred for blood preservation. In order to avoid formation of 
caramel while autoclaving glucose-containing anticoagulant preservative solution due to its 
alkaline pH, Loutit, Mollison and Young tried counterbalancing less sodium citrate by addition 
of citric acid [17]. They screened blood storage at 3-7 °C during 4 weeks in preservative 
solutions presenting different sodium citrate/citric acid ratios, and observed degree of 
caramelisation and loss of glucose after autoclaving as well as end-storage hemolysis. 
Satisfactory solutions were further analyzed for post-transfusion in vivo survival and several 
biochemical parameters such as spontaneous hemolysis, osmotic fragility, pH, glucose, 
 Part 1 - Introduction 
13 
potassium and formation of methemoglobin in comparison to currently used preservative 
solutions (Rous-Turner and the MRC (English Medical Research Council) solutions). The 
conclusions of this study were that acidified citrate-glucose (ACD) preservative solutions are 
satisfactory for blood storage and are recommended because of (1) a better survival in 
recipients circulation, (2) the low caramelisation while autoclaving the whole solution (until 
then, the alternative was the separated autoclave of trisodium citrate and glucose solutions 
followed by an aseptically mixing), (3) the absence of adverse outcome during and post-
transfusion of ACD-stored blood, and (4) the absence of significant increase in storage-related 
methemoglobin formation in comparison with currently used preservative solutions. ACD blood 
preservative solution, allowing blood storage for 3 weeks (based on the 24h post-transfusion 
survival) will stay in use until the introduction of phosphate by Gibson in 1957 [18], which 
increased blood storage up to 4 weeks, through better maintenance of 2,3-DPG levels [19]. 
 
The afterwar period: towards the modern transfusion medicine 
The 1950’s correspond to a critical storage-related technical development. Carl Walter and 
William Murphy presented in 1952 the utilization of closed system of plastic bags (see  
Figure 6) for blood collection, preservation in ACD, and transfusion [20]. The advantages were 
clear regarding bacterial contamination (no contact with air), lighter weight, shock resistance, 
and easiness of storage in refrigerators, in comparison with glass bottles. In 1954, in a 
publication from the army medical service, Artz and coworkers reported the use of plastic bags 
for blood transfusion during the war of Korea [21]. Analyses of plasma potassium levels in such 
bags revealed a favorable comparison with blood storage in glass bottles. Additionally, more 
recent research highlighted the role of the plasticizer (diethylhexyl phthalate, DEHP), released in 
blood bags, interacting with RBCs membranes and limiting the loss of membranes through the 
microvesiculation release [22]. However, plastic bags were not welcome on battlefields. Indeed, 
the gravity-related blood infusion to the recipient did not convey because “about 30 per cent of 
the blood given in a forward surgical hospital must be given under pressure”. Even if plastic bags 
could be squeezed for forcing blood out, “it was impractical to assign one corpsman to each bag 
when 8 or 10 pressure transfusions were being given simultaneously to various patients” [21]. 
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Figure 6: Plastic bag system for collection, storage and infusion of whole blood (reproduced from ref [20]). 
 
Next steps in the improvement of blood storage dealt with the introduction of adenine as a 
constituent of preservative solutions, as proposed in 1962 by Nakao et al. [23]. This 
implementation takes its sources from the demonstrations made by the same group, that 
adenine and inosine enabled the regeneration of ATP and the modification of shape of long-
stored RBCs [24-26] (see Figure 7, panel A), and that ATP level directly impacts the in vivo 
viability of red cells [27] (see Figure 7, panel B). CPDA-1 and its modified version CPDA-2 were 
licensed in USA during the late 70’s / early 80’s, while transfusion medicine already moved to 
the use of packed RBCs concentrates. Sodium-Adenine-Glucose (SAG) was the first additive 
solution for storage of packed RBCs units [28], further modified by addition of mannitol, 
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becoming SAGM, for a reduced end-storage hemolysis [29]. Other additive solutions deriving 
from the original SAG one are used worldwide such as AS-1, AS-3 and AS-5 (USA and Canada) or 
MAP (Japan). The rules of the 75 % of survival in recipient 24 h post-transfusion and less than 1 
% (sometime 0.8 %) of hemolysis allow the storage of erythrocyte concentrates (ECs) in SAGM 
or derivatives for up to 6 weeks at 4 °C. 
 
 
Figure 7: Effects of adenine and inosine on ATP level, shape, and in vivo viability of stored RBCs. Panels A and B are 
reproductions from ref [26] and [27]. 
The last improvement of blood transfusion regarded the removal of leukocytes during the 
processing of ECs. Leucocyte cold lysis release damaging content for RBCs. The leukoreduction is 
performed either by removal of the buffy coat layer after whole blood centrifugation, and/or by 
leukofiltration. In addition to better maintainance of RBCs, leukocyte depletion prevents 
transmission of viruses from the donor to the recipient. More recently, a retrospective study 
also demonstrated decreased rates of febrile non hemolytic transfusion reactions (FNHTRs) in 
case of systematic prestorage leukodepletion [30].  
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Blood transfusion in Switzerland 
 
The Swiss Red Cross and its transfusion service 
Since the beginning of World War II, and more precisely October 9th 1939, The Swiss Red Cross 
(SRC) was asked to recruit blood donors among the civil population in order to establish a 
military blood transfusion service. At the end of this terrible conflict, the US Red Cross offered 
lots of dried plasma units to be distributed in Swiss hospitals, which led the SRC to set up a 
blood transfusion service intended for peace times. In particular, the Swiss federal decree of 
June 13th 1951 concerning the SRC (513.51) states that (1) SRC must provide help to the military 
health service in case of armed conflict, and (2) its main tasks are the voluntary humanitarian 
aid, the blood transfusion service for military and civilian needs, and the encouragement of 
nursing care. The blood transfusion service entrusted to SRC is now delegated to the SRC 
transfusion service (T-CH). T-CH is requested to conduct the national collection of blood, to 
maintain a national blood reserve, and to guaranty the respect of prescriptions, methods and 
materials in the regional blood services. Nowadays, 13 regional centers assume the blood 
supply in Switzerland through the collection, preparation and distribution of blood products to 
hospitals and physicians from their region. As a therapeutic product, blood – and its derivatives 
– collection, storage and utilization are controlled by the competent authority Swissmedic. 
 
Current collection and storage of RBCs concentrates 
As shown above, many efforts have been made to improve transfusion processes, from the 
collection to the infusion, through the storage of blood products. Labile blood products are 
nowadays transfused independently, since each of them can cure different pathological status. 
Indeed, RBCs units are transfused to cure anemia due to hemorrhage, medullar insufficiency, 
and hemoglobin or erythrocyte membrane synthesis anomalies. Platelet concentrates (PCs) and 
plasma units are transfused in case of hemorrhagic or hemostatic disorders, respectively. 
Additionally, storage of each component is optimized in accordance to its intrinsic properties, 
which leads to an overall optimal availability of all components. Such a case-dependent 
transfusion implies to manage each blood component independently. Blood products are 
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obtained either by processing whole blood donations or collecting them individually by an 
apheresis-driven donation of the needed component. This also implies to store each 
component individually, in conditions that are optimized to preserve their specific activities and 
functions. ECs are actually the main labile blood product to be transfused (75 to 80 % of 
delivered blood products in Switzerland during the past 5 years, see Figure 8). In Lausanne, all 
above-listed improvements led the transfusion medicine community to collect, process and 
store RBCs as follow. Whole blood donation (450 ± 50 mL drawn in 63 mL of CPD anticoagulant 
solution) is held at 22±2 °C overnight and is then centrifuged at 3500 g during 14 minutes to 
separate RBCs, plasma, and an intermediate buffy coat layer rich in platelets. RBCs and plasma 
are extracted from the original blood donation bag by a semi-automated pressure. Erythrocytes 
are then transferred into a SAGM-containing bag to a total volume of 275±75 mL and a 
hematocrit of 0.6±0.1. Then, a leukoreduction step is performed by filtration through an 
integrated filter. In these conditions, ECs can be stored at 4 °C up to 6 weeks. The duration of 
storage of RBCs units is a hot matter of debate. The community wonder if long-stored blood 
products are still of the required quality for the patient who need it. Several studies have been 
conducted, in different countries, on the use of blood products that are differently processed, 
and in different pathological cases, to investigate the impact that long-stored blood products 
could have for the recipient, in comparison with short-stored products. 
 
 
Figure 8: Repartition of labile blood products delivered in Switzerland from 2008. PC = platelet concentrate, FFP = fresh 
frozen plasma and EC = erythrocyte concentrate. Data published by Swissmedic in the 2013 hemovigilance report [31]. 
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Transfusion of RBCs units in Lausanne 
Depending on local blood management policies, the blood units’ delivery may vary. In Lausanne, 
the priority of delivery is put to oldest (but not perished) available blood units of the required 
blood group, in order to avoid wasting blood products (rule of first-in, first-out). However, some 
exceptions are allowed, for instance in case of emergency, there is no time for determining the 
patient blood group and O group blood units are thus transfused. Another situation is the 
pediatric transfusion, where short-stored units are given because of the toxicity of high 
extracellular potassium levels to children. Statistics of transfused ECs blood groups at the 
university hospital of Lausanne (CHUV) are presented on Figure 9. Most of EC units are 
transfused during their 1st month of banking, as shown in panels A and B. In particular, 
averaging all blood groups, 90.4 % of RBCs units are transfused by the end of the 4th week of 
storage, with a peak of 39.4 % of transfused units during the 2nd week of storage. Blood groups 
O and A are the most transfused ones, as shown in Figure 9C. It is noteworthy that B and AB 
units (less transfused because more rare blood groups in the population) are mostly transfused 
during the 2nd half of the storage period, as shown in Figure 9D. In particular, the AB+ blood units 
are highly transfused during the last week of storage, reaching nearly 60 % of AB+ RBCs 
transfusion (see graphic A, light blue drawing). 
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Figure 9: Statistics of transfused ECs blood groups and age of transfused ECs in Lausanne. These statistics are based on the 
transfused ECs at the CHUV during the period 2011-2012. For each blood group, the proportion of ECs being transfused 
during each week of the storage period is presented in A. Graph B shows the mean proportion of ECs transfused during each 
week as well as the mean cumulative proportion of ECs transfused throughout the storage period. The proportion of 
transfusion of each blood group appears in the piechart C. Graph D shows the comparison of the mean proportions of 
abundant blood groups (O and A) versus minority blood groups (B and AB) transfused during each week of the storage 
duration, as well as the mean proportions of whole EC units transfused. Data were adapted from the medicine master thesis 
of Marine Gossin [32].  
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Transfusion efficiency and clinical outcomes 
 
Adverse events and outcomes of blood transfusion 
Blood transfusion process can be accompanied by adverse events occurring during the process 
(transfusion reaction) or over a 24h post-transfusion delay (post-transfusion complications). The 
severity of these events can be very moderate or really severe. It is possible to classify the 
different transfusion adverse events, taking into account the pathogenesis (immune reaction?, 
infectious transmission?), the type of reaction (febrile or allergic) and the time from transfusion 
to development of the event (acute vs delayed). Most common events found in the literature 
are acute transfusion reaction (ATR), hemolytic transfusion reaction (HTR), incorrect blood 
component transfused (IBCT), multiple organ dysfunction syndrome (MODS), post-transfusion 
purpura (PTP), transfusion-associated circulatory overload (TACO), transfusion-associated 
dyspnea (TAD), transfusion-related acute lung injury (TRALI), transfusion-associated graft-
versus-host disease (TA-GvHD) and transfusion-transmitted infection (TTI). For the patient, 
transfusion-related events can correspond to increased length of hospitalization, post-operative 
ventilation, deep venous thrombosis, respiratory syndrome, (multiple) organ failure, organ 
rejection, infectious complications, or death. In 1993, Chiu et al. published a poster abstract into 
which they presented data of a prospective study showing that blood transfusion for ICU 
(intensive care unit) patients was associated with the development of infections as well as 
MODS [33].  
The relation between adverse events and the transfusion in critically ill patients has been 
investigated through a systematic review of the literature in 2008 by Marik and Corwin [34]. 
Data from 45 studies (approximately half retrospective and half prospective cohorts) allowed 
them to conclude to an association of RBCs transfusion with an increased morbidity and 
mortality in 93 % of the cases. Most studies seem to associate transfusion of blood to 
outweighed complication risks compared to benefits. However, several factors which are not 
systematically taken into account appear of high importance when performing such 
investigations. In particular, the age of the patient, the severity of illness requiring the 
transfusion of blood, the blood group and the number of blood units being transfused are 
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critical parameters. The transfusion of blood may appear at risk but adverse outcomes may in 
fact be due to a bad health context. In the same way, the more transfusion needed the more 
critical situation and the higher morbidity.  
 
Age of blood products 
The potential role of blood transfusion in adverse outcomes has been further investigated 
regarding the age of the transfused blood products, i.e. their duration of storage before use. An 
overview of the literature shows that the age of transfused blood was not taken into account 
regarding transfusion-related complications until late 1990’s, though blood storage was 
questioned regarding the biochemical efficacy of transfusion (for instance oxygen delivery, see 
reference [35]). Purdy and coworkers reported for the first time in 1997 the association of 
storage duration with survival through a retrospective study on septic ICU patients (admission 
diagnosis) [36]. They did not found any significant difference in age, sex, absolute number of 
transfused ECs or length of stay at the ICU, but the mean age of ECs transfused to patients who 
survived was significantly lower than for non-survivors (17 days vs. 25 days of storage in CPDA-1, 
respectively). It was noteworthy that survivors received a high proportion (85 %) of ECs stored 
for less than 10 days and non-survivors received a high proportion (76 %) of ECs stored for more 
than 20 days. Blood groups were not taken into account. In another retrospective study, 
Vamvakas highlighted an association between wound infection or pneumonia and the storage 
duration of transfused RBCs in patients receiving a coronary artery bypass graft surgery [37]. 
Different complications were thus linked with age of blood in many disease contexts. The 
introduction of leukoreduction made several authors reporting a beneficial effect of the process 
on known adverse outcomes [38, 39]. It appeared that many post-transfusion complications 
were due to the immunomodulative effect attributed to residual leukocytes in RBCs units [40, 
41]. Moreover, leukocyte depletion was recently shown to improve RBCs storage in terms of 
biochemical alteration they undergo during storage (this point will be tackled thereafter) [42]. 
Globally, many studies assessed the impact of age of RBCs on transfusion-related adverse 
clinical outcomes. Most of them impute complications to long-stored RBCs [43-49], with more 
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or less confidence due to the way they were conducted (number of studied cases; control 
conditions; data correction with respect to confounding patient-dependent parameters: age, 
sex, blood group, severity of illness, number of transfused blood units; construction of the 
study: retrospective vs. prospective, randomized or not, blinded or not, dichotomization 
approach?). In particular, the study conducted by Koch in 2008 on the role of aged RBCs (more 
than 14 days of storage) on cardiac surgery patient outcomes had a high impact on the 
transfusion medicine community (see Figure 10) [49]. Other studies also reported no effect of 
RBCs storage duration [50-54] and a few even concluded to worse adverse outcomes when 
fresher blood was transfused [50]. It also appeared that conclusions could be dependent of the 
number of transfused units [55]. Available literature presents very differently conducted 
studies, which makes it difficult to realize meaningful meta-analyses. A particular issue concerns 
geography. Indeed, processes of preparation of blood products are different in America and in 
Western European countries for instance. As mentioned by Van de Watering, characteristics of 
production and storage of ECs, such as donation type, overnight held at room temperature, 
leukocyte reduction method, preparation of RBC component, type of bags and additive solution 
used, should be mentioned to facilitate meta-analyses [56]. 
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Figure 10: Kaplan-Meier estimates of survival and death post-cardiac surgery in function of age of transfused RBCs. The 
figure is reproduced from the controversial study of Koch [49]. 
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RBCs storage lesions  
 
If the clinical relevance of “old-ECs” transfusion on recipient adverse outcomes is still uncertain, 
there is no doubt about changes at the cellular and molecular levels which increase together 
with the storage duration. Three kinds of lesions occurring at the cellular and intracellular levels 
during RBCs cold-storage are now well described. First, erythrocytes undergo biochemical 
lesions, altering their metabolism. In RBCs occurs the anaerobic glycolysis, exclusively 
cytoplasmic, due to the absence of mitochondria. As a consequence, energy metabolism 
through glucose consumption leads to the production of lactate, which has been shown to 
accumulate in the RBCs storage solution [57], inducing its acidification [58]. The metabolism-
related pH fall retro-inhibits the glycolysis rate. Level of 2,3-diphosphoglycerate (2,3-DPG) is 
affected by the pH, through the activities of diphosphoglycerate mutase and phosphatase. In 
stored RBCs, 2,3-DPG was thus shown to be depleted after 2 weeks [59]. Low level of 2,3-DPG 
induces an increased affinity of hemoglobin for oxygen, inhibiting its release and thus altering 
the oxygenation capacity of stored RBCs. However, 2,3-DPG depletion appears to recover in a 
few hours post-transfusion. The cold storage of RBCs induces inactivation of membrane ionic 
pumps, as shown by Na+ uptake and K+ loss throughout the storage period [59]. Low 
temperature also slows down metabolic enzymes activities, inducing a progressive decrease of 
ATP level [59]. D’Alessandro et al. also highlighted an activation of the oxidative phase of the 
pentose phosphate pathway, through accumulation of the metabolic intermediates NADPH and 
6-phosphogluconate [57]. NADPH is needed for the reduction of oxidized glutathione (GSSG), 
recycling reduced GSH to fight against accumulating reactive oxygen species (ROS). However, 
GSH level was shown to continuously decrease over the RBCs storage [57]. There is a 
contradiction in the literature about GSSG level, sometimes increasing [57] or decreasing when 
no concomitant activation of the PPP is observed [60]. 
Constantly exposed to oxygen fluxes, RBCs also have to deal with oxidative stress. Erythrocytes 
are known to contribute to the maintenance of circulatory antioxidant levels, particularly 
through recycling oxidized forms of plasma ascorbic acid [61], and contributing to the 
extracellular pool of glutathione (GSH) [62]. However, RBCs can also act as ROS generators, 
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despite their characteristic absence of mitochondria. Indeed, the dissociation of oxyhemoglobin 
to deoxyhemoglobin through oxygen release can lead to iron electron capture by oxygen. 
Methemoglobin presents a ferric (Fe3+) iron state and cannot bind oxygen, but can be converted 
back to Fe2+ normal hemoglobin (Hb) thanks to the enzyme methemoglobin reductase. This Hb 
autoxidation, occurring at a 3 % rate, leads to the formation of the superoxide radical O2
•- [63], 
further producing highly reactive hydroxyl radical HO• through the iron-catalyzed Haber-Weiss 
reaction [64]. Such radicals are extremely reactive and thus possess a very short half-life, 
estimated 10-9 seconds [65]. Hence, they can unspecifically affect all types of macromolecules of 
their near environment. In particular, lipid peroxidation and protein amino acids modifications 
or protein backbone breaks have been characterized as RBCs storage lesions [66, 67]. A 
particular interest is put on the oxidative lesions, since such damages cannot be reversed 
through the transfusion process, contrarily to biochemical modifications. Since erythrocytes are 
unable to perform protein synthesis, no protein turnover is possible. Damaged proteins 
accumulate until being degraded or eliminated out of the cell. Redox proteomic studies 
performed on stored RBCs have shown increasing hallmark of oxidative stress throughout the 
storage period. More precisely, protein carbonylation investigations bring Lion’s [68], 
Papassideri’s [69, 70] and Zolla’s [57] groups to conclude an increase in carbonylated proteins 
content, associated to the RBC membrane and cytoskeleton for the two formers, or to entire 
erythrocytes for the latter. Zolla and colleagues also demonstrated that protein carbonylation 
was due to an increasing oxidative stress concomitant with an over-activation of the oxidative 
phase of the pentose phosphate pathway, recruited to fight against ROS. Protein oxidation can 
also be investigated through their cysteine redox status, but such approach has not been 
described in the transfusion field yet. As a consequence of oxidation, hemoglobin has been 
shown to crosslink as hemichromes that covalently bind the cytoplasmic domain of the major 
integral glycoprotein of erythrocyte membrane, Band 3, inducing its clustering [71-73]. The 
induced conformational change is known to create a neo-antigen site at the erythrocyte surface 
[74, 75], allowing in vivo recognition by naturally occurring auto-antibodies [76-80], leading to 
RBCs clearance from circulation through activation of the complement [81] and phagocytosis by 
Kupffer liver cells [82, 83]. This is known as the Band 3 clustering model. 
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Hemichromes are also capable of autoxidation, producing ROS in the membrane and 
cytoskeletal environment. Protein carbonylation is a hallmark of oxidative modifications, and it 
has been shown to increase in cytoskeletal protein population during RBCs storage [70]. Such 
alteration of the cytoskeleton involves a third type of storage lesions that are biomechanical 
lesions. Indeed, rheological properties of RBCs appear to be altered all along the storage period, 
directly impacting the in vivo capacities of transfused RBCs. They become more rigid and are 
thus less susceptible to flow through the capillary micro-circulation, diminishing their tissue 
oxygenation power. The most remarkable one is the modification of the shape, evolving from a 
normal discoid shape to spherocytes, with intermediate echinocyte and sphero-echinocyte 
shapes [84] (see Figure 11 for illustration). Along with this shape change, RBCs are known to 
release increasing amounts of microvesicles (MVs) [85], and present a loss of deformability [86], 
a tendency to aggregate [84], an enhanced adherence to endothelial cells [87] and an increasing 
susceptibility to hemolysis [88]. As for the microvesiculation, this phenomenon is believed to be 
a protective mechanism [89] since altered Band 3 (initiating RBCs clearance) is found enriched 
in MVs [90]. 
 
Figure 11: RBCs shape changes during storage. Electron micrograph is from a 42-day sample. Adapted from [57]. 
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Ongoing research to improve RBCs-transfusion efficacy and safety 
 
In a global manner, the doubt concerning transfusion-related adverse outcomes due to aged 
blood products is not really an issue because most ECs appears to be transfused during the first 
half of storage. The dichotomization of young and old blood products was shown to be not 
helpful for assessing an age-related issue of stored RBCs transfusion, and authors of such 
studies are not in accordance with each other regarding the limit of time qualifying stored blood 
as young or old. If clinical studies allow one day characterizing such a limit, time will be to 
change additive solutions, storage conditions, pre-transfusion practices or even hospital policies 
to better preserve blood products, to deliver safer products or patient-specific products, or to 
limit the needs for transfusion. Efforts are being conducted prospectively in this sense. Several 
groups are already developing new solutions for better RBCs preservation as well as special 
storage conditions such as anaerobic storage, and original pre-transfusion practices such as 
washing end-stored RBCs. 
Additive solutions 
As seen before, the storage of RBCs products constituted a big improvement for blood 
transfusion. In addition, the development of solutions allowing the current preservation of 
erythrocytes for 6 weeks has been a long and slow process. Current worldwide used additive 
solutions are approved by local drug administrations. However, the storage of RBCs is not 
optimal regarding the 120-day lifespan of red cells in vivo. Research is conducted in order to 
improve the existing additive solutions, either to improve the quality of stored RBCs or to 
prolong their storage duration. In particular the group of Hess published 4 papers in 4 years in 
the early 2000’s, introducing experimental storage solutions (EAS) allowing the effective 
preservation of RBCs for 9 weeks in EAS-61 [91], 10 weeks in EAS-64 [92], 11 weeks in EAS-67 
[93] and 12 weeks in EAS-76 [94]. In these publications, Hess and colleagues showed 
progressive changes in AS-1-derived EAS to prolong more and more the storage duration of 
RBCs while keeping a hemolysis below 1 % and an in vivo 24-hour recovery higher than 75 %. 
Table 1 shows the compositions of currently approved AS as well as other EAS investigated by 
Hess et al. for RBCs banking. In particular, lower salt concentration, higher adenine content 
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(higher AS volume) and a more alkaline AS pH seem to let RBCs ATP and 2,3-DPG concentrations 
longer preserved, in comparison with the mostly used SAGM and AS-1/3/5 solutions. The main 
drawback of designed EAS is the alkaline pH which favors dextrose caramelization during the 
heat sterilization process. Components should thus be autoclaved separately then mixed 
aseptically. Current and new additive solutions were thus shown to allow the RBCs storage more 
or less longer, regarding their stability in blood bags and in vivo (hemolysis and survival). 
However, regarding all storage lesions described so far, one can wonder if other aging markers 
should not be taken into account for determining an optimal storage period. 
Table 1: Composition of additive solutions for RBCs storage  
Constituents 
(mM) 
SAGM AS-1 AS-3 AS-5 MAP PAGGSM EAS-61 EAS-64 EAS-67 EAS-76 
Adenine 1.25 2 2 2.2 1.5 1.4 2 2 2 2 
Dextrose 45 111 55 45 40 47 110 50 50 50 
Mannitol 30 41 - 45.5 80 55 55 20 20 30 
NaCl 150 154 70 150 85 72 26 75 75 45 
Na2HPO4 - - - - - 16 12 9 9 9 
NaH2PO4 - - 23 - 6 8 - - - - 
NaHCO3 - - - - - - - - 30 30 
Citric acid - - 2 - 1 - - - - - 
Na-citrate - - 23 - 5 - - - - - 
Guanosine - - - - - 1.4 - - - - 
pH 5.7 5.5 5.8 5.5 5.7 5.7 8.2 8.5 8.4 8.4 
Volume (mL) 100 110 110 100 92 100 200 300 300 300 
 
Rejuvenation 
Another possibility for the transfusion of ECs of better quality, instead of developing more 
efficient additive solutions, can consist in the rejuvenation of stored red cells before transfusion. 
Rejuvesol™ is a solution composed of 100 mM Na-pyruvate, 99.9 mM inosine, 5 mM adenine, 
70.4 mM Na2HPO4 and 29 mM NaH2PO4, allowing to replenish depleted ATP and 2,3-DPG levels 
by reactivating RBCs metabolism through a 1-hour incubation at 37 °C. Afterwards, rejuvenated 
cells should be washed to remove excess of inosine, potentially toxic for the recipient. Meyer et 
al. showed efficient ATP and 2,3-DPG increase through this process on ECs samples from AS-1, 
AS-3 and AS-5-stored RBCs stored for 30, 42, 60, 80, 100 and 120 days. Though post-
rejuvenation levels of ATP and 2,.3-DPG decreased with the storage duration of treated RBCs, 
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extremely long-stored RBCs were shown to be capable of a metabolism restart [95]. A study 
conducted by Koshkaryev et al. demonstrated the efficient effect of rejuvenation on reversal of 
stored RBCs adherence to endothelial cells, as well as lowered levels of membrane phosphatidyl 
serine (PS) exposure and intracellular Ca2+ and ROS [96]. Through the washing step, it is possible 
that fragilized older-RBCs suffer from hemolysis and can thus be selectively removed from the 
blood product (see below). 
Pre-transfusion washing of long-stored RBCs 
Recently, Cholette et al. conducted a prospective, randomized, clinical trial to investigate the 
washing of stored RBCs and platelets before transfusion to cardiopulmonary bypass surgery 
children patients [97]. It appeared obvious that such a pre-transfusion practice reduced 
inflammation markers. Though not significant, pre-transfusion washing tended to a reduced 
number of transfused blood units, and to a decreased mortality. In a more recent study, 
Bennett-Guerrero and coworkers compared different devices for washing of long-stored RBC 
units [98]. Over the removal of storage-related accumulating compounds (potassium, lactate), 
they found that the washing procedure can induce higher hemolysis and MV release. Free Hb 
and RBC-derived MVs are known to be scavengers of the vasodilator nitric oxide (NO), and are 
thus responsible for transfusion-induced impaired vascular function [99]. Recovered RBCs do 
not seem to be more sensitive to physical stress-induced hemolysis. On the contrary, filtration-
related hemolysis appeared lowered on previously washed RBCs, presumably due to the fact 
that older erythrocytes already lysed during the washing process. Their results appeared to be 
washing device-dependent, of which the applied g-force seems to impact the quality of the final 
washed product [98]. A particular interest of RBCs washing is related to residual plasma in ECs. 
Depending on how the blood product is processed, from a few to 100 mL of anticoagulated 
plasma can be found in RBC units. In case of donor having anti-HLA Class II antibodies of high 
strength, recipient TRALI events can be attributed to the reactive residual plasma, as shown by 
Weber et al. [100]. Though time-consuming before transfusion, washing has the advantage of 
cleaning the blood products. 
Oxygen-free RBCs storage 
Oxidative lesions to proteins are linked with impaired cellular functions. As for the stored RBCs, 
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proteins involved in redox regulation, energy metabolism, and cytoskeleton organization are 
oxidatively challenged. To deal with the oxidative stress issue, research has been conducted 
towards an anaerobic storage of RBCs. In particular, Yoshida and coworkers brought promising 
results regarding the maintaining of 2,3-DPG and ATP levels, as well as in diminishing the 
number of MVs released by RBCs throughout the storage period. In a first study published in 
2007, they applied 6 gas exchange cycles achieving a 50-fold reduction in free oxygen 
concentrations in RBC units [101]. Though impractical for routine EC storage, such setup showed 
interesting increased in vitro membrane stability below the conventional 6 weeks of storage in 
AS3 (reduced hemolysis and MV release rates). 2,3-DPG was completely depleted after 1 week 
of storage, whatever the oxygenation state. However, ATP preservation appeared better in 
anaerobic conditions, with initial level conserved up to 7 weeks, and an only 15 % decrease 
after 10 weeks (compared to the 64 % decrease in aerobic storage). The authors attributed this 
better ATP maintain to an increase of the glycolytic flux with a reduction of the pentose 
phosphate pathway, because of lower NADPH oxidation rate. In a second paper, Yoshida et al. 
investigated the pH of different AS, as well as a rejuvenation process, on anaerobically stored 
RBCs [102]. They showed that in anaerobic condition, the pH impacted ATP and 2,3-DPG 
preservation. Whatever the pH, both parameters appeared better maintained throughout the 
storage period in anaerobic conditions in comparison with aerobic storage. The pH seems 
particularly important for the preservation of 2,3-DPG in anaerobic environment since it was 
not impacted by oxygen depletion in RBCs stored in a more acidic pH AS (AS3, pH 5.8) [101]. The 
pH of AS appeared to have no effect on hemolysis, but a tendency to reduction of 
microvesiculation was observed in acidic anaerobic conditions [102]. Rejuvenation process after 
7 weeks of acidic anaerobic storage allowed for a 24-hour recovery of 77.3 % of RBCs after 10 
weeks of storage, with a low hemolysis (0.35 %). The 24-hour recovery was still acceptable for 
transfusion after 12 weeks of storage, providing that a second rejuvenation process was 
performed after 11 weeks. Similar improved parameters at current maximal storage duration 
and potential to prolong up to 9 weeks were shown on a novel AS, OFAS3 [103]. Additionally to 
these markers of RBCs storage and in vivo recovery data, D’Amici and colleagues investigated 
early storage-induced membrane proteins degradation and highlighted the role of oxygen 
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depletion in reducing such oxidative damages to proteins [104]. 
Hospital policies towards lowered number of blood transfusion 
In general, blood transfusion services are facing a lowered demand from hospitals and 
physicians. The 2013 hemovigilance report from Swissmedic [31] highlighted a decrease of 6 % 
of delivered ECs for whole Switzerland. Between 2008 and 2013, the decrease rises up to 10.9 % 
(Figure 12). These data are in accordance with global new hospital policies regarding the 
transfusion of blood. For instance, this year, several papers published in Transfusion, the journal 
of the American Association of Blood Banks (AABB), dealt with hospital restrictive blood 
transfusion practices implemented in the USA. A retrospective study from the Roger Williams 
Hospital of Providence (Rhode Island) revealed significant lowered transfusion rates over a 9-
year intervention period during which the ECs transfusion were cancelled or reduced based on 
patients Hb levels, in nonbleeding cases [105]. Interestingly, this decrease in RBC transfusion 
was closely correlated to a decrease of mortality (r = 0.88). Similarly, Yerrabothala and 
colleagues from the Dartmouth-Hitchcock Medical Center of Lebanon (New Hampshire) 
reported decreased number of transfused ECs thanks to local new policies, without change in 
length of stay nor in mortality rates [106]. Another example came from the Stanford Hospital & 
Clinics (California) where Goodnough and coworkers conducted a retrospective study of RBC 
transfusions and patient outcomes before and after the establishment of patient Hb level-based 
new transfusion policy [107]. Significantly decreased mortality, length of stay and 30-day 
readmission rates were determined thanks to the induced decline of transfusion rates. 
In addition to lowered needs for RBCs blood products, works are being conducted to artificially 
produce red blood cells from culture of hematopoietic stem cells. The works of Luc Douay are 
very promising in this sense. Cultured RBCs were shown functional regarding deformability, 
enzyme content, Hb capacity to fix and release molecular oxygen and expression of blood group 
antigens [108]. In addition, cultured RBCs appeared to survive in vivo in human, presenting up 
to 63 % survival 26 days post-injection. 
Even though these adaptations are reasonable, they will not cancel the need for blood 
donation. Artificial blood should not be soon commercially available, and natural blood will still 
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be transfused for many decades. 
 
 
Figure 12: Number of ECs delivered in Switzerland from 2008 to 2013. Data published by Swissmedic in the 2013 
hemovigilance annual report [31]. 
  
 Part 1 - Introduction 
33 
Objectives 
 
Based on the present knowledge, a research project was designed at the Service Régional 
Vaudois de Transfusion Sanguine, aiming at tackling RBCs as they are stored for blood 
transfusion in Vaud, from a redox point of view. In a first step, the quantitation of storage-
induced oxidative lesions to proteins will be presented. In particular, the oxidation of protein 
cysteine residues is investigated in cytoplasmic extracts of stored RBCs through an original 2D-
DIGE-like approach, combining infrared labeling of reversibly oxidized proteins, 2D-
electrophoresis separation, and densitometry quantitation. In addition, the carbonylation of 
proteins is addressed in 4 subcellular compartments: soluble Hb fraction, Hb-depleted soluble 
fraction, integral membrane protein fraction and cytoskeleton protein fraction. Carbonylated 
proteins from these different populations were quantified through chemical derivatization, 1D-
electrophoresis separation, immunological detection and densitometry analysis. The goal of this 
part is to give more weight to the knowledge on occurrence of oxidative injuries to proteins in 
stored RBCs, by (1) investigating for the first time the occurrence of cysteine oxidation and 
trying to highlight different groups of proteins that would be differentially affected by this 
specific oxidative modification, and (2) specifically assessing subcellular protein populations to 
update and extend existing data on protein carbonylation. 
In a second step, the present thesis will focus on the characterization of proteins that are 
affected by both oxidative modifications. Mass-spectrometry-driven identification of proteins of 
interest will give clues on how RBCs are affected by these oxidations. In particular, by 
investigating the function families of altered proteins, it should be possible to address whether 
such modifications occur in a targeted way or not. To this purpose, proteins presenting cysteine 
oxidation will be excised, digested and identified by LC-MS/MS and carbonylated proteins will 
be investigated by an affinity-capture strategy coupled to 1D-electrophoresis and LC-MS/MS 
identification. Gene ontology analyses will allow the study of protein functions engaged by 
oxidative lesions throughout the storage.  
After the characterization of increasing oxidative injuries to proteins, the third step will regard 
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defense mechanisms that RBCs can implement to deal with oxidatively denatured proteins. This 
concerns (1) their proteolytic degradation by the 20S proteasome complexes, implying 
enzymatic assays for degradation of a specific fluorogenic substrate with samples of different 
storage durations, and (2) their elimination out of RBCs via the microvesiculation process, for 
which the quantitation of carbonylated protein content will be assessed, and its impact on 
cellular storage-related carbonylation evolution discussed.  
Finally, the fourth part will conclude this PhD thesis, putting together each investigated points 
and picturing out an oxidative pathway model of the red blood cells storage. Efforts will be put 
on highlighting age-related storage damages, and an age limit for RBCs banking based on my 
investigations will be discussed.  
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Context 
 
Among all the storage lesions described so far (see Part 1), a particular interest is put on the 
oxidative-derived ones, since such damages cannot be reversed through transfusion processes, 
contrarily to some morphological or metabolism modifications, such as ATP level that is 
recovered after a few hours post-transfusion [1, 2]. Since erythrocytes are unable to perform 
protein synthesis, no protein turnover is possible. Damaged proteins should accumulate until 
being degraded or eliminated out of the cell. Redox proteomic studies performed on stored 
RBCs have shown increasing hallmark of oxidative stress throughout the storage period. Two 
main oxidative protein modifications, the oxidation of cysteine residues and the protein 
carbonylation, will be investigated here. Additionally to collecting data relative to protein 
oxidation in stored erythrocytes, this part of my research intends to bring new comprehensive 
information about RBCs aging in blood banking conditions, as well as high importance clues 
potentially regarding causes of transfusion-related adverse outcomes, to the blood transfusion 
community. 
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Chapter one 
 
Evolution of protein cysteine oxidation 
 
 
 
 
 
 
 
This chapter refers to the article 
 
“Cysteine redox proteomics of the hemoglobin-depleted cytosolic fraction of stored red blood 
cells” 
 
In preparation 
  
 Part 2 – Quantitation of hallmarks of protein oxidation 
46 
Introduction 
Protein oxidation is widely investigated through the cysteine redox status. Disulfide bridge 
formation (inter- or intra-molecular), mixed disulfides involving cysteines and low-molecular 
weight thiols (e.g. S-glutathionylation or S-cysteinylation), and sulfenic acid, can be transient 
oxidation states involved in processes regulating protein functions. It is particularly the case of 
several enzymes (e.g. peroxiredoxin, thioredoxin, glutaredoxin, glutathione peroxidase, catalase 
or superoxide dismutase), as well as small molecules (e.g. glutathione, cysteine, vitamin C or 
vitamin E) involved in anti-oxidant defenses of the RBC. Quite recently, it has also been 
demonstrated that the sulfinic acid (double oxidation of cysteine) can be reduced by 
sulfiredoxin, enabling the re-activation of peroxiredoxins [3, 4].  Alterations of such proteins and 
molecules at thiol moieties, known to be highly prone to oxidation, can lead to the RBCs 
incapacity to protect themselves against reactive oxygen species (ROS), amplifying their 
deleterious effects. 
Few methods are available to study thiol oxidative states, most of them being gel-based 
approaches coupled to mass spectrometry identification. Disulfides have been detected by 
diagonal electrophoresis (consisting in a first non-reducing SDS-PAGE followed by a second 
reducing one, most protein spots being on a diagonal, and proteins detected upper or lower the 
diagonal present intra- or inter-molecular disulfide bridges, respectively) [5-7]. Disulfide 
proteins have also been analyzed by 2DE using labeling with fluorescent or radioactive 
derivatives of alkylating reagent iodoacetamide [8, 9]. Proteins susceptible to glutathionylation 
have been revealed or purified after labeling with biotin-coupled oxidized glutathione (R-S-SG-
Biot), either by western blot using streptavidin-HRP or by affinity chromatography using 
streptavidin-coupled sepharose beads [10]. Nitrosylated-cysteines and sulfenic acids can be 
reduced specifically by ascorbic acid [11] and arsenite [12], respectively, and then labeled by 
biotin-derivatives for detection [11-13]. These approaches are specific to some oxidative-related 
modifications, and do not assess all thiol-related oxidations. Such approach has been made 
feasible since the development of 2D-DIGE and the use of amine reactive dyes [14]. Applied to 
cysteines, the redox-DIGE uses fluorescent labeling of cysteines based on thiol reactivity. 
Coupled to MS identification, redox-DIGE appears to be a technique of choice for identification 
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and quantitation of redox proteomes [15, 16]. This involves sequential alkylation, reduction and 
labeling of thiol groups. Depending on the order at which these reactions are performed, one 
can label and visualize either free cysteines or oxidized ones (for a review, see [17]). Moreover, 
the availability of different probes allows mixing differently-labeled samples and visualizing 
proteins on only one 2D gel, getting rid of the low reproducibility of this separation technique. It 
enables the direct comparison of either reduced versus oxidized cysteines or oxidized cysteines 
in different samples or different conditions.  
To the best of our knowledge, the evolution of cysteine oxidation in RBCs throughout their 
banking as erythrocyte concentrates (ECs) has never been studied so far. A particular interest 
has risen on protein glutathionylation since the early 2000’s, which is now known to transiently 
modulate protein functions [18, 19]. As for RBCs [20], this modification has been shown to be 
involved in some pathophysiological processes [21-23]. Also, oxidative stress-induced 
membrane and cytoskeletal protein glutathionylation in erythrocytes was correlated with 
decrease in membrane deformability and stability [24-27]. 
Study design 
Five independent erythrocyte concentrates (namely EC1, EC2, EC3, EC4 and EC5) were followed 
during the 42-days storage period. Some details about the donors can be found in annex A. 
Samples were collected at three time-points during the storage period, giving access to the 
cysteine oxidation status at an early storage duration (sample “day 6”), at the middle (sample 
“day 27”) and at the end (sample “day 41”) of the storage period. This study focused on the 
erythrocyte soluble fraction, since many redox-related proteins, whose mechanisms of action 
rely on the oxidation status of a cysteine, are found in the cytoplasm of RBCs. A 2D-DIGE-like 
approach based on labeling of oxidized proteins with infrared dyes, developed by Riederer’s 
group [28], was applied here in order to make direct two-by-two comparisons of samples from 
each EC. The effect of the storage period on the oxidation of cysteines was evaluated by 
comparing the infrared (IR) images of labeled proteins thanks to dedicated software. The study 
design is graphically described in Figure 13. 
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Figure 13: Study design for the characterization of cysteine oxidation in soluble extracts of stored RBCs. 
 
Material and methods 
Sample collection and preparation 
Each day of sample collection, around 15 mL of each EC were centrifuged at 2000 g during 10 
minutes and at 4 °C to remove additive solution and hemolysis-derived components. Then, RBCs 
were washed three times by resuspending the cellular pellets in physiological 0.9 % NaCl 
solution, and centrifugation in the same conditions as before. Depending on the hemolysis rate, 
that is higher for end-storage ECs, additional washing steps were performed until obtaining a 
clear washing supernatant, free of residual Hb. Washed RBCs were lyzed by a one hour 
incubation with two pellet volumes of a 0.1x PBS solution supplemented with a mixture of anti-
proteases (1 Complete protease inhibitor cocktail tablet per 50 mL of lysis buffer), under 
agitation at 4 °C. RBC soluble cytoplasmic extracts were finally separated from membranes by 
ultracentrifugation at 100’000 g for 30 minutes at 4 °C. 
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RBC soluble extracts were depleted of Hb through nickel-based metal ion affinity 
chromatography using a 5 mL HisTrap column, on a low pressure chromatography system 
(Biologic Workstation, BIO-RAD, Hercules, CA, USA), based on reference [29]. Each flow-through, 
corresponding to the RBC Hb-depleted soluble extracts, was collected as a single fraction upon 
detection of the protein 280 nm UV signal. This depletion step, even if not technically required, 
was implemented due to the important dynamic range between Hb and other proteins.  
Protein concentrations were determined using the Bradford Protein Assay (BIO-RAD, Hercules, 
CA, USA) based on reference [30]. 
Oxidized cysteines labeling 
The labeling of oxidized-cysteines, schematized in Figure 14, was designed as follow: first, free 
cysteines from 500 μg of proteins were blocked by alkylation with 8 mM N-ethylmaleimide 
(NEM) in 1/1000 Tween 20-containing PBS solution, overnight at 4 °C under gentle shaking. 
Excess of NEM was then removed by filtration over a D-salt dextrane desalting column (Thermo, 
Rockford, IL, USA), and proteins were recovered in several fractions. Afterwards, high protein 
content-fractions were detected by dot assays, pooled, and concentrated using Vivaspin 
ultrafiltration spin columns (Sartorius AG, Goettingen, Germany) with a MW cut off of 5000 Da. 
Secondly, cysteines engaged in disulfide bridges (R-S-S-R) as well as reversibly oxidized cysteines 
(R-SOH sufenic acid and R-SO2H sulfinic acid states) were reduced by incubation with 21 mM 2-
mercaptoethylamine (2-MEA) in 0.1 M sodium phosphate dibasic, 2.5 mM EDTA reducing buffer, 
for 90 minutes at 37 °C under gentle shaking and protected from light. Then, samples were 
desalted and high protein content-fractions were pooled and concentrated as before, except 
that the desalting buffer contained 1 mM EDTA. Finally, newly free cysteines were labeled by 
incubation with 20 ng of thiol-reactive infrared DY-680 or DY-780 maleimides, revealed as red 
and green IR signals, respectively. For each EC followed, the day 6 samples were labeled with 
the DY-680 maleimide whereas the day 27 and day 41 samples were labeled with the DY-780 
maleimide. Labeled samples were again desalted, and high protein content-fractions were 
pooled and concentrated, and protein concentrations were determined using the Bradford 
Protein Assay. Samples were stored at -20 °C, protected from light, until used. 
 Part 2 – Quantitation of hallmarks of protein oxidation 
50 
 
Figure 14: Labeling of different cysteine thiol states. The behavior to labeling process is depicted for free cysteines (A), intra-
molecular disulfide bridge (B), inter-molecular disulfide bridge (C), sulfenic (D), sulfinic (E) and sulfonic (F) acid states. 
 
2D gel electrophoresis 
In order to compare the three storage durations, samples were mixed two by two at a total of 
150 μg, for each EC. The day 6 sample was taken as the reference and was mixed either with the 
day 27 sample or with the day 41 one. Mixed samples were resuspended in 125 μL of 
rehydration buffer composed of 7 M urea, 2 M thiourea, 4 % CHAPS, 1 % DTE, 0.8 % carrier 
ampholytes, and traces of bromophenol blue. Proteins were separated on a first dimension 
according to their isoelectric point (pI) through isoelectric-focusing on 7 cm 4-10 Immobilized 
pH Gradient (IPG) strips (GE Healthcare, Fairfield, CT, USA). Once the IEF finished, the strips 
were first incubated during 15 minutes with gentle shaking in 6 M Urea, 8.75 mM Tris-HCl, 30 % 
(v/v) glycerol and 0.002% Bromophenol Blue equilibration buffer supplemented with 0.1 mM 
DTE, then during 15 minutes in equilibration buffer supplemented with 125 mM IAA. IPG strips 
were then loaded onto precast SDS-PAGE gels (Mini-PROTEAN TGX Gels 4-15 %, BIO-RAD, 
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Hercules, CA, USA) for 2DE, sealed with 0.5 % agarose, and proteins were separated on a second 
dimension according to their MW, through SDS-PAGE, at constant 35 mA per gel. 5 μL of 
BenchMark Protein Ladder (Life Technologies Europe B.V., Zug, Switzerland) were also loaded on 
each gel in a separate well. Proteins were finally revealed using the ODYSSEY® CLx infrared 
imaging system (LI-COR, Lincoln, NE, USA), allowing excitation at 685 nm and 785 nm through its 
“700” and “800” channel laser sources, respectively. The two images from the two 2D gels (two 
sample mixes) of each EC were acquired simultaneously for easy comparison of both the two 
“700” patterns and the two “800” patterns (same acquisition parameters). It is thus possible to 
visualize labeled proteins originating from only one sample of the mix, from the other sample, 
or from both samples. Basically, samples labeled with the DY-680 maleimide are visualized in 
red and samples labeled with the DY-780 maleimide are visualized in green. Once the IR images 
obtained, the 2D gels were stained for total protein labeling with Coomassie Blue, and images 
were acquired using a classical gel scanner. 
Image analysis 
The mixed images showing both DY-680- and DY-780-labeled proteins allow comparing the 
oxidative status of cysteine-containing proteins (as shown in Figure 14 and Figure 15) along the 
storage period of the five ECs followed. Spots appearing in yellow correspond to proteins 
presenting reversible cysteine oxidation in both conditions (two storage durations), whereas 
spots appearing mostly in red, or mostly in green correspond to proteins presenting more 
cysteine oxidation in the first (day 6) or the second (day 27 or day 41) condition, respectively. 
Spots of interest can thus be directly detected this way. 
For each of the five ECs, the IR patterns of four 2D gel images were compared: a first day 6 
pattern corresponding to the mix [day 6 + day 27], the second day 6 pattern corresponding to 
the mix [day 6 + day 41], the day 27 pattern and the day 41 pattern. Spots were semi-
automatically detected and matched among the five sets of four images via the ImageMaster™ 
2D Platinum 7 software (version 7.0.6, GE Healthcare, Fairfield, CT, USA). Spots successfully 
matched between at least four of the five sets were analyzed to compare their intensities, 
expressed as “volume %”, that is to say the percentage that each spot volume represents over 
the total volume of all detected spots in the same gel. The “volume %” of spots of the day 6 
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sample, common to both sample mixes of each EC, allowed data normalization. 
 
 
Figure 15: Representative 2D gel images after IR detection of labeled proteins. Six 2D gel images of infrared detection can be 
obtained per EC, corresponding to the two sample mixes [Day 6 + Day 27] (A, C and E) or [Day 6 + Day 41] (B, D and F): in red 
the patterns of labeled proteins in the Day 6 sample (A and B), in green the patterns of Day 27 (C) or Day 41 (D) samples, and 
in yellow the two corresponding mixed images (E and F). 
 
Data processing and statistics 
Spot intensities at days 27 and 41 were normalized relatively to the corresponding day 6 
intensities for each of the five ECs. Then, the mean normalized intensities were used to classify 
spots in four categories depending on their evolution over the storage period, i.e. mean 
increasing tendency (referred to as “up” category), mean decreasing tendency (referred to as 
“down” category), up peak pattern at day 27 (referred to as “mid-up” category) and down peak 
pattern at day 27 (referred to as “mid-down” category). Spots at days 27 or 41 were considered 
of lower or higher intensity in comparison to the day 6 if mean fold changes were below 0.8 or 
above 1.2, respectively. In the same way, intensity ratio between days 27 and 41 was calculated 
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according to Equation 1. 
Statistics were performed using the free open source RStudio IDE software (Version 0.97.551). 
The significance of spot segregation in four categories was checked by one-way Analysis of 
Variance (ANOVA) followed by a Tukey HSD test for pairwise multiple comparisons. The 
influence of storage duration on spot intensity was investigated the same way in each category. 
 
ܴሺ݀ܽݕݏͶͳǡʹ͹ሻ ൌ ܫԢሺ݀ܽݕͶͳሻ ܫԢሺ݀ܽݕʹ͹ሻΤ ൌ  ܫሺ݀ܽݕͶͳሻܫሺ݀ܽݕ͸ǡͶͳሻ ܫሺ݀ܽݕʹ͹ሻܫሺ݀ܽݕ͸ǡʹ͹ሻ൘  
Equation 1. Determination of spot intensity ratio. ۷Ԣሺ܌܉ܡ܆ሻ is the normalized intensity of a spot at day X, ۷ሺ܌܉ܡ܆ሻ is the raw 
intensity of the same spot at day X, and ۷ሺ܌܉ܡ૟ǡ ܆ሻ is the intensity of the same spot from sample “day 6” corresponding to 
the mix [day 6 + day X]. 
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Results and discussion 
 
Infrared detection of 2D gels revealed lot of labeled proteins, even in the day 6 samples, as it 
can be seen in Figure 15A and B. This means that many proteins present a reversible oxidation 
state at their cysteine residue(s), early in the storage period. It is known that the oxidation state 
of cysteines can be determinant for protein structure and function (for instance, intra-molecular 
disulfide bridges are sometimes required for the proper folding of proteins, and misfolding can 
lead to loss of function) and that redox variation of cysteines is involved in several physiological 
processes, thus naturally occurring independently of any stress condition, as for instance the ex 
vivo storage and aging of RBCs. Differences of labeled proteome 2DE patterns were observed 
according to the storage duration (see Figure 15), implying an evolution of cysteine oxidation in a 
storage time-dependent manner, in addition to the basal physiological cysteine redox states. In 
particular, the densitometric analysis of the 20 2D gel images highlighted 32 spots that were 
successfully matched among the four images (2x Day6 + Day 27 + Day 41) of at least four out of 
the five ECs. An important inter-sample variability was observed, in term of intensity ratio, and 
even sometimes revealing different pattern evolution for a same spot. Thus, mean relative 
abundances were here associated with relatively high standard deviation. A mean coefficient of 
variation of 55 % was thus calculated over the 32 spots. This value was similar whatever the 
mean evolution tendency of the spots. 
The 32 spots of interest were classified in four categories, depending on their intensity 
evolution throughout the storage period (see Figure 16 and Figure 17). This segregation based on 
mean standardized intensities was proven statistically significant by one-way ANOVA (p < 5·10-10 
for the global data set, p < 5·10-6 at day 27 and p < 1·10-8 at day 41, see Figure 16 and Figure 17). 
Test for multiple comparisons further confirmed this, showing significant differences between 
categories “up” and “down” (p < 5·10-5), “mid-up” and “down” (p < 0.001), “mid-up” and “mid-
down” (p < 0.01) and “up” and “mid-down” (p < 5·10-4) at day 27 (see Figure 16A), and between 
categories “up” and “down” (p < 10-7), “up” and “mid-down” (p < 0.005), “up” and “mid-up” (p < 
10-5) and “mid-down” and “down” (p < 0.05) at day 41 (see Figure 16B). 
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Figure 16: Comparison of mean spot intensities as a function of spot evolution category. Boxplots represent the mean 
normalized spot intensities of each of the four categories of spot evolution, at day 27 (A) and at day 41 (B). The red 
horizontal line represents the reference i.e. spot intensity at day 6. Numbers on top of each boxplot are the population size. 
Stars represent the degree of significance of the difference between the groups, calculated by ANOVA and TukeyHSD: ** p < 
0.05, *** p < 0.01 and **** p < 0.001. 
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Figure 17: Comparison of mean spot intensities as a function of storage duration. Boxplots represent the mean normalized 
spot intensities of each of the four categories of spot evolution at days 27 and 41. Numbers on top of each boxplot are the 
population size. Stars represent the degree of significance of the difference between the two time-points of each category, 
calculated by Student paired t-test: * p < 0.1, ** p < 0.05, *** p < 0.01 and **** p < 0.001. 
 
Seventeen spots showed a mean decreasing tendency, either decreasing between days 6 and 
27, then being stable until day 41 (9 spots), or being stable between days 6 and 27, then 
decreasing until day 41 (6 spots). Additionally, 2 spots tended to decrease continuously 
throughout the storage period. The decreasing intensity means that less reversible cysteine 
oxidation is detected, either explained by cysteine residues becoming free over time or on the 
contrary by the appearance of irreversible oxidative states, making the labeling process 
inefficient, which is the case for the sulfonic acid R-SO3 state. The decrease can also be 
explained by the disappearance of oxidized proteins by proteolysis or expulsion out of the cell. 
Six spots appeared to increase during the storage period, mostly between days 6 and 27 (5 
spots). Only one spot was stable between days 6 and 27, and then increased during the two last 
weeks of the storage period. The increase in intensity over time can only be explained by an 
accumulation of reversibly oxidized copied of proteins. Some other spots (9) presented a peak 
pattern at day 27, either a top peak (6 spots) or a down peak (3). The top-peak pattern can be 
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due to a starting accumulation of reversible oxidation further progressing to irreversible states 
of oxidation. The down-peak pattern could correspond to a specific oxidized protein population 
being efficiently degraded in the beginning of the storage period. Afterwards, for some 
unknown reason, the degradation could be altered, resulting to the accumulation of these 
oxidized proteins. 
Once the data processing for spot segregation into the four categories validated, it was possible 
to investigate the effect of storage duration on each category, as depicted on Figure 17. One-way 
ANOVA revealed really significant effect of time of storage on spots presenting a mean 
decreasing pattern (p < 5·10-10) or a mean increasing pattern (p < 0.005). As for spots presenting 
a mid-peak pattern, mean normalized intensity at day 41 comes back to around 1, so the 
storage duration do not appear to have an effect in respect with the three storage durations 
investigated (p = 0.6388 and p = 0.7317 for the mid-down and mid-up categories, respectively). 
Considering all the 32 spots of interest, there was no statistically significant global effect of 
storage duration on spot intensity (p = 0.8383). However, the pairwise multiple comparisons 
revealed significant differences between some couples of storage durations, even in the 
categories of spots with a peak pattern (see details on Figure 17). This means that proteins are 
differentially altered by oxidative processes at their cysteine residues during the storage period. 
Several oxidative states are involved, with more or less deleterious effect, and it is very probable 
that some protein populations, thus some molecular functions are specifically affected through 
cysteine oxidation. 
In addition to its major implications in protein structure and function and in cellular processes, 
we have shown here that the oxidation of cysteine residues also occurs as a marker of RBCs 
aging during their storage. Moreover, it seems that this oxidative hallmark of RBCs storage is not 
a random phenomenon since we successfully highlighted different categories of evolution of 
this modification over the storage period. As a consequence, it is likely that specific populations 
of proteins are affected, which will be investigated in Part 3 through the MS-based identification 
of proteins present in the detected spots of interest. 
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Introduction 
Protein carbonylation is also commonly investigated as a marker of oxidative stress [31, 32] and 
aging [33-35] in many eukaryotic cell populations, including RBCs [36-38]. This irreversible 
modification consists in the introduction of aldehyde or ketone chemical functionalities onto 
amino acid side chains (mainly at arginine, lysine, proline and threonine residues), or results 
from protein backbone cleavage through α-amidation or β-scission [39]. Contrary to cysteine 
oxidation, protein carbonylation does not target a specific amino acid involved in cellular 
function such as the redox regulation of the cell. However, the multiplicity of potential targeted 
amino acids, thus the multiple changes that a protein can undergo through carbonylation, 
makes higher the probability to affect active sites (for instance, see a non-exhaustive list of 
amino acid carbonylation products in reference [40]). Amino acid carbonylation can directly 
affect an active site or impact the protein structure, both affecting protein function. 
Several approaches were developed to assess protein carbonylation [41, 42]. Basically, there are 
two main existing strategies to detect and quantify this modification. They are based either on 
reaction with tritiated borohydride, or on derivatization with 2,4-dinitrophenylhydrazine (2,4-
DNPH). The former relies on borohydride-induced reduction of carbonyl groups to alcohols, 
with incorporation of a tritium atom, and radioactivity determination by scintillation counting. 
The latter is based on a condensation reaction (loss of water) that leads to the formation of a 
protein-hydrazone complex, whose optical density allows quantitation of carbonylation. If the 
tritiated borohydride approach appears to be more sensitive as a test for aldehydes or ketones 
detection, the method based on 2,4-DNPH derivatization presents the advantage of the 
availability of a wider range of commercial reagents, and easiness of derivatization detection by 
photometry, compared to radioactivity. Moreover, more hindsight are available relative to this 
approach, through literature from influent research groups, renowned in the fields of 
transfusion medicine and protein chemistry (groups of Professor Zolla (Tuscia university, 
Viterbo, Italy), Professor Papassideri (University of Athens, Athens, Greece), and Professor 
Regnier (Purdue University, IN, USA). 
Several methods based on derivatization with hydrazide-containing compounds have thus been 
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developed for detection and quantitation of carbonyl protein content [43-48]. Among those 
utilizing 2,4-DNPH derivatization, the apparently simplest one is a spectrophotometric assay. 
Indeed, the resulting protein-hydrazone complexes absorb in the UV at 375 nm, with a molar 
extinction coefficient of 22000 M-1·cm-1. Erythrocyte samples first need to be depleted in Hb 
since this extremely abundant RBC protein also absorbs at this wavelength. Moreover, a protein 
precipitation step is required following the derivatization reaction in order to get rid of excess of 
derivatizating reagent that otherwise will interfere with the absorbance reading. The availability 
of antibodies directed against DNP moieties made possible to perform carbonylation 
quantitation through western-blotting or ELISA assays. Compared to photometric assay, these 
approaches present the advantage of running several samples in a same analysis, limiting the 
experiment-related variability. Moreover, there is no technical need for Hb depletion since the 
detection is immunologically-mediated. As for the western-blot approach, reagent removal after 
derivatization is unnecessary because excess of 2,4-DNPH is removed during SDS-PAGE. There is 
thus no need for precipitation step, avoiding potential protein loss. In the same manner, low 
molecular-weight non-protein compounds such as lipids or sugars that can bear carbonyl groups 
will migrate out of the gel and will not interfere for the quantitation of protein carbonylation. 
Finally, the gel-based experiments can give access to an additional kind of information, the 
molecular weight (MW) of carbonylated proteins. 
Such approach has allowed investigations on protein carbonylation in stored RBCs, bringing 
Papassideri’s [36, 37] and Zolla’s [49] groups to conclude to an increase in carbonylated protein 
content. In particular, Kriebardis et al. have shown via immunodetection of 2,4-DNPH 
derivatized proteins that the oxidative index of non-leukodepleted CPDA-stored (CDP 
anticoagulant plus adenine) erythrocyte membrane proteins increased along the storage period 
[36], later emphasized to the cytoskeletal proteins [37]. Moreover, Zolla et al. have shown that 
total erythrocyte protein carbonylation increased uniformly during the first four weeks of 
storage in leukodepleted, CPDA-collected, SAGM-stored RBCs, followed by a steady state 
evolution or slight decrease [49]. They have also measured an accumulation of ROS and lipid 
oxidation increasing parallel to protein carbonylation. Metabolic investigations allowed them to 
correlate these findings with an over-activation of the oxidative phase of the pentose 
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phosphate pathway, leading to the conclusion that protein carbonylation is due to an increasing 
oxidative stress along storage, reaching a maximum level after three weeks [49]. 
Study design 
The first step of this work was to develop a subcellular fractionation in order to investigate the 
evolution of protein carbonylation on the four following protein populations: soluble Hb 
fraction, Hb-depleted soluble fraction, integral protein-enriched membrane fraction and 
cytoskeleton-enriched membrane fraction. Then, three independent ECs (namely EC6, EC7 and 
EC8) were followed weekly (see donor details in annex A). Cell lysis, separation of membranes 
from soluble fraction, and membranes washes were performed on the collection day before 
sample freezing. Further fractionation processes were performed just before protein 
carbonylation analyses, once all samples were collected. The study design is pictured out on 
Figure 18. 
 
Figure 18: Study design for the quantitative evolution of protein carbonylation in subcellular fractions of stored RBCs. 
Weekly collected samples were fractionated into four subcellular extracts (soluble Hb fraction, Hb-depleted soluble extract, 
integral protein membrane and cytoskeleton membrane DDM and DC extracts), then carbonylated proteins were derivatized 
with 2,4-DNPH, and detected by western-blot. Densitometric analyses allowed the quantitation of carbonylation in the four 
protein populations over the storage of ECs.  
 Part 2 – Quantitation of hallmarks of protein oxidation 
63 
Material and methods 
Collection and subcellular fractionation of erythrocytes 
Erythrocytes were collected weekly at days 2, 5*, 7, 14, 21, 29, 36 and 43 (*: note that for EC6, a 
sample was taken at day 5 instead of days 2 and 7, due to a provision delay of the concentrate 
after its rejection from the blood bank). Erythrocytes were first spun down at 2000 g during 10 
minutes at 4 °C. RBCs were then washed three times in a physiological 0.9% NaCl solution and 
spun down with the same conditions as before, to get them free of additive solution and 
hemolysis products. RBCs were lyzed by one-hour incubation at 4 °C in a hypotonic 0.1x PBS 
solution under agitation. Then, cytoplasmic extracts and membranes were separated by 
centrifugation at 18000 g during 30 minutes at 4 °C. 
Hb was depleted from the soluble cytoplasmic extracts by nickel-based IMAC chromatography 
with a HisTrap HP 5 mL column (GE Healthcare, Fairfield, CT, USA) on a BioLogic Workstation 
(BIO-RAD, Hercules, CA, USA), based on ref [29]. The flow through (RBC soluble Hb-depleted 
fraction) was collected in a single fraction, and the corresponding Hb fraction was eluted with a 
gradient of imidazole-containing PBS buffer, from 10 to 100 mM in 20 minutes. 
RBC membranes were washed several times with the lysis solution until no more soluble Hb was 
released in the wash supernatant after 30 minutes of centrifugation at 18000 g at 4 °C. Typically, 
membranes free of soluble Hb were obtained after 3 washes in a buffer-to-membrane volume 
ratio of 2, followed by 4 washes in a buffer-to-membrane volume ratio of 10. Washed 
membranes were then sequentially solubilized with 5 volumes of dodecyl-maltoside (DDM) 
buffer composed of 7.8 mM DDM in 50 mM Tris-HCl, 750 mM aminocaproic acid, 0.5 mM EDTA, 
pH 7.0, vortexed and centrifuged (same conditions as before), which gave the first membrane 
protein extract (DDM membrane fraction). DDM is a non-ionic detergent allowing extraction of 
integral membrane proteins (based on ref [50]). Afterwards the remaining pellet was solubilized 
with 5 initial membrane volumes of deoxycholate (DC) buffer, composed of 1 % DC in 50 mM 
Tris-HCl, 150 mM NaCl, pH 8.1, and vortexed. DC is an anionic detergent allowing to solubilize 
the DDM-insoluble material, i.e.peripheral membrane proteins (based on ref [51]). After a last 
centrifugation (same conditions as before), the supernatant contained the second membrane 
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protein extract (DC membrane fraction). It has to be noted that no wash was performed 
between DDM and DC extractions in order to keep all the carbonylated membrane proteins. 
Protein assay and sample preparation 
Protein concentrations of RBC Hb-depleted fraction and membrane extracts were determined 
using the Bradford Protein Assay (BIO-RAD, USA), with a calibration curve composed of BSA 
dilutions. The concentration of Hb fractions was calculated thanks to the Harboe direct 
spectrophotometric method [52] with the 3-point “Allen correction” [53]. Harboe’s method has 
the advantage to be the more accurate Hb measurement method in the presence of interfering 
substances [54]. Hemoglobin-depleted soluble extracts were concentrated via centrifugation at 
4750 g through Vivaspin ultrafiltration spin columns (Sartorius, Götingen, Germany) with a 5000 
Da MW cut off. Lower-volume extracts (DDM and DC membrane extracts, both 500 μL) were 
vacuum centrifuged upon dryness and resuspended both in DC buffer to desired concentration. 
Detection of carbonylated proteins 
Protein carbonylation content was followed along the storage of three ECs as mentioned earlier. 
Carbonylation detection and quantitation experiments were performed with the Oxyblot™ 
Protein Oxidation Detection Kit (Millipore, Billerica, MA, USA), with 15 to 20 μg of proteins. 
Proteins were derivatized with 2,4-DNPH according to the manufacturer’s instructions. Briefly, 
samples were mixed with SDS for protein denaturation, and incubated for 15 minutes at room 
temperature with the 2,4-DNPH derivatization solution. A RBC soluble extract was oxidized via a 
metal-catalyzed oxidation reaction and was used as derivatization positive control (through 
incubation with the derivatization solution) as well as negative control (through incubation with 
the control derivatization solution that did not contain 2,4-DNPH). The derivatization reaction 
was then stabilized by addition of the neutralization solution, and samples were finally reduced 
with β-mercaptoethanol (final concentration 0.74 M). SDS-PAGE protein separation was then 
performed using NuPAGE® 4-12 % Bis-Tris precast mini-gels (Invitrogen, USA), and gels were run 
individually in MOPS buffer (Invitrogen, USA) with a constant low voltage of 100 V. Proteins 
were then transferred onto Hybond™ hydrophobic polyvinylidene difluoride (PVDF) membranes 
(GE Healthcare, USA) using a liquid transfer system. Transfer efficiency as well as homogenous 
protein quantity loading were checked with membrane Ponceau Red staining. Membranes were 
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then blocked overnight at 4 °C by incubation with a 5 % BSA, 0.1 % Tween 20, in PBS solution 
under agitation. Immunodetection of carbonylated proteins was performed by incubating 
membranes with a primary antibody solution (rabbit anti-DNP IgG antibody) during 1h at RT, 
followed by three washes with 0.1 % Tween 20 in PBS solution. Afterwards membranes were 
incubated with a secondary antibody solution (HRP-conjugated goat anti-rabbit IgG antibody) 
during 1h at RT, and then washed three times as before. Carbonylated proteins were revealed 
by Enhanced Chemiluminescence (ECL™ Western Blotting Detection Reagents, GE Healthcare, 
USA) reaction. Films (Amersham Hyperfilm™ ECL, GE Healthcare, USA) were then scanned with 
a Personal Densitometer SI (GE Healthcare, USA), and quantitation of protein carbonylation 
content was achieved with the ImageQuant TL 7.0 software (GE Healthcare, USA). 
Quantitation of protein carbonylation per EC 
The quantitation of carbonyl groups was performed by densitometric analysis of the 
immunodetection films. Quantitation was assessed on whole migration lanes for each sample in 
order to work with the entire carbonylation status of each RBC fraction. Densitometric values 
were measured and expressed by the software as “volumes”, then converted in femtomoles of 
carbonyl groups by comparison with the densitometric volume of the carbonylated BSA, 
included in the Oxyblot mixture of standard proteins (band at 68 kDa), and of which the 
carbonylation status is known. According to the quantity of proteins derivatized and loaded for 
SDS-PAGE, the quantitation was then reported as femtomoles of carbonyl groups per microgram 
of proteins (fmol/μg). Finally, considering extract protein concentrations and fraction volumes, 
results were expressed as μmol/EC. 
Statistics 
Reproducibility of the quantitation of protein carbonylation was evaluated on triplicates of 
measures. The mean CV % was determined as 7.2 %. 
Statistics were evaluated using the SigmaStat 3.10 software (SYSTAT Software Inc., Point 
Richmond, CA, USA). Significant evolution of carbonylation during storage was determined using 
the one-way Analysis of Variance (ANOVA) followed by a Tukey test for pairwise multiple 
comparisons. As for EC6, data at day 7 were interpolated via a linear regression between values 
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at days 5 and 14. Differences were considered statistically significant for p-values < 0.05. 
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Results and discussion 
Protein carbonylation in stored RBCs 
A sequential extraction of membrane proteins was set up to enable the separation of integral 
membrane proteins from cytoskeletal ones, beyond the main membrane/cytosol cellular 
fractionation. The characterization of both membrane extracts is described in annex B. The 
Carbonylated proteins were detected by anti-DNP immunodetection after 2,4-DNPH 
derivatization of protein extracts from each of the four RBC subcellular fractions mentioned 
above (i.e. soluble Hb fraction, Hb-depleted soluble fraction, DDM membrane fraction and DC 
membrane fraction). Protein carbonylation appeared to be a specific modification affecting 
proteins in a non-random manner. In particular, Figure 19 shows two proteins with similar 
Ponceau red staining intensities (total protein detection), but different immunodetection 
intensities (specific carbonylated proteins), proving that carbonylation quantitation is not 
determined by protein abundances. 
 
 
Figure 19: Specificity of protein carbonylation modification. A: Ponceau red staining of a part of a PVDF membrane onto 
which a sample from Hb-depleted soluble fraction (EC6, day 43) was transferred, as well as a carbonylated protein ladder 
(“Oxyblot Marker”) and a prestained protein ladder (“Prestained Marker”). B: Film corresponding to the same part of the 
membrane after the immunodetection of DNP moiety-containing proteins (i.e. derivatized carbonylated proteins). The 
arrows show two proteins with similar Ponceau red staining intensities, but different immunodetection intensities, proving 
that the carbonylation is a specific modification that does not affect proteins according to their abundance. 
 
Carbonylation in RBC soluble fractions 
The quantitation of carbonylated protein contents in soluble Hb and in Hb-depleted soluble 
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fractions during the storage of RBCs revealed that Hb carbonylation level varied between 40 and 
90 fmol/μg (Figure 20A) whereas the one of the Hb-depleted soluble fraction was comprised 
between 300 and 1000 fmol/μg (Figure 20B). Soluble Hb is thus around 10 times less 
carbonylated than the pool of all the other soluble proteins. However, Hb is much more 
abundant than other proteins in RBC cytoplasm. Indeed, it represents 96.96 ± 0.25 % of the RBC 
soluble protein content (measured from 18 soluble extracts). When dealing with the entire EC, 
between 1 and 4 μmol of total carbonyl groups were carried by soluble Hb (Figure 21A) and 
between 0.2 and 1.7 μmol were carried by all the other soluble proteins (Figure 21B). The mean 
ratio between the carbonylation carried by soluble Hb and the carbonylation carried by the rest 
of soluble proteins along the storage of the three ECs monitored during storage is 3.74 ± 1.51. 
This value is coherent with a global ratio of 3.19, which is the combination of the ratios of 
protein abundance (96.96/3.04 = 31.89 in favor of Hb) and carbonylation status (10 in favor of 
the rest of soluble proteins). 
Soluble Hb and Hb-depleted soluble fractions present both similar carbonylation patterns along 
the storage. As a result, it appeared that the total soluble carbonylation of each EC monitored 
presented a decrease of 23.1 %, 26.1 % and 36.6 % (EC6, EC7 and EC8, respectively) in the 
beginning of the storage period afterwards it was globally stable (Figure 21C). 
Carbonylation in RBC membrane fractions 
Both DDM and DC membrane extracts showed protein carbonylation rates of the same order of 
magnitude than the Hb-depleted soluble fraction one, i.e. a few hundreds of fmol/μg all along 
the storage period. However, DDM fraction protein carbonylation rate was a little bit lower (300 
to 500 fmol/μg) than the DC fraction one (500 to 1000 fmol/μg) (Figure 20C and D). This 
approximately two-fold difference was conserved in terms of membrane carbonylation content 
in ECs, which fluctuated between 0.4 and 1.2 μmol/EC for DDM extracts and between 0.5 and 
2.5 μmol/EC for DC extracts (Figure 21D and E). Carbonylation content along storage showed 
interesting patterns in both membrane extracts. Concerning DDM extracts, a constant level of 
carbonylation was observed until day 21. These mean basal values of 0.400, 0.445 and 0.732 
μmol for EC6, EC7 and EC8 respectively, were taken as 100 % of DDM fraction carbonylation for 
each corresponding EC. Then, for two of the three ECs followed (EC7 and EC8), an increase of 51 
 Part 2 – Quantitation of hallmarks of protein oxidation 
69 
% and 64.5 % was observed between days 21 and 29, respectively. Finally, carbonylation fell 
down to less than its basal level (93.5 % and 73.8 %, respectively) until the end of the storage 
period. The third EC followed (EC6) showed a constant carbonylation level at around 0.4 
μmol/EC throughout the storage period (Figure 21D). 
 
 
Figure 20: Protein carbonylation rates in subcellular extracts. Protein carbonylation rates along the storage in Hb (A) and Hb-
depleted (B) soluble extracts, and in DDM (C) and DC (D) membrane extracts. In terms of quantity of carbonylation per 
quantity of protein, data in soluble extracts are globally stable throughout the storage period whereas there is a slight global 
increase of protein carbonylation rates in the two membrane extracts. 
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Figure 21: Absolute quantitation of protein carbonylation along the storage period of ECs. Quantitation of carbonylated 
proteins in ECs in Hb (A), Hb-depleted (B) and total (C) soluble fractions, in DDM (D), DC (E) and total (F) membrane fractions, 
and in total erythrocyte concentrates (G). The carbonylation content of total soluble and total membrane fractions is the 
sum of Hb and Hb-depleted soluble fractions, and of DDM and DC membrane fractions, respectively. Soluble Hb 
carbonylation accounts for half of the total carbonylation, thus attenuating the influence of the other compartments. 
Membrane fraction carbonylation is however of interest due to its fluctuating patterns, and tends to increase in the end of 
storage. The increase of carbonylation between days 29 and 43 is statistically significant in DC membrane fractions (p < 0.01) 
and in total membrane fractions (p < 0.05). 
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DC membrane extracts also revealed an increasing pattern of carbonylation content, but in a 
different way. Indeed, the carbonylation content was also stable at 1.5 and 1.3 μmol from day 7 
to day 21 for EC6 and EC8, and at 1.6 μmol from day 7 to day 29 concerning EC7. These mean 
basal values were taken as 100 % of DC fraction carbonylation for each corresponding EC. Then, 
EC6 and EC8 presented a decrease of 64.0 % and 38.8 %, respectively, until day 29, and EC7 
presented a decrease of 24.7 % until day 36. Finally, the carbonylation content reached up to 
173.0 %, 165.5 % and 174.9 % until the end of the storage period for EC6, EC7 and EC8 
respectively (Figure 21E). Effect of storage on protein carbonylation evolution in DC membrane 
extracts was found statistically significant (p @ 0.01), with a particular significant increase 
between days 29 and 43 (p < 0.01). 
The global pattern of RBC membrane carbonylation (Figure 21F) appeared stable until day 29 at 
around 2 μmol for EC7 and EC8, and then increased up to 3 μmol until the end of the storage 
period. As for EC6, the global membrane pattern presented the same decrease after day 29 
than in the DC fraction, due to the stable carbonylation of DDM fraction proteins in this EC, as 
shown in Figure 21D. Effect of storage on the membrane protein carbonylation was statistically 
significant (p < 0.05), as well as the carbonylation increase between days 29 and 43 (p < 0.05). 
Carbonylation in whole RBCs 
Adding the carbonylation content of each RBC compartment, this storage lesion may appear 
stable in the entire RBCs since similar amounts were calculated at day 7 and at day 43 (around 
7.3 μmol for EC6 and 5.0 μmol for EC7 and EC8, Figure 21G). However, this global pattern was 
divided in a starting soluble-related decrease and an ending membrane-related increase of 
carbonylation, as described above. These variations are more easily observed in Figure 22 where 
one can see, expressed in percentages, the means distribution of protein carbonylation and 
total protein content throughout the storage period (Figure 22A-1 to A-6, and Figure 22B-1 to B-6, 
respectively). Moreover, the part of carbonylation content in each fraction highly differed from 
the protein abundance repartition (Figure 22A vs. Figure 22B), again highlighting the non-random 
occurrence of protein carbonylation. 
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Figure 22: Mean repartition of protein carbonylation and total protein content in RBC compartments during storage. The proportions of carbonylation and protein content in 
each fraction are shown according to storage duration (A1 to A6 and B1 to B6, respectively). Data are the means of the three ECs followed. One can notice that the 
carbonylation distribution in each compartment does not match the protein repartition, indicating a targeted modification. Carbonylation in DC membrane fraction increases 
remarkably during the second half of storage. 
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Conclusions 
 
First of all, the sample fractionation has become a nearly mandatory step in every proteomic 
analysis. The dynamic range improvement is a very important parameter to access the more 
comprehensive information possible. Hence, the protein oxidation (both cysteine oxidation and 
protein carbonylation) was explored in soluble and/or membrane compartments. Hb being the 
ultra-abundant erythrocyte soluble protein, it was successfully depleted from the cytoplasmic 
fraction, allowing a better investigation of its whole pool of proteins. Such depletion procedure 
is particularly important in gel-based approaches where data rely on visual information. Global 
membrane content was also fractionated since some proteins such as spectrin chains and band 
3 are also very abundant. For instance Burton and Bruce highlighted the high protein 
abundance range in red cell membranes with extremes being band 3 and CR1 (1.2·106 vs. 20 
copies per cell, respectively) [55]. A sequential membrane protein extraction was thus 
established for the protein carbonylation investigation, allowing the separation of integral 
membrane and cytoskeletal proteins. 
Protein oxidation during the EC storage of RBCs was here investigated as both transient and 
irreversible oxidative states, through the detection of proteins bearing reversibly oxidized 
cysteine residues or irreversible acquisition of reactive carbonyl functional groups, respectively. 
In a first part, a redox-DIGE approach allowed to detect reversibly oxidized proteins in stored 
erythrocytes, and to study their evolution over the storage period. Up to date, and to the best 
of our knowledge, this is the first time that such a study is performed in a transfusion medicine-
related point of view. Studying the evolution of protein cysteine oxidation throughout the 
storage of blood products, and in particular of ECs, is of great interest since oxidation-reduction 
of reactive thiol species plays an important role in health and disease biological processes. In 
vitro storage of banked erythrocytes is often associated with their in vivo aging, for which the 
oxidative challenge undergone by RBCs seems to be of importance. This study brings new 
quantitative data related to protein oxidation. It can be concluded that cysteines of proteins 
from Hb-depleted soluble extracts of stored RBCs are not equally affected by oxidation. Beyond 
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the kind of modification (disulfide, glutathionylation, nitrosylation, sulfenylation and so on), the 
oxidation evolution along the storage duration differs among affected proteins. The different 
categories of evolution allowed us to determine groups of proteins either being more and more 
oxidized until moving to an irreversible state, or staying in a reversible state, or proteins being 
less oxidized throughout the storage, suggesting an action of antioxidant enzymes or a 
degradation of such proteins. Cysteine oxidation thus appears as a heterogeneous modification 
targeting specific proteins. 
As for the carbonylation of proteins, several studies have already characterized its extent over 
the storage period. Through this study, we obtained data partially in adequacy with the existing 
literature. Indeed, we were able to highlight end-storage related significant changes in 
membrane and associated skeleton only after three to four weeks of storage, whereas others 
detected changes right after two weeks. In particular, this storage limit of 14 days, proposed by 
Koch based on debatable poorer post-surgery transfusion-related clinical outcomes [56], seems 
to fit with the work conducted by Zolla and coworkers [49]. In addition to confirm a time-related 
evolution of the protein carbonylation content, this study also highlighted a particularly 
interesting subcellular compartment-dependent evolution of protein carbonylation. In blood 
flow as well as in ECs, a heterogeneous population of RBCs is encountered in term of cell age 
(up to 120 days in vivo). A mean basal carbonylation content is thus quantified early in the 
storage period. Thanks to data obtained, it is now clear that RBCs undergo changes in protein 
carbonylation content along the storage period, and that these changes are compartment-
dependent. During the first two weeks of storage, a decrease of the basal carbonylation was 
quantified in soluble fractions. RBCs are known to be well equipped in antioxidant defenses, 
preventing or slowing down effects of oxidative stress. Moreover, proteasomal activity has been 
described in human RBCs [57], with an aspecific affinity for mildly oxidized proteins [58]. Such 
activity could explain the loss of protein carbonylation observed in soluble fractions. As for 
membrane extracts, protein carbonylation showed a significant increase from three to four 
weeks of storage. This increase is however attenuated with a decrease of carbonylation in 
integral membrane fractions at the end of the storage period. It is of particular interest to note 
that throughout this period, RBCs have been shown to release an exponential amount of 
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microvesicles [59] enriched in membrane proteins [60, 61]. This can possibly explain the 
dramatic loss in membrane protein carbonylation in the end of the storage.  
Both cysteine oxidation and protein carbonylation are modifications able to alter protein 
functions. The big deal of this redox investigation is now to put names on the altered proteins. 
Two possibilities are to be considered here: either oxidative lesions globally affect all types of 
RBC proteins, or some protein populations, thus some protein functions, are targeted by a 
specific mechanism. In order to answer this question, we chose to apply existing and newly-
develop mass-spectrometry based approaches for identification of cysteine-oxidized and 
carbonylated proteins, respectively. This part of my research will be explored hereafter. 
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Introduction 
 
RBCs were clearly shown to be challenged by oxidative modification in vivo as well as during 
their in vitro storage as ECs (see general introduction and part 2). Detection of carbonylation 
and cysteine oxidation allowed proving the occurrence of protein oxidative modifications inside 
RBCs, as storage duration- and cellular compartment-dependent phenomena. Proteomic studies 
conducted so far in the transfusion medicine field mainly focused on global storage-induced 
changes in erythrocyte proteome. Of particular interest is to question the identity of proteins or 
protein function families that are particularly affected by above-mentioned modifications. One 
can legitimately wonder whether all proteins in a given cellular compartment are equally 
susceptible to oxidation, or if oxidative alterations target specific proteins, thus altering some 
target molecular functions inside the cell. EC storage-related oxidized proteins compose a sub-
proteome that needs to be characterized in time-dependent and localization-dependent 
manners, in order to bring new clues enabling a better understanding of biochemical and 
rheological changes occurring during the RBCs storage, thus potentially allowing the 
development of new storage conditions for a better efficiency of transfused blood products. 
Erythrocytes are considered as a model of choice for multiple studies due to their relatively low 
complexity. Indeed, their maturation process includes the depletion of all intracellular 
organelles, making it easy to investigate cell membranes in particular. However, RBCs extracts 
are complex samples regarding proteomic tools for protein identification (i.e. mass 
spectrometry, MS). In particular, the dynamic range of protein concentrations inside a sample is 
critical for a good proteome analysis. To investigate sub-proteomes from such complex samples, 
it is necessary to fractionate samples before analysis. In Part 2, the interest of subcellular 
fractionation and electrophoresis protein separation for a better visualization of proteins of 
interest was shown. As for MS-based protein identification, the rule is the same: the lower the 
sample complexity, the better the identification. Sub-proteome profiling can rely on three 
approaches: physico-chemical isolation (2DE for instance), cellular fractionation (as the 
subcellular fractionation developed in the part 2 of this PhD thesis), or chemical targeting by 
specific probes (e.g. enrichment of a particular PTM-related sub-proteome).  
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A sub-proteome-targeted approach is based on MS-coupled affinity purification (AP-MS). The 
AP step can be conducted through antibody/antigen affinity (immunopurification) or other 
ligands such as oligonucleotides, proteins or chemicals. Carbonylated proteins enrichment has 
been realized with derivatives of hydrazines, Girard’s P reagent or O-ECAT labeling. The group of 
Fred E. Regnier successfully investigated carbonylated proteins from bovine serumalbumine 
(BSA) solution [1], yeast extract [2, 3] or rat plasma [4] through biotin-hydrazide derivatization 
followed by avidin-affinity based fluorescent labeling and MALDI-MS/MS identification [3] or 
chromatographic purification and ESI-MS/MS identification [1, 2, 4]. This group also made use of 
hydrazide derivative Girard’s P reagent (GPR, 1-(2-hydrazino-2-oxoethyl)pyridinium chloride) 
enabling the purification of derivatized peptides by strong cation exchange chromatography 
(SCX) [5]. GPR derivatization provides a quaternary amine function allowing ionic interaction 
between the positively charged derivatized peptides and a negatively charged solid phase. 
Widely used for spectrophotometric quantitation of carbonylation content, 2,4-DNPH 
derivatization was also used as first step of carbonylome immunoprecipitation to study 
apoptosis induction in the human promyelocytic leukemia HL60 cell line [6]. Also, ICAT-like 
reagent O-ECAT standing for oxidation-dependent element coded affinity tags was developed by 
Meares and coworkers to assess carbonylome through AP coupled to nano flow liquid 
chromatography and fourier transform ion cyclotron resonance-MS (AP-nanoLC-FT-ICR-MS) 
analysis on recombinant human serum albumin [7]. For a methodological review on ways of 
investigating the carbonylated proteins, see reference [8]. 
Several groups have thus studied the carbonylated proteome of some prokaryote or eukaryote 
organisms, as a response to in vitro-induced oxidative stress as well as an in vivo pathological or 
aging biomarker [9-11]. Investigating protein carbonylation in the case of RBCs storage is a little 
bit particular in the sense that it is both an unprovoked and non-physiological modification. As 
mentioned in Part 2, this PTM is widely investigated as a quantitative biomarker of oxidative 
stress and aging, including in the transfusion-purposed RBC storage. However, the following 
work is the first time that a time-dependent characterization of this sub-proteome is assessed in 
this field. To this purpose, two additional separation steps were included over the subcellular 
protein segregation. Modified proteins were isolated by affinity purification before 1D-PAGE, 
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and digested peptides were separated based on hydrophobicity prior to MS/MS analysis.  
As for proteins prone to cysteine oxidation, the different approaches described in Part 2 allowed 
some groups to investigate redox-sensitive proteomes from diverse cellular origin, either as a 
response of in vitro stimulation or as pathology biomarker. Mainly proteins involved in 
metabolism, redox homeostasis, signal transduction, cytoskeleton or vesicle trafficking 
appeared sensitive to reversible cysteine sulfenation [12-14]. In particular, these protein 
functions were shown targeted in a mice model presenting a peroxiredoxin II knock out [15]. 
Spots of interest detected in Part 2 will be here analyzed for protein identification and 
bioinformatics-based determination of targeted function families.   
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Study design 
This study directly follows the investigation on the evolution of the oxidation of protein cysteine 
residues (see Part 2, Chapter 1). Briefly, five ECs were followed throughout the storage period, 
and reversibly oxidized cysteine residues were labeled by IR maleimide dyes. Redox-DIGE 
analyses allowed discriminating several protein populations according to the evolution of their 
cysteine-related oxidative state. Spots of interest were excised from Coomassie Blue stained 2D-
gels and contained proteins were digested prior to peptide fractionation and sequencing 
through LC-MS/MS experiments. Proteins corresponding to differentially storage-affected 
cysteine residues were identified by database searching. Proteomes corresponding to the 
different categories of oxidation evolution were analyzed relatively to engaged molecular 
functions. The workflow is pictured out on Figure 1 in Part 2, Chapter 1. 
Material and methods 
Spot excision, in-gel tryptic digestion and peptide extraction 
Spots of interest were manually excised as depicted in Figure 23, from Coomassie Blue-stained 
2D gel corresponding to the mix [Day 6 + Day 41] from the EC5 (see details in annex A). The gel 
pieces were then washed in 50/50 ethanol/50 mM ammonium bicarbonate (AB) pH 8.4, until 
getting destained. Proteins were then reduced and alkylated during one hour with 10 mM 
dithioerythritol (DTE) in 50 mM AB pH 8.4 and during 45 minutes with 55 mM iodoacetamide 
(IAA) in 50 mM AB pH 8.4, respectively, at 37 °C under shaking and protected from light. 
Proteins were digested by incubating the spots in a 12.5 ng/μL trypsin solution in 50 mM AB pH 
8.4, 10 mM calcium chloride, over night at 37 °C under shaking. Tryptic peptides were finally 
extracted from the spots by shrinking the gel pieces in a 5 % formic acid (FA) solution containing 
increasing concentrations of ethanol. Peptide extracts were vacuum centrifuged upon dryness, 
washed in 100 % acetonitrile (ACN), and stored as dried pellets at -30 °C until use. 
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Figure 23: 2DE spot excision for MS-based identification of proteins presenting storage-related changes in cysteine oxidation 
status. Spots of interest were detected thanks to densitometric analysis of 2D gels from 5 biological replicates (10 2D gels, 
giving access to 20 2D gel images, see details in Part 2 Chapter 1), and were excised from coomassie-blue stained 2D gel of 
the mix [day 6 + day 41] from EC5. First dimension was a 7 cm long 3-10 non linear pH gradient and 2
nd
 dimension was a 4-15 
% polyacrylamide precast minigel. Spot tags are the matchID assigned by ImageMaster during the manual spot matching 
step. Labels on the left side of the gel are molecular weights (in kDa) of the protein ladder. 
 
LC-MS/MS analysis 
Proteins identification was carried out on a LC system (Dionex™ UltiMate™ 3000-RSLCnano 
System, Thermo Scientific, Rockford, IL, USA) coupled to a MS (amaZon ETD, Bruker Daltonics, 
Bremen, Germany). Peptide extracts were resuspended in 2 % ACN, 20 % FA, and halves of 
extracts were loaded on a Dionex Acclaim PepMap RSLC column (300 μm x 15 cm, C18, 2 μm, 
100 Å) at a 4 μL/min rate in 95 % eluent A (0.1 % FA aqueous solution) and 5 % of eluent B 
(dH2O/CAN/FA 2/8/0.8). Peptides were separated through a 40 minutes gradient, rising to 25 % 
of eluent B in 30 minutes, then to 40 % in 5 minutes, and finally to 90 % in 10 minutes. Mass 
spectra of separated peptides were acquired in the positive scan mode from 300 to 1500 m/z. 
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An automatic MS/MS CID fragmentation was performed on the three most intense precursor 
ions of each spectrum. Precursor ions were excluded from MS/MS fragmentation after 
appearance in 1 spectrum, and released after 0.15 minute. Precursors presenting a 5 % increase 
in instensity during their exclusion time were reconsidered for fragmentation then again 
excluded. 
Data processing, database query and functional comparison 
Once an LC-MS/MS run has finished, data are automatically processed in DataAnalysis (Bruker 
software for LC-MS data analysis). The process consists in compounds detection, mass spectra 
deconvolution, and exportation of the compound list. Compounds are all detected peaks. 
Parameters for automatic data processing were set as follows: only the 2000 most intense 
compounds were taken into account.  
Spectra were submitted via Mascot to database search with the following parameters: Database 
= SwissProt; Taxonomy = Homo sapiens (human); Enzyme = Trypsin, allow up to 1 missed 
cleavage; Variable modifications = Methionine oxidation, Cysteine NEM-alkylation, Cysteine 
DY680 maleimide labeling, Cysteine DY780 maleimide labeling; Peptide tolerance = ± 0.35 Da; 
MS/MS tolerance = ± 0.35 Da; Peptide charge = 2+, 3+ and 4+. Proteins were automatically 
validated for Mascot scores above 40, and a manual validation was applied to consider only 
proteins identified from at least 2 peptides. 
Identified proteins were submitted to GO analysis using Blast2GO®, an on-line software for 
functional annotation of sequences and analysis of annotation data (www.blast2go.com) [16]. 
Protein fasta sequences were thus loaded, submitted to blast search, mapped and annotated 
(GO annotation, InterPro annotation and enzyme code annotation) in order to assign molecular 
functions to sequences. Sub-proteomes corresponding to the previously determined categories 
of evolution of cysteine residues redox state (see Part 2 Chapter 1) were compared based on 
molecular function. 
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Results and discussion 
 
Among the 32 spots presenting storage-related variation in IR signal (labeling of reversibly 
oxidized cysteines), 43 proteins were identified. Table 2 summarizes the identification of these 
proteins, presenting the percentage of sequence coverage, the number of sequenced peptides, 
and the Mascot score attributed to the identification. For each protein, these parameters are 
shown for its global identification (merged LC-MS/MS data from all spots, proteins classified by 
accession number) as well as in an individual spot manner (for each protein, the spots in which 
it has been identified are organized based on the highest Mascot score). 
It appears that some proteins were identified in several spots that presented different evolution 
of labeling intensity over the storage period. This can be due to the proximity of spots on mini 
2D gels, making possible the detection of traces of a protein in adjacent spots. Also, the 
existence of protein isoforms (variants of a protein presenting pI shifts on 2D gels) allows the 
detection of a protein in several distinct spots. Finally, even if the pI-mass combination gives a 
good protein separation, spots can easily contain several proteins, sharing identical pI-mass 
couple, or at least showing the same migration behavior in the two dimensions. Two or more 
proteins being differentially affected by cysteine oxidation along the RBC storage can thus be 
found in a single spot. The most abundant protein can thus mask the labeling signal of others, 
and all proteins in such a spot can be falsely assigned to a given category of evolution of 
cysteine oxidation. For instance, the protein flavin reductase (NADPH) was identified in spots 
belonging to each of the four categories of evolution of cysteine oxidation (see Table 2). 
However, it was much better identified in the “up” category, regarding number of sequenced 
peptides and sequence coverage, though these parameters cannot be considered as 
quantitative. 
In Part 2 Chapter 1, the spots of interest were classified into 4 categories corresponding to 
different evolution of signal intensity, thus different evolution of cysteine oxidation status 
throughout the RBCs storage period. As shown in Figure 24, more than half (56 %) of identified 
proteins present a category-related specificity. Particularly, 30 % and 16 % of identified proteins 
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are specific to the “down” and “up” categories, respectively. Moreover, it is noteworthy that 
only one protein, the above-mentioned flavin reductase (NADPH), was commonly identified in 
all the four determined categories. These elements are interestingly concordant with our 
working hypothesis about protein sub-populations being differentially affected by oxidative 
damages during RBC storage. 
 
 
Figure 24: Venn diagram of identified proteins showing a storage-induced change in their cysteine oxidation state. 43 
proteins were identified, of which 55 % are category-specific. 
 
The molecular functions involved through identified proteins were investigated by gene 
ontology annotation (GO annotation), and are presented in Figure 25. From the list of all the 43 
identified proteins presenting variation of cysteine redox status over storage, it appears that 
binding and catalytic activities were the two mostly represented molecular functions, 
corresponding to 36.7 and 30.3 % of assigned functions, respectively (see Figure 25A). 
Antioxidant and enzyme regulation activities were also well represented with both 6.4 % of 
assigned functions (see Figure 25A). When looking at proteins identified in each category, some 
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changes in molecular function proportions were clearly observed. Proteins belonging to the 
“down” category (decrease of labeling signal over storage, see Figure 25B) showed an increase in 
enzyme regulation activity (+32 %). However, dealing with proteins specific to this category, it 
appears that antioxidant and enzyme regulation activities were down-represented (-42% each), 
and catalytic activity up-represented (+35 %), as shown in Figure 25F. Concerning the “mid-
down” category (decrease of labeling signal until day 27 then increase until day 41), the whole 
pool of identified proteins showed an increase in proportions of catalytic (+65 %) and 
antioxidant (+95 %) activities (see Figure 25C). Only one protein was specifically identified in this 
category (L-lactate dehydrogenase B chain) and the annotation process revealed equally 
distributed binding, catalytic and structural molecule activities (see Figure 25G). Dealing with the 
“mid-up” category (increase of labeling signal until day 27 then decrease until day 41), the 
proportions of the four above-mentioned mostly represented molecular functions are increased 
by 17 %, 18 %, 11 % and 67 %, respectively. Others under-represented molecular functions were 
not assigned in this category, except transporter activity (3.57 %, see Figure 25D). Only three 
proteins were specific to the “mid-up” category (coiled-coil domain-containing protein 158, 
probable phosphoglycerate mutase 4 and selenium-binding protein 1). These 3 proteins, as 
shown in Figure 25H, only involved binding and catalytic activities, increased by 82 % and 10 %, 
respectively, in comparison to the mean global molecular functions repartition. Finally, the “up” 
category (increase of the labeling signal from day 6 to day 41) showed nearly the same mean 
distribution of molecular functions, except for the antioxidant activity which was increased by 
91% and the enzyme regulation activity which was lowered by 36 % (see Figure 25E). As for the 7 
proteins specifically identified in this category, Figure 25I shows that the catalytic and enzyme 
regulation activities were decreased by 21 and 26% respectively, and that the antioxidant and 
transporter activities were increased by 48 and 107 %, respectively. 
To assess molecular functions differentially affected by cysteine oxidation, it is better to work 
with data that are specific to the categories of evolution of this oxidative modification. Due to 
the low number of proteins specifically identified in the “mid-down” and “mid-up” categories, 
the proportions of engaged molecular functions in these two groups will not be taken into 
account. As for the “down” group, where IR labeling signal of reversibly oxidized cysteines 
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Figure 25: Repartition of molecular functions in differentially cysteine-oxidized protein populations in stored RBCs. Diagram A represent the repartition in the whole 
identified cysteine redox proteome. Diagrams B to I represent the repartitions in the “down” (B and F), “mid-down” (C and G), “mid-up” (D and H) and “up” (E and I) 
categories, either for all proteins identified in these categories (B to E) or for proteins specific to each category (F to I). The bracketed numbers following some “0 %”-labels 
indicate that number of following unrepresented molecular functions, according to the ranking in the legend. Under each diagram is the number of identified proteins. The 
color shading in the legend should be read from left to right then top to down. 
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tended to decrease or disappear with the storage period, the hypotheses are either the increase 
of irreversible sulfonic cysteine oxidation state and/or the degradation of these oxidized 
proteins. Catalase was the unique protein involved in RBC antioxidant defenses to be specifically 
identified in this group. It represented a lower part of antioxidant (AO) proteins than in the 
entire group of identified proteins (9 % of annotated sequences vs. 17 %). Moreover, despite the 
higher abundance of proteins showing a catalytic activity (100 % of annotated sequences vs. 82 
%), proteins related to a catalytic oxidoreductase (OR) activity were lowered in this group (27 % 
of annotated sequences vs. 32 %). Some oxidoreductases are involved in direct as well as 
indirect AO defenses. Here, three OR proteins were identified: catalase, biliverdin reductase A 
(BIEA) and GDP-L-fucose synthase (FCL). The former is part of RBCs AO defenses, dismutating 
hydrogen peroxide into water and molecular oxygen [17]. The second is involved in porphyrin 
metabolism, allowing the NAD(P)H-dependent reduction of the hemoglobin-catabolism product 
biliverdin into bilirubin [18]. The latter acts in the fructose and mannose metabolism pathway, 
converting GDP-4-oxo-6-deoxy-D-mannose into GDP-L-fucose, in an NADPH-dependent manner 
[19]. MS/MS data that allowed us to identify the catalase protein revealed sulfonic acid state on 
Cys-460 from day 41 samples, but not from days 6 and 27 ones, from which only chemical 
alkylation of Cys-460 was observed (data not shown). This means that catalase Cys-460 was 
either unmodified or reversibly oxidized during the 4 first weeks of storage, then became 
irreversibly oxidized by the end of RBCs banking, supporting the redox-DIGE information of a 
storage time-dependent irreversible cysteine oxidation. As for BIEA and FCL, MS/MS analysis did 
not reveal cysteine sulfonic acid state due to the absence of sequenced cysteine-containing 
peptide. These two proteins were also identified in other analyses that did not involve any 
chemical cysteine modification. No Cys-peptide was sequenced as well. It is possible that 
intrinsic properties of these Cys-peptides prevent their correct ionization thus detection by MS. 
Another explanation could be that other storage-related modifications, such as the 
carbonylation of amino acids in the near area of cysteines, prevent the good MS/MS assignment 
of these peptides. 
Contrary to the “down” category, proteins from the “up” group, characterized by an increase of 
the IR labeling signal, could find an explanation in the accumulation of reversibly cysteine-
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oxidized protein copies. This group was characterized by a decrease in catalytic activity 
proportion (62 % of annotated sequences versus 82 % for the pool of all the 43 identified 
proteins in this study) and an increase in AO activity proportion (25 % of annotated sequences 
versus 17 %). As for the catalytic activities, of interest is the absence of constituent of isomerase 
and transferase activities in comparison to the mean function distribution (were 12 % and 20 % 
of annotated sequences, respectively). However, the catalytic lyase activity proportion was 
found increased (25 % of annotated sequences versus 15 %). Peroxiredoxin-1 (Prdx1) and 
protein DJ-1 were the two identified constituents of both OR and peroxidase antioxidant activity 
groups. If the proportion of the former was found to be slightly decreased in the “up” category, 
the latter was found increased by a factor 2 (both 25 % of annotated sequences versus 32 and 
12 %, respectively). Prdx1 is a 2-cysteines thioredoxin peroxidase that reduces peroxides with 
concomitant homodimerization through sulfenyl formation at the peroxidatic cysteine (Cys-52) 
and inter-molecular disulfide bridging with the resolving cysteine (Cys-173) of another subunit 
[20]. The enzyme is regenerated via reduction by thioredoxin. In the case of Prdx1, cysteines are 
thus essential for the antioxidant activity. It can happen that the peroxidatic cysteine (Cys-52) 
goes further oxidized into sulfinic and even sulfonic states upon oxidative stress. The Cys-SO2H 
can be reduced by sulfiredoxins whereas Cys-SO3H cannot. Throughout the storage period, it 
seems that this enzyme was accumulating in still reversible oxidized form. It cannot be here 
distinguished whether the accumulation concerns Cys-SOH or Cys-SO2H, so it can be 
hypothesized a progressive defect of thioredoxin and/or sulfiredoxin, preventing the 
regeneration of prdx1 in its active form. 
As for the protein DJ-1, it is known to prevent oxidative stress-induced cell death by eliminating 
hydrogen peroxide in an atypical peroxiredoxin-like peroxidase activity [21] and by displaying a 
cysteine protease activity through removal of a 15-amino acid C-terminal peptide [22]. Protein 
DJ-1 contains three cysteine residues. In particular, the Cys-106 residue is responsible for 
cytoprotection against oxidative stress, and is easily oxidized (for a review on the role of 
cysteine oxidation in DJ-1 function, see [23]). Though it is not clearly stated in the literature, it 
can be hypothesized that Cys-106 oxidation would alter protein DJ-1 ability to take over H2O2 
thus to protect cell from oxidative stress. Moreover, MS/MS analysis allowed detecting 
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carbamidomethylation of Cys-46 throughout the storage period (data not shown). This 
modification is the result of the chemical alkylation of reduced cysteines, and sustains the 
redox-DIGE information of reversible cysteine oxidation on this protein. 
This proteomic analysis of storage-induced cysteine-oxidized soluble proteome revealed 
differences in the proportions of molecular functions engaged through reversibly or irreversibly 
oxidized proteins, as suggested by the different evolutions of labeling intensity shown in Part 2 
Chapter 1. In particular, proteins presenting AO activity appear more prone to reversible 
oxidation of their cysteine-containing active sites, which would suggests a preserved AO activity 
potential in stored RBCs. 
 
Table 2: Proteomic identification of proteins showing a storage-dependent variation of cysteine oxidation status. 
Name AC # 
Global analysis Spots analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Match 
ID 
Intensity 
evolution 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Acylamino-acid-
releasing enzyme 
ACPH_HUMAN 19.3 10 559.91 111 Down 16.5 10 558.91 
Actin, cytoplasmic 1 ACTB_HUMAN 19.5 3 198.93 111 Down 9.9 3 179.83 
Retinal 
dehydrogenase 1 
AL1A1_HUMAN 38.1 13 497.33 
113 
114 
112 
Mid-up 
Down 
Down 
25.1 
17.2 
9.8 
11 
6 
4 
457.03 
291.99 
192.90 
Serum albumin ALBU_HUMAN 18.7 10 336.55 
127 
137 
113 
5 
133 
120 
4 
114 
125 
104 
Mid-up 
Down 
Mid-up 
Up 
Up 
Down 
Down 
Down 
Down 
Down 
12.6 
4.3 
3.1 
4.8 
1.8 
1.8 
3.0 
3.1 
1.8 
1.8 
8 
2 
2 
3 
1 
1 
2 
2 
1 
1 
264.99 
114.09 
112.19 
111.33 
98.67 
69.13 
68.40 
61.35 
56.97 
56.93 
Apolipoprotein A-I APOA1_HUMAN 20.2 4 157.07 
106 
120 
117 
Down 
Down 
Down 
13.5 
8.6 
4.5 
3 
2 
1 
100.29 
90.16 
49.23 
Biliverdin reductase A BIEA_HUMAN 25.3 5 183.95 107 Down 16.6 4 161.61 
Flavin reductase 
(NADPH) 
BLVRB_HUMAN 65.0 12 857.49 
115 
130-2 
130-1 
0 
103 
132 
Up 
Up 
Up 
Mid-up 
Down 
Mid-down 
65.0 
50.5 
50.5 
18.9 
21.8 
7.3 
12 
11 
9 
4 
2 
1 
835.29 
738.02 
542.79 
168.42 
133.90 
59.40 
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Name AC # 
Global analysis Spots analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Match 
ID 
Intensity 
evolution 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Carbonic anhydrase 1 CAH1_HUMAN 70.9 15 1002.17 
124 
116 
123 
5 
130-1 
118 
117 
133 
115 
0 
114 
Mid-up 
Up 
Mid-up 
Up 
Up 
Down 
Down 
Up 
Up 
Mid-up 
Down 
61.7 
70.9 
70.9 
24.1 
13.4 
15.3 
8.0 
8.8 
11.9 
8.0 
4.6 
14 
14 
14 
6 
4 
5 
3 
2 
3 
2 
1 
926.13 
869.77 
794.63 
312.43 
223.78 
221.60 
163.65 
118.31 
117.01 
99.41 
49.54 
Carbonic anhydrase 2 CAH2_HUMAN 7.3 2 106.03 116 Up 7.3 2 106.03 
Carbonic anhydrase 3 CAH3_HUMAN 21.2 2 107.35 116 Up 11.2 2 107.35 
Catalase CATA_HUMAN 26.9 10 462.88 
114 
118 
117 
Down 
Down 
Down 
15.7 
12.5 
1.9 
7 
6 
1 
358.56 
247.83 
42.75 
Coiled-coil domain-
containing protein 158 
CD158_HUMAN 1.4 1 70.18 123 Mid-up 0.8 1 41.51 
Alpha-enolase ENOA_HUMAN 30.9 11 445.35 
117 
118 
Down 
Down 
29.5 
18.9 
10 
6 
435.09 
199.36 
GDP-L-fucose 
synthase 
FCL_HUMAN 16.2 4 124.85 107 Down 11.8 3 113.30 
Fibrinogen beta chain FIBB_HUMAN 31.6 8 495.35 
114 
113 
Down 
Mid-up 
17.7 
10.4 
7 
5 
452.84 
167.51 
Fumarate hydratase, 
mitochondrial 
FUMH_HUMAN 2.4 1 42.43 117 Down 2.4 1 42.43 
Glucose-6-phosphate 
1-dehydrogenase 
G6PD_HUMAN 4.7 1 99.92 
113 
114 
Mid-up 
Down 
2.1 
2.1 
1 
1 
66.42 
50.42 
Rab GDP dissociation 
inhibitor beta 
GDIB_HUMAN 50.6 17 778.93 
6 
103 
104 
Mid-up 
Down 
Down 
44.5 
17.1 
2.5 
17 
5 
1 
755.19 
192.42 
55.87 
Hydroxyacylglutathion
e hydrolase, 
mitochondrial 
GLO2_HUMAN 6.5 2 73.96 116 Up 6.5 2 73.96 
Glutathione S-
transferase omega-1 
GSTO1_HUMAN 33.4 8 327.32 
133 
3 
Up 
Mid-down 
34.4 
25.7 
8 
6 
259.97 
229.39 
Delta-aminolevulinic 
acid dehydratase 
HEM2_HUMAN 8.8 2 108.84 
132 
5 
107 
Mid-down 
Up 
Down 
8.8 
8.8 
8.8 
2 
2 
2 
108.84 
78.77 
67.98 
Hypoxanthine-
guanine 
phosphoribosyltransfe
rase 
HPRT_HUMAN 33.5 6 368.47 
1 
0 
Down 
Mid-up 
26.1 
20.2 
6 
4 
317.24 
226.25 
Heat shock cognate 71 
kDa protein 
HSP7C_HUMAN 5.0 2 92.12 111 Down 3.4 2 75.70 
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Name AC # 
Global analysis Spots analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Match 
ID 
Intensity 
evolution 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
L-lactate 
dehydrogenase B 
chain 
LDHB_HUMAN 19.2 1 156.76 132 Mid-down 4.5 1 140.79 
Malate 
dehydrogenase, 
cytoplasmic 
MDHC_HUMAN 16.2 5 187.09 
5 
132 
Up 
Mid-down 
13.2 
9.6 
4 
3 
148.92 
81.44 
Protein DJ-1 PARK7_HUMAN 43.4 5 172.01 2 Up 35.4 5 172.01 
Phosphatidylethanola
mine-binding protein 
1 
PEBP1_HUMAN 35.3 4 137.80 115 Up 27.3 4 137.80 
Probable 
phosphoglycerate 
mutase 4 
PGAM4_HUMAN 12.6 3 153.89 
124 
123 
Mid-up 
Mid-up 
12.6 
12.6 
3 
2 
133.88 
76.55 
Protein-L-
isoaspartate(D-
aspartate) O-
methyltransferase 
PIMT_HUMAN 21.6 4 162.99 1 Down 21.6 4 162.99 
Phosphatidylinositol 
transfer protein alpha 
isoform 
PIPNA_HUMAN 5.9 1 53.38 5 Up 3.7 1 53.38 
Bisphosphoglycerate 
mutase 
PMGE_HUMAN 37.5 7 397.80 
133 
0 
Up 
Mid-up 
29.7 
7.3 
7 
1 
397.80 
40.84 
Purine nucleoside 
phosphorylase 
PNPH_HUMAN 21.5 6 244.70 
132 
5 
Mid-down 
Up 
21.5 
11.8 
6 
3 
224.03 
95.24 
Peroxiredoxin-1 PRDX1_HUMAN 16.1 3 153.44 115 Up 13.6 3 111.92 
Peroxiredoxin-2 PRDX2_HUMAN 49.0 10 683.10 
4 
2 
99 
Down 
Up 
Mid-down 
40.9 
40.9 
40.9 
10 
10 
10 
614.71 
561.12 
549.03 
Peroxiredoxin-6 PRDX6_HUMAN 77.7 20 1164.10 
0 
1 
133 
Mid-up 
Down 
Up 
74.1 
62.9 
15.6 
20 
14 
3 
1125.75 
688.44 
111.04 
Serine/threonine-
protein phosphatase 
2A activator 
PTPA_HUMAN 20.9 4 169.31 120 Down 12.8 4 169.31 
Bifunctional purine 
biosynthesis protein 
PURH 
PUR9_HUMAN 15.2 5 202.17 135 Down 9.3 5 192.69 
Ras-related protein 
Rap-1b 
RAP1B_HUMAN 26.1 3 151.24 
99 
4 
Mid-down 
Down 
17.9 
6.5 
3 
1 
151.24 
96.61 
Adenosylhomocystein
ase 
SAHH_HUMAN 17.6 5 223.43 
7 
6 
Down 
Mid-up 
14.1 
6.7 
5 
3 
192.07 
97.80 
Selenium-binding 
protein 1 
SBP1_HUMAN 44.9 15 743.20 
127 
113 
Mid-up 
Mid-up 
38.6 
11.9 
15 
5 
743.20 
230.92 
Stress-induced-
phosphoprotein 1 
STIP1_HUMAN 6.4 3 127.22 
122 
137 
Down 
Down 
5.2 
1.8 
3 
1 
87.08 
76.74 
Transaldolase TALDO_HUMAN 9.8 2 105.41 
107 
120 
Down 
Down 
3.3 
6.5 
1 
2 
68.50 
60.24 
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Name AC # 
Global analysis Spots analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Match 
ID 
Intensity 
evolution 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Triosephosphate 
isomerase 
TPIS_HUMAN 46.5 11 535.92 
124 
123 
133 
0 
Mid-up 
Mid-up 
Up 
Mid-up 
46.5 
31.8 
15.4 
5.2 
11 
7 
3 
1 
521.88 
384.60 
89.19 
59.62 
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Chapter two 
 
Characterization and qualitative evolution of the storage-induced red 
blood cell carbonylome 
 
 
 
 
 
 
 
This chapter refers to the article 
 
“Proteomics of the red blood cells carbonylome during banking of erythrocyte concentrates” 
 
In preparation  
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Study design 
Soluble and membrane extracts from day 6, day 27 and day 41 collected ECs (see Annex A for 
details) were submitted to carbonyl derivatization with a biotin derivative, allowing their 
purification by mean of avidin-biotin affinity. Purified proteins were then separated by SDS-
PAGE, and identified by LC-MS/MS analyses. Carbonylome was analyzed and compared at each 
storage duration, relatively to engaged molecular functions and biological processes. The 
workflow is described in Figure 26. 
 
 
Figure 26: Study design for the analysis of the carbonylome in stored RBCs. Hb-depleted soluble fraction, integral protein 
membrane fraction and cytoskeleton membrane fraction were obtained from three ECs at days 6, 27 and 41 of the storage 
period. Proteins bearing functional carbonyl group(s) were derivatized with biotin-hydrazide and purified via affinity with 
monomeric avidin-coupled magnetic beads. Captured proteins were separated by SDS-PAGE and identified by LC-MS/MS 
analysis. Automatic GO annotation allowed the comparison stored RBCs carbonylome along the storage period. 
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Material and methods 
Sample collection and preparation 
Samples were collected at day 6, 27 and 41 from the same three ECs utilized for cysteine 
oxidation investigations. The preparation of Hb-depleted soluble extracts and integral and 
cytoskeleton membrane extracts is extensively detailed in the Part 2, Chapter 2. Briefly, washed 
collected RBCs were submitted to hypotonic lysis, cytoplasm and membranes were separated by 
ultracentrifugation, soluble fraction was depleted in hemoglobin by IMAC, membranes were 
washed of any residual soluble components and membrane proteins were sequentially 
extracted by a non-ionic then an ionic detergent-containing buffer, solubilizing integral and 
cytoskeleton membrane proteins, respectively. The soluble Hb fraction was not investigated 
here. 
Derivatization of carbonylated proteins 
Five hundred μg of protein extract were submitted to protein carbonyl derivatization by 
incubation with 1 sample volume of a 10 mM Biotin-Hydrazide (BHZ) solution, during 1 hour at 
room temperature. The derivatization reaction was then stabilized through 40 minutes 
incubation with 2 sample volumes of a 30 mM CH3BNNa solution on ice. Afterwards, excess of 
BHZ was removed by 3 concentration-dilution cycles (final dilution factor @ 1000), realized by 
centrifuge-driven filtration through 5000 MWCO-PES membranes. 
Affinity-purification of derivatized proteins 
Derivatized proteins were then purified using the biotin-avidin affinity. Samples were incubated 
with an excess of monomeric avidin-coated magnetic beads (Bioclone Inc, USA), during 1 hour 
at room temperature under slight agitation. The flow-through was collected, and beads were 
washed 3 times with 1x PBS. Then, captured proteins were eluted by incubating beads with 2 
mM D-Biotin in PBS during 10 minutes, followed by another 10 minutes-incubation with 0.1 M 
Glycine, pH 2.8, both under agitation at room temperature.  
1D-SDS-PAGE fractionation of purified proteins 
Eluates were pooled, proteins were TCA-precipitated and acetone-washed. The entire pellets 
were resuspended in Laemmli buffer and loaded onto precast SDS-PAGE gels (Mini-PROTEAN 
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TGX Gels 4-15%, BIO-RAD, Hercules, USA). Unbound material (flow through, 20 μg) as well as 5 
μL of BenchMark Protein Ladder was also loaded. Electrophoresis was performed in a 
Tris/Glycine/SDS buffer at constant 120 V for 5 minutes then constant 300 V until complete 
migration. Total proteins were finally revealed by Coomassie Blue staining. 
LC-MS/MS identification of carbonylated proteins 
Eluates migration lanes were cut in several pieces and some bands were also cut individually. 
The pre-analytics for LC-MS/MS identification is widely described in Chapter 1. Briefly, gel pieces 
were destained, proteins were submitted to reduction, alkylation and trypsin-driven digestion. 
Peptides were extracted, washed, and dried-stored prior to analysis. LC-MS/MS protein 
identifications were carried out as described in Chapter 1, except that no cysteine-labeling was 
considered as variable modification for database searching. In addition, no variable modification 
for specific detection of carbonylation was included, due to the high variation of existing 
modifications. Sites of carbonylation will thus not be assessed here, and carbonylated peptides 
will not be sequenced. As a consequence, the sequence coverage is inversely proportional to 
the amount of carbonylation. 
At each storage point, only proteins that were identified in at least 2 out of the 3 biological 
replicates were considered as truly representative of the condition. List of proteins were 
submitted to GO annotation using Blast2GO®. 
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Results and discussion 
Storage-related evolution of SDS-PAGE patterns of soluble and membrane carbonylome 
One dimensional electrophoresis patterns of carbonylated proteins purification (eluates and 
flow through) from Hb-depleted soluble fraction and DDM-soluble membrane fraction of three 
ECs stored for 6, 27 and 41 days are presented in Figure 27. Focusing on soluble carbonylated 
proteins (Figure 27A), it is noteworthy that SDS-PAGE patterns at day 41 presented clear 
differences from days 6 and 27 samples, for each of the three ECs studied. In particular, a loss of 
content of more than 80 kDa was clearly observed. This is also, at a lower extent, the case for 
the unbound material (Figure 27B). This phenomenon inducing a loss of soluble high MW 
carbonylated content should thus be due to a storage-dependent mechanism. However, it does 
not seem concordant with quantitative analysis presented in Part 2, where a quantitative 
decrease of soluble carbonylated content was highlighted in the beginning of the storage period 
and not in the end. Some SDS-PAGE pattern differences were also detected at day 41 with the 
appearance of novel bands at 40 kDa and just below 20 kDa as well as a clear intensity decrease 
of the band just below 40 kDa. 
Concerning DDM-soluble membrane carbonylated proteins, the SDS-PAGE patterns presented in 
Figure 27C do not reveal difference between storage duration. One can only note the appearance 
of a novel band at around 35 kDa, but only for the three samples from EC2. What should be 
noted is that the global patterns of carbonylated membrane proteins differed from a classic 
pattern of DDM-soluble RBCs membrane proteins (see Annex B), which much looks like the 
pattern of unbound membrane material, shown in Figure 27D. In particular, the highly abundant 
Band 3 protein (diffused band around 100 kDa) appeared very lowered in intensity in 
carbonylated protein samples (Figure 27C), suggesting that most copies of this protein should not 
suffer from carbonylation modification. Enrichment of altered Band 3 in microvesicles released 
during RBCs storage could probably explain this observation [24]. 
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Figure 27: 1D electrophoresis patterns of the purification of carbonylated proteins in soluble and membrane extracts of 
stored RBCs. All purified carbonylated protein contents stemming from 500 μg of Hb-depleted soluble extracts (A) and DDM-
soluble membrane extracts (C), as well as 20 μg of corresponding unbound proteins (B and D respectively) were submitted to 
SDS-PAGE on 4-15 % precast mini-gels and proteins were revealed by Coomassie Blue staining. 
 
RBCs soluble storage-related carbonylome 
Migration lanes of the 9 samples of soluble carbonylated proteins (3 ECs x 3 storage durations) 
were cut in 5 gel pieces so that bands were mostly equally distributed, avoiding overabundance 
issue. Proteins in each gel pieces were destained, trypsin-digested, and peptides were 
resuspended in LC-MS-compatible buffer for LC-MS/MS analyses. A total of 142 proteins were 
identified. Table 3 summarizes the identification parameters of each protein in a global analysis 
(merged LC-MS/MS data from all gel pieces). Proteins are sorted according to their accession 
number. Then for each protein, identification parameters are presented per storage duration. 
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For each storage duration, a protein was validated if identified in at least 2 out of the 3 
biological replicates (3 ECs). As shown in the Venn diagram representation (see Figure 28), lots of 
identified proteins were common either between the 3 storage durations (28 %) or between 
days 6 and 27 (38 %). Only 56 proteins were identified at day 41. This low number seems 
obvious regarding SDS-PAGE pattern differences above-highlighted (see Figure 27A). Day 6 
samples allowed the specific identification of 16 % of proteins, whereas days 27 and 41 samples 
revealed only 6 and 4 % of specific proteins, respectively. A few proteins (5 %) were commonly 
identified in days 27 and 41 samples, and 2 % of identified proteins appeared to be common to 
days 6 and 41 samples. 
 
Figure 28: Venn diagram of cytosolic carbonylome during RBCs storage. 142 proteins were identified, of which 27.6 % present 
storage-time specificity. 28.3 % of identified proteins are found throughout the storage period. 83.4 % and 76.6 % of 
carbonylated proteins are detected at days 6 and 27 respectively, whereas there is a clear decrease in carbonylome content 
at day 41 (only 40.7 % of identified proteins). 
 
Molecular functions engaged with identified soluble carbonylated proteins were investigated by 
GO annotation. Figure 29 shows the repartition of these molecular functions for the entire pool 
of identified proteins as well as for all proteins identified in each storage duration sample, and 
for the proteins that were specifically identified in each storage duration. The mean distribution 
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(Figure 29A) revealed a high part of binding and catalytic activities (46.4 and 44.7 %, 
respectively). Others molecular functions are antioxidant activity (3.4 %), enzyme regulation 
activity (1.7 %) and transporter activity (1.1 %). When looking at proteins identified without 
specificity for days 6, 27 and 41 samples (Figure 29B, C and D, respectively), this repartition 
appears quite similar to the mean one. There is however a tendency over the storage period of 
increasing part of the catalytic activity in disfavor of the binding activity. In addition, the 
proportion of annotated sequences related to antioxidant activity showed a 2-fold increase, 
from 2.6 % at day 6 to 5.2 % at day 41. This is interestingly concordant with the results of 
cysteine oxidation concerning the category of spots showing an increasing labeling signal (“up” 
group) where annotated sequences related to a peroxidase-antioxidant activity were twice as 
abundant as in the main distribution. 
When dealing with carbonylated proteins specifically identified in the different storage 
durations (Figure 29E, F and G for days 6, 27 and 41, respectively), the repartition diagrams 
appeared very different compared to the main distribution (Figure 29A). The binding-related 
annotated sequences decreased from 48.9 % at day 6 to 36.8 % at day 41, with a main decrease 
in the first half of the storage (31.8 % at day 27). On the contrary, catalytic activity shows an 
increasing proportion from 24.4 % at day 6 to 36.8 % at day 41, with a main increase during the 
first half of the storage period too (36.4 % at day 27). As for antioxidant activity proportion, it 
was null at day 6, then increased to reach 13.6 % at day 27 and was finally decreased at 5.3 % at 
day 41. It thus seems that soluble antioxidant proteins undergo high carbonylation events 
during the first half of the storage period, then part of them are somehow processed making 
more difficult to purify them from soluble extracts of end-stored RBCs. When looking at 
oxidoreductase activity-related proteins (comprising the antioxidant ones), 15 proteins were 
identified as carbonylated at day 6, 18 proteins at day 27 and 12 proteins at day 41. Nine OR 
proteins were carbonylated throughout the storage period (6PGD, AL1A1, CATA, DCXR, LDHB, 
PRDX1, PRDX2, PRDX6 and THIO), 4 OR proteins were carbonylated at days 6 and 27 (A16A1, 
Al9A1, CBR1 and G3P), but were not identified at day 41, and 2 OR proteins were not found 
carbonylated at day 6 but were identified at days 27 and 41 (BIEA and LDHA).
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Figure 29: Repartition of molecular functions corresponding to cytosolic carbonylated proteins during RBCs storage. Diagram A represents the repartition of molecular 
functions for all identified soluble carbonylated proteins. Diagrams B to G represent the repartitions at days 6, 27 and 41, either for all proteins identified at each day (B, C 
and D, respectively) or for proteins that were specifically identified at each day (E, F and G, respectively). The bracketed numbers following some “0 %”-labels indicate that 
number of following unrepresented molecular functions, according to the ranking in the legend. Under each diagram figured the number of identified proteins. The color 
shading in the legend should be read from left to right then top to down. 
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Table 3: Proteomic identification of the RBC soluble carbonylome during storage 
Name AC # 
Global analysis Storage-time analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score Sample 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
14-3-3 protein epsilon 1433E_HUMAN 57.70 13 651.49 
D6 
D27 
D41 
34.10 
25.90 
55.70 
6 
5 
12 
284.76 
237.92 
617.39 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform 2AAA_HUMAN 25.80 10 470.26 
D6 
D27 
21.40 
24.40 
10 
9 
412.79 
373.76 
6-phosphogluconate dehydrogenase 6PGD_HUMAN 42.00 17 797.82 
D6 
D27 
D41 
32.50 
33.10 
19.90 
13 
11 
7 
581.63 
566.77 
385.31 
Aldehyde dehydrogenase family 16 member A1 A16A1_HUMAN 17.80 12 579.48 
D6 
D27 
17.80 
15.50 
12 
10 
497.92 
406.35 
Abhydrolase domain-containing protein 14B ABHEB_HUMAN 14.30 3 109.01 
D6 
D27 
14.30 
9.50 
3 
2 
99.27 
86.71 
ATP-citrate synthase ACLY_HUMAN 12.30 11 420.55 D6 8.40 8 293.01 
Acylamino-acid-releasing enzyme ACPH_HUMAN 18.70 12 663.99 
D6 
D27 
D41 
16.40 
16.70 
13.90 
10 
12 
10 
517.78 
565.19 
519.68 
Retinal dehydrogenase 1 AL1A1_HUMAN 37.30 19 930.77 
D6 
D27 
D41 
37.30 
35.10 
31.70 
18 
17 
17 
815.64 
806.84 
821.79 
4-trimethylaminobutyraldehyde dehydrogenase AL9A1_HUMAN 15.60 5 279.01 
D6 
D27 
12.80 
14.00 
4 
5 
211.46 
248.26 
Serum albumin ALBU_HUMAN 19.00 10 410.81 
D6 
D27 
D41 
5.40 
11.80 
16.40 
3 
4 
9 
115.34 
194.29 
357.35 
Fructose-bisphosphate aldolase A ALDOA_HUMAN 54.40 18 1050.79 
D6 
D27 
D41 
46.20 
47.80 
52.70 
12 
12 
17 
624.48 
641.48 
944.57 
Protein arginine N-methyltransferase 5 ANM5_HUMAN 12.60 6 292.71 
D6 
D27 
12.60 
6.90 
6 
4 
281.17 
174.86 
ADP-ribosylation factor 4 ARF4_HUMAN 19.30 4 187.96 D6 9.40 2 89.97 
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Name AC # 
Global analysis Storage-time analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score Sample 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Arginase-1 ARGI1_HUMAN 26.40 7 286.46 
D6 
D27 
D41 
17.40 
21.10 
19.90 
4 
4 
7 
192.28 
194.16 
248.49 
Biliverdin reductase A BIEA_HUMAN 37.50 9 379.83 
D27 
D41 
27.40 
37.50 
4 
9 
225.00 
329.85 
Flavin reductase (NADPH) BLVRB_HUMAN 47.10 7 496.15 
D6 
D27 
D41 
35.00 
30.60 
47.10 
4 
4 
7 
309.58 
290.85 
492.05 
Carbonic anhydrase 1 CAH1_HUMAN 61.30 12 674.19 
D6 
D27 
D41 
26.80 
18.80 
61.30 
5 
4 
12 
309.76 
175.59 
674.19 
Carbonic anhydrase 3 CAH3_HUMAN 26.90 4 226.41 D41 26.90 4 226.41 
Calpain-1 catalytic subunit CAN1_HUMAN 21.10 14 650.39 
D6 
D27 
19.30 
18.80 
14 
13 
590.42 
558.77 
Cullin-associated NEDD8-dissociated protein 1 CAND1_HUMAN 33.00 32 1463.17 
D6 
D27 
27.50 
31.10 
26 
28 
1131.33 
1284.39 
F-actin-capping protein subunit beta CAPZB_HUMAN 14.40 3 178.70 
D6 
D27 
6.90 
14.40 
2 
3 
76.09 
176.33 
Catalase CATA_HUMAN 68.10 33 1868.26 
D6 
D27 
D41 
65.70 
62.80 
65.80 
30 
28 
31 
1563.58 
1612.91 
1639.67 
F-actin-capping subunit alpha-1 CAZA1_HUMAN 11.90 2 125.34 
D6 
D27 
11.90 
9.80 
2 
2 
108.90 
101.39 
Carbonyl reductase [NADPH] 1 CBR1_HUMAN 23.50 5 240.24 
D6 
D27 
23.50 
11.20 
5 
2 
240.24 
143.51 
Cell division control protein 42 homolog CDC42_HUMAN 19.90 3 148.74 
D6 
D27 
19.90 
19.90 
3 
3 
135.88 
141.13 
Calcium-regulated heat stable protein 1 CHSP1_HUMAN 28.60 4 118.69 D6 28.60 4 116.40 
Cofilin-1 COF1_HUMAN 60.80 10 477.86 
D6 
D27 
60.80 
57.20 
10 
9 
406.98 
439.90 
COP9 signalosome complex subunit 1 CSN1_HUMAN 7.50 2 119.24 D6 5.50 2 100.11 
COP9 signalosome complex subunit 3 CSN3_HUMAN 12.80 5 216.05 
D6 
D27 
12.80 
10.90 
4 
4 
205.83 
162.57 
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Name AC # 
Global analysis Storage-time analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score Sample 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
COP9 signalosome complex subunit 4 CSN4_HUMAN 26.60 8 387.07 
D6 
D27 
25.40 
20.00 
8 
5 
362.27 
242.09 
COP9 signalosome complex subunit 5 CSN5_HUMAN 7.50 3 121.47 D27 7.50 3 114.30 
COP9 signalosome complex subunit 6 CSN6_HUMAN 16.20 5 166.21 D6 16.20 5 148.45 
Uncharacterized protein C22orf25 CV025_HUMAN 8.30 3 114.51 D41 5.80 2 76.21 
Uroporphyrinogen decarboxylase DCUP_HUMAN 10.60 3 116.48 D41 10.60 3 116.48 
L-xylulose reductase DCXR_HUMAN 48.00 10 431.49 
D6 
D27 
D41 
42.60 
48.00 
20.50 
8 
9 
4 
318.13 
399.31 
172.03 
DNA damage-binding protein 1 DDB1_HUMAN 12.40 12 507.28 D6 11.00 9 405.29 
Protein DDI1 homolog 2 DDI2_HUMAN 38.30 9 472.91 
D6 
D27 
29.30 
36.10 
8 
8 
389.61 
412.38 
Putative deoxyribose-phosphate aldolase DEOC_HUMAN 23.90 5 232.30 
D6 
D27 
20.80 
13.20 
4 
3 
207.25 
154.77 
Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing) DHAK_HUMAN 21.90 9 364.53 
D6 
D27 
19.50 
17.90 
6 
7 
306.39 
256.99 
Alpha-enolase ENOA_HUMAN 54.40 20 913.09 
D6 
D27 
D41 
53.70 
50.90 
42.20 
15 
18 
16 
729.81 
772.31 
723.96 
S-formylglutathione hydrolase ESTD_HUMAN 55.30 10 418.68 
D6 
D27 
D41 
34.80 
35.10 
39.40 
6 
7 
9 
302.85 
287.69 
320.83 
Hsc70-interacting protein F10A1_HUMAN 29.80 9 547.19 
D6 
D27 
29.80 
29.80 
9 
9 
486.41 
482.58 
Fatty acid synthase FAS_HUMAN 5.50 7 425.35 D6 4.00 5 270.74 
F-box only protein 7 FBX7_HUMAN 10.70 5 205.33 D27 3.80 2 92.03 
GDP-L-fucose synthase FCL_HUMAN 11.50 3 142.26 D6 8.10 2 90.75 
Fumarate hydratase, mitochondrial FUMH_HUMAN 19.20 7 293.41 
D6 
D27 
11.60 
14.70 
5 
6 
208.71 
228.84 
Glyceraldehyde-3-phosphate dehydrogenase G3P_HUMAN 54.30 17 898.23 
D6 
D27 
54.00 
50.70 
16 
14 
786.94 
764.75 
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Name AC # 
Global analysis Storage-time analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score Sample 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Hydroxyacylglutathione hydrolase, mitochondrial GLO2_HUMAN 29.90 8 303.51 
D6 
D27 
D41 
22.40 
26.30 
22.40 
5 
7 
6 
179.42 
255.36 
192.17 
Glutaredoxin-1 GLRX1_HUMAN 31.10 3 175.17 D27 31.10 3 173.48 
Glutathione peroxidase 1 GPX1_HUMAN 40.40 8 249.20 D27 40.40 7 220.40 
Glutamate-cysteine ligase catalytic subunit GSH1_HUMAN 20.40 11 481.65 
D6 
D27 
12.90 
19.50 
7 
10 
275.51 
402.32 
Glutathione S-transferase omega-1 GSTO1_HUMAN 38.60 9 425.76 
D6 
D27 
D41 
27.00 
24.10 
38.60 
6 
7 
8 
245.39 
219.55 
418.69 
Hemoglobin subunit alpha HBA_HUMAN 92.30 11 558.14 
D6 
D27 
D41 
91.50 
72.50 
91.50 
10 
9 
10 
493.56 
423.97 
484.47 
Hemoglobin subunit beta HBB_HUMAN 95.20 14 811.18 
D6 
D27 
D41 
95.20 
95.20 
95.20 
13 
13 
14 
733.45 
686.97 
730.77 
Hemoglobin subunit delta HBD_HUMAN 54.40 9 503.32 D41 54.40 9 448.95 
Hemoglobin subunit gamma-2 HBG2_HUMAN 22.40 2 148.15 D6 15.60 2 106.45 
Delta-aminolevulinic acid dehydratase HEM2_HUMAN 52.10 18 984.52 
D6 
D27 
D41 
46.10 
52.10 
50.60 
13 
15 
18 
645.32 
719.53 
925.51 
Hypoxanthine-guanine phosphoribosyltransferase HPRT_HUMAN 47.20 8 408.38 
D6 
D27 
D41 
44.00 
42.71 
35.30 
7 
8 
7 
331.99 
361.47 
309.27 
Heat shock protein HSP 90-alpha HS90A_HUMAN 24.60 15 713.38 
D6 
D27 
18.30 
19.30 
12 
11 
486.53 
539.38 
Heat shock 70 kDa protein 1A/1B HSP71_HUMAN 19.80 9 456.97 D27 10.60 6 268.93 
Heat shock 70 kDa protein 4 HSP74_HUMAN 4.60 2 121.21 
D6 
D27 
4.60 
2.30 
1 
2 
100.21 
86.91 
Heat shock cognate 71 kDa protein HSP7C_HUMAN 30.50 15 706.84 
D6 
D27 
24.00 
18.10 
14 
11 
573.77 
447.68 
Eukaryotic initiation factor 4A-I IF4A1_HUMAN 19.00 7 229.10 D6 19.00 7 229.10 
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Name AC # 
Global analysis Storage-time analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score Sample 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Importin subunit beta-1 IMB1_HUMAN 14.40 9 427.40 
D6 
D27 
13.40 
9.70 
9 
5 
400.32 
243.47 
Importin-5 IPO5_HUMAN 4.50 3 150.83 
D6 
D27 
1.70 
4.40 
2 
3 
74.50 
134.56 
Importin-7 IPO7_HUMAN 2.80 2 146.04 D6 2.00 2 127.07 
Adenylate kinase isoenzyme 1 KAD1_HUMAN 73.70 10 625.80 
D6 
D27 
D41 
69.10 
60.30 
33.00 
10 
9 
6 
545.68 
459.35 
276.42 
Pyruvate kinase isozymes R/L KPYR_HUMAN 50.30 22 1033.64 
D6 
D27 
40.40 
49.30 
18 
21 
820.35 
911.79 
L-lactate dehydrogenase A chain LDHA_HUMAN 29.20 10 478.44 
D27 
D41 
21.40 
16.90 
7 
4 
317.51 
284.27 
L-lactate dehydrogenase B chain LDHB_HUMAN 40.40 13 682.36 
D6 
D27 
D41 
40.40 
37.70 
32.90 
13 
10 
9 
662.69 
556.25 
513.09 
Lactoylglutathione lyase LGUL_HUMAN 52.20 9 392.86 
D27 
D41 
17.40 
51.10 
3 
9 
142.64 
374.50 
Leukotriene A-4 hydrolase LKHA4_HUMAN 16.00 6 264.20 
D6 
D27 
10.00 
11.00 
5 
4 
191.50 
197.53 
Latexin LXN_HUMAN 19.40 3 125.41 D6 19.40 3 125.41 
Moesin MOES_HUMAN 34.00 21 1043.78 
D6 
D27 
D41 
13.70 
21.00 
34.00 
9 
12 
21 
462.42 
513.57 
939.83 
Nucleoside diphophate kinase A NDKA_HUMAN 69.10 12 682.96 
D6 
D27 
D41 
65.80 
69.10 
65.80 
9 
9 
12 
479.82 
460.01 
614.87 
Nucleoside diphosphate kinase B NDKB_HUMAN 67.10 11 510.04 
D6 
D41 
50.00 
67.10 
8 
11 
355.91 
456.28 
NIF3-like protein 1 NIF3L_HUMAN 13.80 4 193.54 
D6 
D27 
7.40 
13.80 
3 
4 
130.53 
169.69 
Obg-like ATPase 1 OLA1_HUMAN 22.00 5 355.23 
D6 
D27 
D41 
14.60 
17.90 
10.60 
4 
5 
4 
284.28 
293.67 
216.92 
 Part 3 – Characterization of oxidized proteomes 
115 
Name AC # 
Global analysis Storage-time analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score Sample 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Platelet-activating factor acetylhydrolase IB subunit beta PA1B2_HUMAN 8.30 1 76.33 
D6 
D41 
8.30 
8.30 
1 
1 
1 
67.42 
64.14 
Platelet-activating factor acetylhydrolase IB subunit gamma PA1B3_HUMAN 29.00 5 277.82 
D6 
D27 
D41 
17.70 
29.00 
21.20 
5 
5 
4 
202.24 
265.59 
206.75 
Proliferation-associated protein 2G4 PA2G4_HUMAN 21.60 7 283.54 
D6 
D27 
14.50 
21.60 
6 
7 
219.95 
269.71 
Protein DJ-1 PARK7_HUMAN 30.20 6 250.19 
D6 
D27 
D41 
30.20 
30.20 
30.20 
6 
6 
6 
231.93 
234.54 
216.27 
Programmed cell death 6-interacting protein PDC6I_HUMAN 19.80 14 575.81 D6 17.30 12 438.01 
Phosphoglucomutase-2 PGM2_HUMAN 18.50 8 412.83 
D6 
D27 
14.40 
13.40 
6 
6 
309.83 
302.99 
Glucose 1,6-bisphosphate synthase PGM2L_HUMAN 22.20 12 453.29 
D6 
D27 
13.70 
20.70 
8 
10 
303.56 
400.90 
Protein –L-isoaspartate(D-aspartate) O-methyltransferase PIMT_HUMAN 39.20 6 279.54 
D6 
D27 
19.80 
39.20 
3 
6 
169.70 
249.49 
Nicotinate phosphoribosyltransferase PNCB_HUMAN 22.70 9 515.29 
D6 
D27 
19.50 
20.30 
8 
8 
385.87 
450.60 
Purine nucleoside phosphorylase PNPH_HUMAN 62.60 18 772.79 
D27 
D41 
14.90 
62.60 
3 
18 
139.63 
772.79 
Low molecular weight phosphotyrosine protein phosphatase PPAC_HUMAN 44.30 8 346.24 
D6 
D27 
D41 
36.70 
44.30 
43.70 
6 
7 
6 
301.74 
306.30 
238.45 
Peptidyl-prolyl cis-trans isomerase A PPIA_HUMAN 31.50 5 302.80 
D6 
D27 
31.50 
25.50 
4 
4 
269.59 
241.71 
Peroxiredoxin-1 PRDX1_HUMAN 81.40 14 742.19 
D6 
D27 
D41 
54.80 
81.40 
54.80 
10 
12 
13 
488.24 
639.82 
627.52 
Peroxiredoxin-2 PRDX2_HUMAN 65.70 16 978.05 
D6 
D27 
D41 
63.10 
63.60 
60.10 
16 
16 
14 
857.13 
881.29 
880.42 
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Name AC # 
Global analysis Storage-time analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score Sample 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Peroxiredoxin-6 PRDX6_HUMAN 79.50 15 730.32 
D6 
D27 
D41 
79.50 
76.30 
51.30 
14 
15 
10 
582.09 
677.10 
371.88 
Ribose-phosphate pyrophosphokinase 1 PRPS1_HUMAN 26.10 8 289.67 
D6 
D27 
26.10 
26.10 
8 
8 
246.06 
260.43 
Puromycin-sensitive aminopeptidase PSA_HUMAN 16.80 14 543.77 
D6 
D27 
12.20 
16.80 
9 
14 
334.76 
519.48 
Proteasome subunit alpha type-3 PSA3_HUMAN 14.90 4 162.58 D41 14.90 3 155.84 
Proteasome subunit alpha type-6 PSA6_HUMAN 13.80 2 120.73 
D27 
D41 
10.20 
5.30 
1 
1 
93.73 
82.25 
26S proteasome non-ATPase regulatory subunit 7 PSD7_HUMAN 7.40 2 79.83 D6 7.40 2 79.83 
26S proteasome non-ATPase regulatory subunit 2 PSMD2_HUMAN 26.20 17 797.08 
D6 
D27 
25.10 
20.20 
15 
12 
709.68 
533.21 
26S proteasome non-ATPase regulatory subunit 3 PSMD3_HUMAN 10.90 6 264.00 D6 8.40 5 189.71 
26S proteasome non-ATPase regulatory subunit 6 PSMD6_HUMAN 24.70 9 356.83 D6 24.70 9 349.86 
Proteasome activator complex subunit 1 PSME1_HUMAN 36.90 8 330.39 D6 23.70 6 206.29 
Serine/threonine-protein phosphatase 2A activator PTPA_HUMAN 6.40 2 91.42 
D6 
D41 
6.40 
4.70 
1 
1 
79.20 
76.20 
Putative peptidyl-tRNA hydrolase PTRHD1 PTRD1_HUMAN 12.10 2 76.98 D6 12.10 2 76.98 
Phosphoribosylformylglycinamidine synthase PUR4_HUMAN 19.80 19 941.55 
D6 
D27 
17.60 
16.00 
17 
14 
717.83 
758.12 
Multifunctional protein ADE2 PUR6_HUMAN 33.90 9 413.33 
D6 
D27 
24.50 
23.80 
8 
7 
322.69 
308.76 
Adenylosuccinate lyase PUR8_HUMAN 15.90 7 341.88 
D6 
D27 
13.00 
13.60 
5 
6 
301.04 
281.24 
GTP-binding nuclear protein Ran RAN_HUMAN 45.40 10 482.70 
D6 
D27 
D41 
42.60 
45.40 
25.00 
8 
9 
5 
406.09 
427.30 
186.05 
Ran-specific GTPase-activating protein RANG_HUMAN 18.90 3 180.78 
D6 
D27 
15.40 
18.90 
3 
3 
149.44 
180.78 
Ribonuclease inhibitor RINI_HUMAN 41.20 12 688.01 
D6 
D27 
31.70 
27.10 
9 
8 
552.09 
402.63 
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Name AC # 
Global analysis Storage-time analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score Sample 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Ubiquitin-60S ribosomal protein L40 RL40_HUMAN 46.10 3 190.59 D27 46.10 3 190.59 
E3 ubiquitin-protein ligase RNF123 RN123_HUMAN 14.50 16 714.62 
D6 
D27 
13.30 
10.70 
16 
11 
634.00 
433.54 
Ribose-5-phosphate isomerase RPIA_HUMAN 19.60 7 344.65 
D27 
D41 
17.00 
19.30 
5 
6 
278.14 
245.10 
Ubiquitin-40S ribosomal protein S27a RS27A_HUMAN 42.30 4 219.64 D6 42.30 4 186.48 
RuvB-like 1 RUVB1_HUMAN 12.50 2 112.15 D6 12.50 2 112.15 
RuvB-like 2 RUVB2_HUMAN 13.40 6 278.11 D6 13.40 6 266.66 
Protein S100-A4 S10A4_HUMAN 45.50 9 410.24 
D6 
D27 
D41 
41.60 
45.50 
35.60 
7 
5 
5 
316.00 
267.17 
253.87 
Adenosylhomocysteinase SAHH_HUMAN 36.10 14 716.56 
D6 
D27 
D41 
22.70 
26.60 
33.80 
8 
9 
13 
398.57 
433.54 
636.15 
Selenium-binding protein 1 SBP1_HUMAN 81.10 31 1742.78 
D6 
D27 
D41 
67.60 
67.60 
76.10 
23 
24 
31 
1271.27 
1252.25 
1614.49 
S-phase kinase-associated protein 1 SKP1_HUMAN 40.50 4 231.78 
D6 
D27 
36.80 
36.20 
4 
4 
199.40 
171.05 
Superoxide dismutase [Cu-Zn] SODC_HUMAN 51.30 5 198.11 D27 51.30 4 191.80 
Sorcin SORCN_HUMAN 30.30 6 230.21 
D6 
D27 
D41 
26.30 
30.30 
30.30 
5 
6 
3 
192.24 
215.27 
161.48 
Spectrin alpha chain, erythrocyte SPTA1_HUMAN 5.90 9 386.39 D6 4.90 7 310.11 
Stress-induced-phosphoprotein 1 STIP1_HUMAN 32.40 14 617.45 
D6 
D27 
28.90 
22.30 
14 
12 
562.17 
466.99 
Alpha-synuclein SYUA_HUMAN 60.00 8 400.83 
D6 
D27 
60.00 
53.60 
6 
7 
252.24 
352.51 
Transaldolase TALDO_HUMAN 15.10 3 149.44 D41 12.50 3 126.34 
T-complex protein 1 subunit gamma TCPG_HUMAN 15.00 7 353.43 
D6 
D27 
9.20 
15.00 
4 
7 
205.57 
329.75 
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Name AC # 
Global analysis Storage-time analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score Sample 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
T-complex protein 1 subunit theta TCPQ_HUMAN 27.90 14 735.76 
D6 
D27 
D41 
27.90 
19.70 
6.60 
14 
11 
4 
689.65 
580.68 
145.86 
Transitional endoplasmic reticulum ATPase TERA_HUMAN 42.70 28 1322.44 
D6 
D27 
D41 
41.70 
34.00 
22.00 
26 
16 
12 
1188.87 
807.71 
476.62 
Protein-glutamine gamma-glutamyltransferase 2 TGM2_HUMAN 35.10 21 1123.36 
D6 
D27 
D41 
33.80 
29.90 
8.00 
20 
16 
5 
1024.04 
886.44 
181.90 
Acetyl-CoA acetyltransferase, cytosolic THIC_HUMAN 17.40 5 236.66 D27 13.40 4 171.22 
Thioredoxin THIO_HUMAN 42.90 4 250.57 
D6 
D27 
D41 
41.00 
31.40 
21.00 
3 
4 
2 
190.28 
201.49 
146.47 
3-mercaptopyruvate sulfurtransferase THTM_HUMAN 17.20 4 144.90 D6 17.20 4 139.72 
Transketolase TKT_HUMAN 10.60 4 211.78 
D6 
D27 
D41 
5.60 
10.60 
6.10 
3 
4 
3 
135.33 
197.02 
133.75 
Tripeptidyl-peptidase 2 TPP2_HUMAN 7.50 8 314.51 
D6 
D27 
4.70 
7.50 
5 
8 
198.31 
295.65 
Ubiquitin-conjugating enzyme E2 variant 1 UB2V1_HUMAN 22.40 4 165.46 
D27 
D41 
22.40 
22.40 
4 
4 
152.82 
143.35 
Ubiquitin-like modifier-activating enzyme 1 UBA1_HUMAN 9.50 8 361.72 
D6 
D27 
2.90 
4.00 
2 
4 
116.20 
170.94 
Ubiquitin-associated domain-containing protein 1 UBAC1_HUMAN 21.00 7 312.40 
D6 
D27 
18.00 
7.40 
6 
3 
273.68 
143.00 
Ubiquitin carboxyl-terminal hydrolase 14 UBP14_HUMAN 24.90 9 524.01 
D6 
D27 
21.30 
24.90 
7 
8 
444.89 
448.73 
Ubiquitin carboxyl-terminal hydrolase 5 UBP5_HUMAN 27.70 21 831.08 
D6 
D27 
21.60 
27.50 
16 
18 
618.82 
680.76 
V-type proton ATPase catalytic subunit A VATA_HUMAN 18.00 9 148.58 
D6 
D27 
13.80 
12.20 
7 
6 
348.96 
221.57 
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Name AC # 
Global analysis Storage-time analysis 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score Sample 
Seq. 
cov. 
(%) 
Peptide 
# 
ID score 
Exportin-7 XPO7_HUMAN 24.70 23 935.84 
D6 
D27 
23.60 
20.20 
20 
16 
848.80 
729.88 
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RBC membrane storage-related carbonylome 
Migrations lanes of the 9 samples of DDM-soluble membrane carbonylated proteins were cut in 
6 gel pieces and processed as described above. A total of 20 carbonylated proteins were 
identified with the same validation criteria as before. Table 4 summarizes the global 
identification parameters (merged LC-MS/MS data from all gel pieces) of proteins sorted by 
accession number, as well as in a storage-duration specific manner. As shown in Figure 30, most 
of the identified DDM-soluble membrane carbonylated proteins (55 %) were common to the 3 
investigated storage durations. Only 2 proteins (10 %) were specifically identified in day 6 
samples, and 4 proteins (20 %) were specific to day 27 samples. No protein was specific to end-
stored samples, but the carbonylation of 2 proteins (10 %) seemed to be related to the second 
half of the storage period, being commonly identified in days 27 and 41 samples. 
 
 
Figure 30: Venn diagram of integral membrane carbonylome during RBCs storage. Twenty proteins were identified as 
carbonylated proteins during the storage period of RBCs. More than the half (55 %) were common between the 3 
investigated storage periods. 
 
Through the 20 identified membrane carbonylated proteins, it appears that the more 
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represented molecular functions are binding activity (39.6 %), catalytic activity (18.8 %), 
antioxidant activity (8.3 %), transporter activity (12.5 %) and structural molecule activity (14.6 
%), as shown in Figure 31A. If the 3 former ones are highly represented commonly with 
investigations on soluble proteins (both cysteine oxidation and protein carbonylation), the 
proportions taken by two latters seems obviously more specific to membrane proteins. As 
mentioned above, a very few proteins were specifically identified in a given storage duration. 
Interpreting the molecular functions distribution in storage time-specific membrane 
carbonylomes (Figure 31E and F for days 6 and 27 samples, respectively) seems thus not 
appropriate. Following descriptions will thus concern all identified proteins at each storage 
duration, as shown in Figure 31B, C and D. Along the storage period, it can be noted a slight 
increase in the proportion of catalytic activity-related annotated sequences (from 16.7 % at day 
6 to 20.7% at day 41) and a concomitant slight decrease in the proportion of the transporter 
activity (from 16.7 % at day 6 to 13.8 % at day 41). The proportion of annotations related to 
structural molecule activity (cytoskeleton components) fluctuated between 20 % at day 6, 15.8 
% at day 27 and 17.2 % at day 41. The loss of membrane-bounded carbonylated cytoskeletal 
proteins can be explained by the dissociation of cytoskeleton from membranes under ATP 
depletion conditions [25, 26], such as occurring during the EC storage. It is noteworthy that 
cytoskeleton oxidation increase during RBC storage, as shown in Part 2 and by others [27], and 
thiol oxidation of cytoskeleton was linked to the microvesiculation process [28, 29]. Morever, 
this membrane loss is thought to be a protective mechanism, allowing the elimination of 
dimerized Band 3, that is the RBC immunological clearance signal [30]. 
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Figure 31: Repartition of molecular functions corresponding to integral carbonylated membrane proteins during RBCs storage. Diagram A represents the repartition of 
molecular functions for all identified membrane carbonylated proteins. Diagrams B to F represent the repartitions at days 6, 27 and 41, either for all proteins identified at 
each day (B, C and D, respectively) or for proteins that were specifically identified at each day (E and F, respectively). Note that no proteins were specifically identified for the 
day 41 condition. The bracketed numbers following some “0 %”-labels indicate that number of following unrepresented molecular functions, according to the ranking in the 
legend. Under each diagram figured the number of identified proteins. The color shading in the legend should be read from left to right then top to down. 
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Table 4: Proteomic identification of the RBC membrane carbonylome during RBCs storage 
Name AC # 
Global analysis Storage-time analysis 
Seq. cov. (%) Peptide # ID score Sample Seq. cov. (%) Peptide # ID score 
Protein 4.1 41_HUMAN 28.70 17 969.48 
D6 
D27 
D41 
20.80 
22.50 
17.60 
12 
13 
13 
645.97 
767.61 
697.80 
ATP-citrate synthase ACLY_HUMAN 6.70 3 215.50 D27 6.70 3 185.11 
Actin, cytoplasmic 1 ACTB_HUMAN 16.80 4 175.22 D6 9.90 3 105.81 
Alpha-adducin ADDA_HUMAN 4.90 3 123.17 D27 4.90 3 123.17 
Ankyrin-1 ANK1_HUMAN 29.30 40 2292.69 
D6 
D27 
D41 
19.50 
27.60 
17.30 
24 
38 
25 
1279.31 
2135.72 
1358.86 
Band 3 anion transport protein B3AT_HUMAN 39.30 28 1608.26 
D6 
D27 
D41 
32.20 
32.70 
35.80 
25 
21 
22 
1246.24 
1343.07 
1313.26 
55 kDa erythrocyte membrane protein EM55_HUMAN 8.80 4 180.34 
D27 
D41 
8.80 
8.80 
2 
4 
159.05 
156.00 
Erythrocyte membrane protein band 4.2 EPB42_HUMAN 46.90 25 1334.49 
D6 
D27 
D41 
21.60 
46.90 
32.40 
11 
25 
17 
550.88 
1301.76 
790.66 
Glyceraldehyde-3-phosphate 
dehydrogenase 
G3P_HUMAN 31.60 7 428.62 
D6 
D27 
D41 
17.00 
19.40 
31.60 
4 
5 
7 
276.99 
291.86 
359.51 
Golgi-associated plant pathogenesis-
related protein 
GAPR1_HUMAN 16.90 2 137.13 
D27 
D41 
16.90 
16.90 
2 
2 
114.02 
133.76 
Solute carrier family 2, facilitated glucose 
transporter member 1 
GTR1_HUMAN 8.10 5 288.42 
D6 
D27 
D41 
8.10 
8.10 
7.90 
5 
5 
4 
288.28 
253.84 
238.44 
Hemoglobin subunit alpha HBA_HUMAN 68.30 7 389.44 
D6 
D27 
D41 
47.90 
47.90 
68.30 
7 
6 
5 
334.86 
348.51 
313.71 
Hemoglobin subunit beta HBB_HUMAN 73.50 9 535.42 
D6 
D27 
D41 
73.50 
73.50 
73.50 
9 
8 
8 
459.41 
460.18 
490.24 
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Name AC # 
Global analysis Storage-time analysis 
Seq. cov. (%) Peptide # ID score Sample Seq. cov. (%) Peptide # ID score 
Hemoglobin subunit delta HBD_HUMAN 67.30 8 353.12 D27 54.40 6 294.03 
Peroxiredoxin-2 PRDX2_HUMAN 35.40 6 332.18 
D6 
D27 
D41 
30.80 
30.80 
35.40 
6 
6 
6 
262.22 
249.53 
308.21 
Blood group Rh(D) polypeptide RHD_HUMAN 4.10 2 82.73 D6 4.10 2 75.25 
Spectrin alpha chain, erythrocyte SPTA1_HUMAN 43.00 84 4166.26 
D6 
D27 
D41 
25.30 
38.90 
21.30 
47 
77 
43 
2065.63 
3956.26 
1932.65 
Spectrin beta chain, erythrocyte SPTB1_HUMAN 27.70 47 2591.54 
D6 
D27 
D41 
16.40 
26.20 
14.60 
30 
45 
26 
1415.67 
2503.99 
1276.51 
Erythrocyte band 7 integral membrane 
protein 
STOM_HUMAN 22.90 4 215.79 
D6 
D41 
12.50 
22.90 
3 
4 
163.46 
172.60 
T-complex protein 1 subunit eta TCPH_HUMAN 6.10 3 110.65 D27 6.10 3 110.65 
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Conclusions 
 
The present studies were conducted to identify the proteins affected by oxidative modifications, 
in particular the oxidation of the cysteine residues and the introduction of carbonyl functions on 
amino-acids side chains. The oxidative modification of cysteine thiol group appeared to 
accumulate in cytosolic proteins along the storage period. However, not all proteins were 
affected, and affected proteins did not respond equally to this modification. Indeed, most 
identified proteins in spots presenting IR signal variation (56 %) were specifically identified as 
suffering from either reversible or irreversible cysteine oxidation. As a consequence, different 
protein populations were identified regarding this reversibility. Molecular functions engaged by 
identified proteins are the same but seem differentially represented in these populations. For 
instance, OR are less abundant in the population related to irreversible oxidation. However, the 
AO enzyme catalase was specifically identified as target of this oxidative cysteine alteration. As 
for proteins targeted by reversible cysteine oxidation, antioxidant-related activity presented a 
higher proportion, as shown by the specifically identified peroxidase-like activities-presenting 
peroxiredoxin-1 and DJ-1 proteins. Cysteine sulfenylation is the mechanism of action of most 
antioxidant enzymes thus it is not surprising that constituents of this function family are found 
more abundant in this population. The OR function is the most relevant example of differentially 
affected proteins due to the nature of the studied modification, but other functions seem to be 
targeted as well by reversible (transporters and peptidase regulators) or irreversible (catalytic 
enzymes other than OR, and phosphatase regulator) protein cysteine oxidation. 
The second part of this study dealt with carbonylated proteins in cytosol and membranes. The 
localization- and time-dependent characters of this modification were here incremented with a 
protein targeting specificity. If membranes were more affected by quantitative changes of 
carbonylated content, the soluble fraction of stored RBCs appeared more prone to qualitative 
changes. In particular, several OR enzymes appeared carbonylated only from the beginning of 
the second half of the storage period. In membranes, on the contrary, the carbonylation 
seemed to equally affect the protein population throughout the storage period. One can 
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however note a higher abundance of carbonylated members of transport proteins and bound 
cytoskeletal constituents at day 6. This is not in contradiction with the membrane-related 
quantitative changes revealed in Part 2 because these results are a matter of qualitative 
changes. More carbonylation can very well occur without changing the proportion of affected 
molecular functions, i.e. more copies of same proteins become carbonylated, or one can easily 
observe several carbonylation sites on a unique protein due to the high spectrum of potential 
amino acid targets. 
Protein oxidative modification thus seems not to be a global massive phenomenon but is most 
likely to target specific proteins or protein functions, in addition to a time- and compartment-
dependent evolution.   
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Introduction 
 
All aerobic living systems are challenged by the production of ROS, causing oxidative injuries to 
nucleic acids, lipids and proteins [1]. Cells, and in particular RBCs, are well equipped to deal with 
these damaging species, relying on enzymatic (e.g. superoxide dismutase, catalase, glutathione 
peroxidase) as well as non-enzymatic defenses (e.g. glutathione, vitamin C). For a review on 
cellular defenses against ROS, see reference [2]. In addition to ROS removal or reduction to less 
reactive species, cells also possess mechanisms to repair (e.g. regarding protein oxidation, 
methionine sulfoxide reductase, thioredoxin, sulfiredoxin, and refolding chaperones) or 
eliminate (e.g. proteasome or vacuolar proteolysis, microvesicle release) oxidized contents [3, 
4]. 
In general, a limited chronic challenge by ROS induces the deployment of the above-mentioned 
defense mechanisms. In case of prolonged stress condition, ROS production can overwhelm all 
these defenses, leading to a situation of oxidative stress. At the protein level, the accumulation 
of oxidative damages involves structural changes, inducing loss of functions and tendency to 
aggregation. Aggregates of misfolded proteins are involved in and are thought to be responsible 
for the clinics of several age-related degenerative pathological conditions such as Alzheimer’s or 
Parkinson’s disease [5, 6]. It thus seems clear that protein aggregates are deleterious for the 
cells, and cell incapacity to prevent or eliminate such protein structures can lead to critical 
situations, as detailed for amyloid fibrils [7]. However, the formation of protein aggregates is 
counterbalanced by cell defense mechanisms. If the “primary” defense composed of ROS 
scavengers and oxidoreductant enzymes are not able anymore to prevent the accumulation of 
oxidized proteins, these modified proteins can be degraded by proteolysis [8] or eliminated by 
microvesiculation [4].  
The proteasome is the catalytic effector of the ubiquitin-proteasome pathway, responsible for 
the highly controlled proteolysis of misfolded or denatured proteins, playing a major role in 
numerous cell processes such as cell cycle regulation, apoptosis or immune response [9]. 
Targeted proteins are specifically addressed to the proteasome through a polyubiquitination 
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process involving three enzymes responsible for activation, conjugation and binding of the 
ubiquitin monomers on the protein to be degraded [10, 11]. Ubiquitination allows survival of 
other proteins, ensuring the selectivity and time-dependent degradation of target proteins [12]. 
Additionally, the 20S catalytic core (P20S), a barrel-shaped structure of four stacked rings of 
seven subunits each, has an opening diameter of 13 Å, and an internal catalytic chamber of 53 Å 
of diameter [13, 14]. As a consequence, native proteins cannot freely enter the P20S, unless 
being first recognized thanks to the polyubiquitin signal, then ATP-dependently denatured by 
subunits of the 19S regulator.  
In the case of oxidative stress, this “contract murderer” system can lose its targeting-based 
procedure. Functional P20S was evidenced in mature RBCs [15], and a degradation pathway 
independent of ATP and ubiquitin was highlighted in these cells [16, 17]. In addition, the protein 
oxidative denaturation-induced exposure of hydrophobic moieties [18, 19] was shown to be the 
signal for such degradation [20]. Throughout the storage period of RBCs, a slight loss in 
intracellular ATP was observed by Hess [21] and Högman [22]. These trends were observed in 
AS-1 and Erythro-Sol additive solutions, respectively. However, storage in AS-3 let Bennett-
Guerrero et al. quantifying an ATP loss of 55 % [23]. When stored in SAGM, preliminary results 
of an LC-MS-based metabolomic study of ECs aging conducted at the SRTS-VD tend to show 
higher progressive ATP-depletion, of 35 %, 85 % and 95 % at days 6, 27 and 41 of the storage 
period, respectively (unpublished data). ATP-depletion conditions were shown to induce the 
dissociation of proteasome complexes (P20S catalytic core dissociates from its main regulator, 
19S) [24]. As a consequence, along with the RBC storage period, the proteasome complexes 
should tend to a higher proportion of P20S catalytic cores presenting a ubiquitin- and ATP-
independent proteolytic activity. 
Another cellular mechanism, whose defensive role is suggested but still requires clarification, is 
the microvesicle release [25]. Microvesicles are characterized by their rich membrane 
phospholipid content, jailing part of the cytoplasmic material from their mother cells [26], and a 
size ranging from 100 nm to 1 μm. Originating from RBCs, leukocytes, platelets, or endothelium 
cells, MVs are naturally present in the bloodstream of healthy people, and the variation of their 
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concentration was characterized, though not specifically, in some pathologies [27-29]. 
Described long as cell dusts, several biological functions were finally attributed to these MVs, 
more particularly in thrombosis, hemostasis, or inflammation [30-32]. Similarly to the ferryman 
Charon carrying souls of the newly deceased across the hell river Acheron towards the land of 
the dead, a concept of transporter has emerged, in which MVs would be the rowing boat 
navigating through the bloodstream to introduce lost proteins to the final judgment of liver 
Kupffer cells [33]. In addition, MVs seem allowing intercellular signal exchange through their 
externalized phospholipids and/or proteins, or their intern content [34-36]. The direct release in 
the bloodstream allows fast signal delivery to target cells or organs, even far away from the 
emitting cell, as hormones do. Physiology of blood MVs has been recently reviewed by Tissot 
and colleagues, see reference [29]. 
Regarding the blood banking of RBCs, MV release was characterized as an irreversible 
rheological storage lesion, presenting a storage-related 20-fold increase at the end of the 
storage period [37]. Proteomic studies allowed hypothesizing the microvesiculation as a 
protective mechanism, since altered band 3, the molecular origin of immunological clearance of 
aged RBCs in vivo [33, 38, 39], was characterized in abundance in MVs [25, 26]. The release of 
MVs thus allows erythrocytes to get rid of removal signals and to postpone their clearance by 
liver Kupffer cells [25]. 
This part of the present PhD thesis aims to assess the RBCs capacity to handle intracellular 
oxidized protein content. In particular, below-presented experiments will focus on the RBCs 20S 
proteasomal activity throughout their blood banking, as well as their susceptibility to increasing 
quantities of oxidized protein content. In a second chapter, the elimination of oxidized proteins 
through the microvesiculation process will be addressed and its impact on whole EC oxidation 
will be discussed.   
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Chapter one 
 
Characterization of ATP- and ubiquitin-independent proteolytic 
degradation through the multi-catalytic complex 20S proteasome (P20S) 
in stored RBCs 
 
 
 
 
 
 
 
This chapter refers to the article 
 
“Storage induced inhibition of the stored red blood cells multicatalytic proteinase complex 
proteasome is due to the accumulation of oxidized proteins” 
 
In preparation 
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Study design 
The RBCs proteolytic capacity was investigated by the assay of chymotrypsin-like activity of the 
20S proteasome complex. Soluble extracts collected from three ECs at short, intermediate and 
long storage durations were tested. In addition, this activity was challenged in young samples by 
the addition of exogenous oxidized proteins. 
Material and methods 
Sample extracts 
Soluble extracts were obtained from EC1, EC2 and EC3 (see details in annex A), as described in 
Part 2, Chapter 1. Soluble extracts were used as is, without the Hb-depletion step. 
Protein oxidation 
Solution of commercial human Hb and BSA were prepared in P20S assay buffer (50 mM Tris/HCl, 
pH 7.5, 25 mM KCl, 10mM NaCl, 1 mM MgCl2). Proteins were chemically oxidized by incubation 
with 1 volume of 2 X oxidation buffer (50 mM HEPES, pH 7.2, 200 μM FeCl3, 50 mM ascorbic 
acid), under agitation during 5 h at 37 °C. Then, aggregates were spun down and supernatant 
were dialyzed overnight against P20S assay buffer at 4 °C. Protein concentrations were 
determined by the Bradford protein assay for BSA solutions and by the method of Harboe for 
Hb solutions (see details in Part 2, Chapter 2). 
In order to evaluate their behavior to chemical oxidation, Hb and BSA preparations were 
assayed, after treatment, for their protein carbonyl content by western blot, as described in Part 
2, Chapter 2. 
P20S activity assay 
Soluble proteins extracts (300 μg in P20S assay buffer) were incubated with 200 μM of the 
fluorogenic peptide substrate Suc-LLVY-AMC, at 37 °C during 4 h. This substrate is specific for 
cleavage by the catalytic subunits bearing chymotrypsin (ChT)-like protease activity, hereafter 
referred to as P20S activity. To specifically assess the P20S activity, experiments were also 
conducted in the presence of 0.5 μM of epoxomicin, a natural highly specific inhibitor of the 
P20S [40]. The inhibited conditions allow the fluorescence background substraction, to get rid of 
signal from buffer, sample, substrate auto-degradation, and substrate unspecific degradation by 
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other proteases. The substrate cleavage by proteases from the samples allows the release of the 
7-amino-4-methylcoumarin (AMC) molecule. Kinetics of AMC release was measured over time 
by fluorescence detection at 442 nm upon excitation at 342 nm, on a SPECTRAmax® GEMINI XS 
microplate spectrofluorometer (Molecular Devices Corporation, Sunnyvale, CA, USA). Standards 
of AMC dilutions allowed determining a conversion factor (in μM/A.F.U.) for P20S activity 
calculation in samples. Additionally, a standard of dilutions of commercial 20S proteasome, 
purified from human erythrocytes, allowed estimating the quantity of active P20S in samples. 
To determine the effect of exogenous oxidized proteins on P20S activity, day 6 samples were 
spiked with different quantities of oxidized BSA or oxidized Hb, corresponding to different 
carbonyl contents. Control conditions where samples were spiked with same amounts of 
untreated proteins were also conducted. 
Statistics 
Effect of storage on the P20S activity was assessed by one-way ANOVA followed by a Tukey HSD 
test for pairwise multiple comparisons between each storage duration couple. Statistics were 
evaluated using the free open source RStudio IDE software (version 0.97.551).  
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Results and discussion 
 
The P20S activity assays were realized in absence of ATP which is required for the unfolding and 
ubiquitin-recycling activities bore by the subunits of the main 19S regulator complex. In ATP-
depleted conditions, such as occurring during the storage of RBCs, the proteasomal degradation 
is thus mainly assumed by the 20S catalytic core on its own, and protein degradation occurs 
independently of the ubiquitination targeting. Indeed, P26S (20S core particle, CP, associated 
with 19S regulatory particles, RP) dissociates under ATP-depletion conditions, as revealed by 
Tanaka and colleagues [24] through the loss of substrate degradation in corresponding glycerol 
density gradient fractions, in comparison with ATP-regeneration conditions. Moreover, they 
have shown that immunodetection signal of 20S and 19S subunits shifted from fast sedimenting 
fractions (26 S) to low sedimenting ones (20 S) upon ATP depletion. The following results are 
thus assumed to be mainly related to the 20S CP only. This is an important point to consider 
because the small-sized Suc-LLVY-AMC peptide substrate used here does not need ATP-
dependent denaturation to enter the proteasome catalytic core and would be degraded by P26S 
if such complexes were stable in ATP-depletion conditions. 
Determination of P20S activity during RBCs storage 
The assay of P20S activity in stored RBCs reveals a late-occurring change during the storage 
period (see Figure 32). The triplicate measures of P20S activities from three ECs sampled at days 
6, 27 and 41 of storage shows similar mean activities determined as 2.42±0.8·10-3 and 
2.40±0.7·10-3 pmol·min-1·μg-1 at days 6 and 27, respectively. A mean activity of 1.44±0.5·10-3 
pmol·min-1·μg-1, measured at day 41, represents a decrease of 40.5 % in comparison with the 
activity at day 6. This decreasing activity could be explained either by a quantitative loss of 
proteasome complexes (degradation of the multicatalytic complexes) or by a loss of function 
due to the inhibition of the enzyme/substrate interaction (protein modification, blocking of the 
access to the catalytic chamber). During RBCs storage, the ATP depletion tends to prevent the 
ubiquitin-targeted degradation of misfolded proteins, due to dissociation of the P26S 
complexes, as mentioned above. Moreover the present study shows an inhibition of the P20S 
activity at the end of the storage period. This inhibition decreases the less controlled 
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degradation of mildly oxidized proteins, supporting their accumulation, over-oxidation and 
aggregation in aging stored RBCs. 
 
 
Figure 32: 20S proteasome Chymotrypsin-like activity in stored RBCs. P20S activity was assessed in stored RBCs collected at 
days 6, 27 and 41 of the storage of three ECs, through kinetics of the ChT-like proteolytic degradation of the specific 
fluorogenic substrate Suc-LLVY-AMC. The ANOVA analysis revealed a significant effect of the storage duration (p @ 0.014), 
with a significant difference at day 41, in comparison with day 6 (p @ 0.025) and day 27 (p @ 0.029), as revealed by pairwise 
multiple comparison test. 
 
Effect of exogenous oxidized proteins on P20S activity in short-stored RBCs 
As shown in Part 2, along with the increasing storage duration comes an increasing oxidation of 
RBC proteins. This accumulation of oxidized material is amplified by the inhibition of their 
degradation machinery, the 20S proteasome. Protein hydrophobic moieties exposure through 
oxidative modifications allows their interaction with the P20S. This interaction was shown to 
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favor the degradation, but without the ATP-dependent denaturation, one can wonder whether 
oxidized material binding could also trigger the inhibitory effect shown above. Indeed, Pacifici 
and colleagues have shown that the more hydrophobe damaged-Hb, the more and faster 
degraded by proteasome [20]. However, they also documented that hemin, a highly 
hydrophobic molecule characterized by a structure very similar to Hb, presents a strong 
inhibitory effect on proteasome-mediated degradation of oxidized proteins [20].        
Day 6 sample from EC1 was mixed with different quantities of exogenous untreated or oxidized 
Hb (Figure 33A) or BSA (Figure 33B). The addition of exogenous untreated proteins induces a little 
decrease in the measured activity of the day 6 sample, compared to the control sample (see 
Figure 33). The increase in quantity of untreated exogenous proteins does not seem to induce 
any significant activity variation (three first light histograms, Figure 33). On the contrary, the P20S 
activity appears to be decreased by rising quantities of oxidized exogenous proteins, as shown 
in Figure 33 (three first dark histograms). If both oxidized Hb and oxidized BSA induce this dose-
dependent activity decrease, the Hb-associated inhibition seems higher than the BSA one. 
Indeed, the addition of 50 μg of oxidized Hb induces a loss of 18 % of P20S activity in 
comparison with the same amount of untreated Hb (Figure 33A). As for oxidized BSA, the 
addition of 150 μg only produces a 10 % loss of activity when compared to the same amount of 
untreated BSA (Figure 33B). The oxidized versions of the two tested proteins, Hb and BSA, seems 
thus to have an inhibitory effect on the proteasomal degradation of the Suc-LLVY-AMC peptide 
substrate, in ATP-depleted conditions. However, it seems that oxidized Hb has a higher 
inhibitory effect than oxidized BSA. It is possible that these two proteins differentially react to 
the same chemical oxidation process. The two oxidized protein preparations were thus assessed 
for protein carbonylation, and were found to be equally carbonylated at around 500 fmol/μg 
(data not shown). The different inhibitory effects observed through the addition of oxidized Hb 
or oxidized BSA is thus not due to different oxidation rates of these proteins. On the contrary, 
the proteasome susceptibility to inhibition by oxidized content seems protein-dependent. 
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Figure 33: P20S activity in young RBC samples challenged by exogenous oxidized proteins. RBC soluble extracts from short-
stored ECs (6 days of storage) were spiked with different quantities of untreated (light histograms) or oxidized (dark 
histograms) exogenous Hb (A) and BSA (B). Measures were done in triplicate on a unique biological sample. 
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Chapter two 
 
Elimination of oxidized proteins out of the cell through the 
microvesiculation process 
 
 
 
 
 
 
 
This chapter refers to the article 
 
“Subcellular fractionation of stored red blood cells reveals a compartment-based protein 
carbonylation evolution” 
 
Published in 
Journal of Proteomics, 76 (2012) 181-193 
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Study design 
MVs were isolated from three short-stored ECs (less than 10 days) as well as from three long-
stored ECs (approx. 40-days). Total protein extracts were incubated with 2,4-DNPH for carbonyls 
derivatization, and modified proteins were quantified by western blot and densitometry. Data 
were combined with a previous study assessing the quantity of MVs released by RBCs 
throughout the storage period, in order to estimate the elimination of carbonylated protein 
content through this mechanism. 
Material and methods 
Microvesicles enrichment 
Three young ECs (EC9, EC10 and EC11, at 5, 8 and 9 days of storage, respectively) and three old 
ECs (EC12, EC13 and E14, at 38, 39 and 40 days of storage, respectively) were used for this 
study. Details on blood donors can be found in annex, table 1. ECs were centrifuged at 2000·g 
during 10 minutes at 4 °C in order to pellet the RBCs. The supernatants were centrifuged once 
again in the same conditions to eliminate residual erythrocytes. Then, the cell free storage 
media were ultracentrifuged three times during 1 hour at 120000·g and at 4 °C. Intermediate 
pellets of MVs were washed in 0.9 % NaCl solution, and the final pellets were resuspended in a 
small volume (usually 1 mL) of the same solution. 
Microvesicles counts 
MVs were counted via a flow cytometry method developed in our lab [37]. Briefly, MVs were 
labeled with FITC-coupled mouse anti-human CD47 antibody during 20 minutes under gentle 
agitation at room temperature. Labeled MVs were then diluted in 0.9 % NaCl into BD Trucount™ 
Tubes containing a precise number of control micro-beads appearing positive to FITC, PE and 
PE-Cy5 fluorescence. These triply-labeled beads allow the quantitation of MVs. 
Protein extracts and carbonyls quantitation 
Total MV proteins were extracted with Laemmli buffer. Protein extracts from 0.5·106 MVs were 
derivatized with 2,4-DNPH, separated by SDS-PAGE and transferred onto PVDF membrane. DNP 
residues were immunologically detected and carbonylated proteins were revealed by enhanced 
chemiluminescence with HRP-conjugated secondary antibodies. Films were scanned with a 
densitometer and intensities of entire migration lanes were determined with the ImageQuant 
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TL 7.0 software, and compared with a control of known carbonyl amount for sample 
quantitation. For details, see the material and methods section of Part 2, Chapter 2. 
Purification and identification of carbonylated proteins from MV extracts 
Total MVs proteins were extracted with DC buffer and Hb was removed by Ni-IMAC. 
Carbonylated proteins were derivatized with BHZ then purified by avidin-biotin affinity 
chromatography. Different extracts (total, Hb-depleted, Hb fraction and carbonylated proteins) 
were separated by SDS-PAGE, and bands of interest were excised, reduced/alkylated and 
digested for protein identification through LC-MS/MS analyses. Method details can be found in 
Part 2, Chapter 2 and Part 3, Chapter 2. 
Data processing and statistics 
Carbonyl detection was expressed as volumes further converted in femtomoles of carbonyls 
then normalized per MV. To investigate the loss of carbonylated proteins from RBCs, an 
exponential regression was interpolated between the mean carbonylation values in “young” 
and “old” MV populations. This hypothetical trend was combined with microvesicle release data 
published in 2008 by our group [37]. This way, it was possible to estimate the progressive 
elimination of carbonylated proteins through the microvesiculation process. 
Quantitation of protein carbonylation in MVs from young and old ECs was realized in triplicate 
(both biological and technical). The reproducibility was evaluated and a mean CV % was 
determined as 7.2 %. The mean difference of carbonyl content between short stored- and long-
stored purified MVs was statistically determined using the Student paired t test with a 2-tailed 
distribution. Data was considered statistically significant for p-values below 5 %. 
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Results and discussion 
 
Western blots of carbonylated proteins revealed the presence of such modified proteins inside 
and/or at the surface of MVs released by RBCs during their blood banking, in young as well as in 
old ECs. Figure 34 shows the immunodetection pattern of SDS-PAGE-separated carbonylated 
proteins extracted from 0.5·106 MVs collected in three ECs stored for less than 10 days and in 
three ECs stored for approximatively 40 days. Panel A shows the Ponceau Red staining of total 
MV proteins efficiently transferred onto the membrane and panel B corresponds to the 
immunodetection of derivatized, i.e. carbonylated, proteins. Interestingly, Figure 34A reveals 
higher Hb content (globin monomers and dimers at around 15 and 30 kDa, respectively) in MVs 
isolated from long-stored ECs, in comparison with short-stored ones. This is in adequation with 
the progressive binding of denatured hemoglobin at the inner face of erythrocyte membranes 
during RBCs storage [41-43] and with the main membrane-related MVs protein composition [25, 
26]. Detecting more Hb in “old” MVs suggest that its loci of membrane binding should, if not 
playing an active role, at least be included in the cell wastes eliminated by the microvesiculation 
process.  
Contrary to the unspecific and low-sensitivity Ponceau Red protein staining, the 
immunodetection of carbonylated content in these MV extracts reveals oxidized material 
throughout the molecular weight distribution, either present as quite resolved bands or as 
diffused signal, with a global high background-like signal in the high MW, relevant of aggregated 
material. The overall detection signal of these modified proteins clearly appears more intense in 
“old” MV extracts than in “young” MV ones, as shown in Figure 34B. The densitometry 
quantitation of the carbonylated protein content highlights a two-fold increase in favor of the 
“old” MV extracts, as presented in Figure 35 (0.013 and 0.026 fmol/MV in “young” and “old” 
MVs, respectively; n=9). Student t test reveals this difference as statistically significant with a 1 
% risk of error. Carbonylation quantitation on the monomer Hb signal reveals a similar 2-fold 
ratio between “young” and “old” MVs (data not shown). Thus carbonylated Hb does not seem 
more oxidized with time, but more eliminated by MVs. This is coherent with the steady state 
pattern evolution of Hb carbonylation shown in Figure 9 in Part 2, Chapter 2. 
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Figure 34: Western Blot detection of carbonylated proteins in MVs. MVs were isolated from short- (EC9, 10 and 11) or long- 
(EC12, 13 and 14) stored ECs. Carbonylated proteins were derivatized with 2,4-DNPH and whole extracts were separated by 
SDS-PAGE, as well as chemically oxidized RBC sample for positive (derivatized) and negative (underivatized) controls. A 
protein ladder and a mixture of carbonylated proteins were included for molecular weight scaling and quantification of 
samples protein carbonylation, respectively. Panel A shows the Ponceau Red staining of total proteins and panel B shows the 
immunodetection of derivatized carbonylated proteins. 
 
The depletion of Hb from MV proteins extracted with DC reveals residual Hb monomers as well 
as low MW material below 10 kDa (see Figure 36). The avidin-biotin capture of derivatized 
proteins from Hb-depleted MV extract allows the elution of these fragments and residual Hb as 
carbonylated material, as shown in Figure 36. The presence of relatively high amount of residual 
hemoglobin is explained by the altered capacity of oxidized Hb to be retained by the Nickel-
loaded IMAC column (see annex C). 
 
 Part 4 – Mechanisms of defense 
148 
 
Figure 35: Quantitation of protein carbonylation in MVs collected from short- and long-stored RBCs. The boxplots represent 
the mean quantitation of protein carbonylation, expressed in fmol/MV, in ECs stored for less than 10 days and ECs stored for 
approximatively 40 days. Measures were done in triplicate and on three biological replicates. The mean fold change of 1.89 
in favor of MVs from long-stored ECs was shown statistically significant with a 1 % risk factor (Student paired t test). 
 
MVs reveal carbonylated protein content which level evolves when comparing MVs isolated 
from ECs of different storage durations (Figure 34 and Figure 35). Carbonylated content inside MVs 
thus seems to be affected by the duration of storage of RBCs, as intracellular RBCs 
compartments were shown to be in Part 2. Microvesiculation process is thought to be a 
protective mechanism for the aging RBCs [25]. It is difficult to say whether carbonylated 
proteins are actively eliminated through this process, or if they are just passively embedded 
because of spatial proximity. Nevertheless, higher protein carbonylation rates inside MVs 
compared to intracellular RBC compartments, even in short-stored ECs, seem to imply a driven 
elimination. The membrane recruitment, such as in the case of hemichromes (aggregated 
oxidized Hb), could play this “targeting” role for elimination. 
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Determination of protein concentration in MVs total extracts shows a mean protein content of 9 
pg/MV, whatever the storage duration of the sampled EC (data not shown). The mean protein 
carbonylation rates in “young” and “old” MVs are thus determined of 1.44 and 2.78 pmol/μg, 
respectively (Figure 35). These values are of the same order of magnitude but higher than the 
rates determined for RBCs membrane fractions (0.3 to 0.5 pmol/μg and 0.5 to 1 pmol/μg for 
integral membrane and cytoskeleton, respectively, as shown in Figure 9 in Part 2, Chapter 2), 
indicating a probable specific elimination mechanism. 
 
Figure 36: 1D-PAGE patterns of hemoglobin depletion and capture of carbonylated proteins from MV extract. MV proteins 
were extracted with DC buffer (lane 1), and Hb was depleted by nickel-based IMAC (lanes 3 and 4). Proteins from Hb-
depleted extract were derivatized with biotin-hydrazide to purify carbonylated proteins (lanes 6 and 7). 
 
If it is relatively easy to quantify MVs from short-stored ECs (a few μL are needed), their low 
absolute count requires the sacrifice of “young” ECs to collect enough material for further 
analyses. It is thus hardly feasible to undertake follows-up of MVs throughout the storage of 
 Part 4 – Mechanisms of defense 
150 
given ECs. With that consideration in mind, an estimation of the carbonylation loss throughout 
the storage period was carried out, based on the protein carbonyls data and MVs counts data 
obtained in our lab in 2008 [37]. Data of protein carbonyls in “young” and “old” MVs were 
extrapolated with an exponential regression model. The exponential model ݕ ൌ ܽ כ ݁௕כ௫ can be 
expressed as ݕ ൌ ܽ כ ሺ݁௫ሻ௕. The low ܾ coefficient (ܾ ؆ ͲǤͲͳͻͺሻ makes the model nearly linear 
for ݔ א ሿͲǢ Ͷʹሿ (ECs storage duration). The extrapolation with a linear regression model (data 
not shown) gave similar results to what is presented below. The exponential model estimating 
the quantity of carbonylated proteins in MVs throughout the storage period is shown in Figure 
37A (blue circles), as well as the counts of MVs per EC (red spots). The latter clearly shows the 
exponential pattern of the release of MVs, particularly increasing after 4 weeks of storage. 
Combining these data, an estimation of protein carbonyls lost per EC through the 
microvesiculation process is shown in Figure 37B. A similar 4 weeks delayed exponential trend is 
observed. Of interest is the carbonylation loss in the end of the storage period, i.e. at 42 days, 
which is comprised between 200 and 300 nmol/EC. This amount of carbonyl content loss is 
coherent with the decrease observed in integral membrane fraction in the end of the RBCs 
storage (Part 2, Chapter 2). 
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Figure 37: Simulation of protein carbonylation loss by microvesiculation. Panel A: blue circles represent the exponential 
regression of carbonylated protein content in microvesicles along the storage (left axis), with in black boxplots the 
experimental values. Red spots are adapted data from a previous study investigating the quantity of MVs in ECs along the 
storage (right axis), with the corresponding exponential regression (red curve). Combined together in panel B, these data 
give an estimation of the loss of carbonylated proteins from RBCs by the MVs (calculated values in red spots and theoretical 
exponential trend in black curve). 
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Conclusions 
 
Handling oxidized protein content is pivotal for cells, since accumulation and aggregation of 
such modified material can lead to severe pathologies. The main machinery responsible for 
degradation of misfolded or denatured proteins involves the multicatalytic complex 
proteasome. In the transfusion context, proteomic studies reported EC storage-related changes 
in proteasome content [26, 44], suggesting a potential alteration of its proteolytic capacities. 
Through the present study, we were able to highlight a P20S-driven proteolysis activity, out of 
the ATP-dependent ubiquitin-proteasome pathway. In RBCs extracts, ATP levels of the low 
millimolar range were shown to allow for the dissociation of up to 70 % of existing P26S 
complexes [45]. Such complexes should not be attributed to the ATP- and ubiquitin-
independent degradation of oxidized proteins. ATP depletion conditions were thus applied to 
measure only proteasomal chymotrypsin-like activity from the dissociated 20S core particles. To 
the best of our knowledge, only one study, conducted in 2008 by Majetschak and Sorell, 
questioned the proteasomal activity in stored RBCs, as a biological application of methods 
developed for quantitation and characterization of proteasome complexes [45]. They observed 
a stable content and a constant activity of 20S complexes over the whole storage period, and a 
recruitment of 26S complexes during the first 3 weeks of storage period to attain a plateau, 
though not relating activity modification. However, the specific P26S activity (activity 
normalized by concentration) revealed a rapid inhibition during storage. This study was 
conducted on CPD-anticoagulated AS-1-stored RBCs. The AS-1 additive solution mainly differs 
from the SAGM one by higher adenine and lower glucose contents (2 vs 1.25 mM and 45 vs 111 
mM, respectively). As a consequence, they only observed a very slight decrease in the 
intracellular ATP content along the storage period. Both AS-1 and SAGM additive solutions are 
known to induce different storage behavior of aging stored RBCs [46], probably related to 
composition-dependent difference of metabolism. It is thus not surprisingly that our results on 
SAGM-stored RBCs show a different proteasome activity trend over the storage period, with a 
significant decrease of P20S activity after 4 weeks of storage. 
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In the oxidizing context of long-stored RBCs, we investigated the impact of increasing quantities 
of oxidized proteins on the control P20S activity in RBCs stored for 1 week. Preliminary results 
confirm the hypothesis of the inhibition of proteasomal activity by accumulation of oxidized 
protein content, recognized by P20S complexes, and likely to spatially hinder the substrate entry 
to proteasome. A dose-dependent inhibition of P20S activity is thus measured through the 
addition of increasing content of exogenous oxidized proteins to cytosolic extracts of young 
RBCs. 
Additionally to oxidative events, the inhibition of proteasome activity could find an explanation 
in assembly capacity issues. In a recent paper, Bousquet-Dubouch et al. highlighted a high part 
of free 20S proteasomes (64 %, mean of nine cell lines), potentially acting as “a reservoir to 
which regulators can associate to quickly modulate the proteolysis state in the cell” [47]. The 
oxidative stress occurring in stored RBCs may activate such a response, which would be 
concordant with the P26S recruitment observed by Majetschak during the first 3 weeks of ECs 
storage, in conditions that seem to better preserve ATP levels [45]. Less free P20S can explain 
the decreased activity that we highlighted after 4 weeks of storage. Moreover, Bousquet-
Dubouch et al. also showed that a part of P20S complexes (from 2.2 to 16.5 % depending on the 
cell line) were in the assembly process, through the co-immunopurification of proteasome 
assembly chaperones (PAC1 to PAC4 and POMP) [47]. Such chaperones can be targeted by 
oxidative lesions (as other chaperones were shown to be in Part 3), potentially preventing the 
assembly of P20S complexes in long-stored RBCs. Investigations in this sense should be 
performed in banked RBCs.  
Shrunk capacities of proteolytic degradation of oxidized protein content can be 
counterbalanced by physical removal through the microvesiculation process. Indeed, this 
phenomenon, exponentially increasing throughout the storage period, appears to clear RBCs, at 
least partially, of their oxidized protein content, with an increasing trend as the storage lasts. 
MVs from long-stored ECs reveal a carbonylated protein content twice as in MVs from short-
stored ECs. The combination of MV counts and quantity of oxidized proteins found in MVs 
throughout the storage period allows estimating the loss of oxidized proteins through this 
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process, and to associate it with the evolution of membrane protein carbonyls shown in Part 2, 
Chapter 2. 
Once in an oxidative stress environment, such as a prolonged storage duration seems to be (see 
supplementary data of ref [48]), RBCs possess mechanism to fight against the accumulation of 
oxidized material. It seems that proteasome plays a first proteolytic degradation role, while a 
moderate level of microvesiculation allows elimination of a few amount of oxidized proteins. 
However, the proteasome machinery seems to be altered, due to a too high level of oxidatively 
damaged material. Around 4 weeks of storage, concomitant to the decreasing proteolytic 
capacities, the MV release enters its exponential phase and could continue the garbage work to 
prevent over-accumulation of oxidized proteins. 
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Context of this PhD thesis 
 
Cold-storage of RBCs in additive solution is of high importance for the transfusion medicine 
field, because it allows the time and space separation of the blood donation and blood 
transfusion processes. In addition, the conservation of blood products enabled the 
establishment of blood banks nationwide, centralizing blood resources for an optimized use of 
these therapeutic products. The current storage conditions of RBCs differ a little bit depending 
on countries, but are globally similar (from 5 to 7 weeks at 4 °C in plastic bags allowing gas-
exchange, in additive solution mainly composed of glucose, adenine and salts). These non-
physiological conditions are not without consequence on erythrocytes, which are known to 
undergo the so-called storage lesions [1, 2], consisting in metabolism alterations [3-5], oxidative 
injuries to the cellular content, in particular the protein content [6-8], and modifications of 
rheological properties [9-11]. A hot debate exists regarding the impact of the storage lesions on 
post-transfusion adverse outcomes to patients. As the lesions occur and accumulate throughout 
the storage period, there is a pressure from physicians to be supplied in the freshest possible 
blood units. This is however not always possible in regard to delivery policy of many blood 
banks, driven by the first-in first-out rule, to avoid wasting blood products. The storage duration 
of ECs is questioned [12], and several clinical studies concluded in advising lowering this limit to 
favor the quality of blood products instead of their availability [13]. Though this is a really 
defendable point, there is still no clearly stated association of the storage duration with clinical 
adverse outcomes, which conducted the World Health Organization Blood Regulators Network 
(WHO BRN) to declare that “regulatory policies to reduce storage shelf life of red blood cells 
would be premature”, considering the “present scientific uncertainty” and the resulting “major 
adverse impact on blood availability”2. Some of the storage lesions are well known, and it 
appears that many of them are reversible through the transfusion of the blood products. On the 
contrary, oxidative lesions to RBC proteins are mostly irreversible. If storage lesions are 
                                                             
2 From the “position statement on reports of inferior clinical outcomes with transfusion of older vs. younger 
stored red blood cells”, available at 
http://www.who.int/bloodproducts/brn/PositionPaperBloodTransfusionOldYoung7Jul09.pdf?ua=1 
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susceptible to provoke patient adverse outcomes, it is most likely that irreversible ones would 
be implied. In this sense, a proteomics investigation of oxidative lesions in RBCs during the 
banking of ECs has been undertook at the Service Régional Vaudois de Transfusion Sanguine of 
Lausanne, among a larger project consisting in the assessment of the potential impacts of 
fabrication processes and storage on blood products quality. 
Proteomics relies on powerful tools such as MS, enabling the identification of protein 
populations, as well as the characterization of PTMs that proteins potentially carry. The major 
limitation of MS is the 104 dynamic range of protein concentrations that can be assessed. In 
order to access the more comprehensive information possible, sample fractionation is 
mandatory. Classic approaches consist in gel-free (chromatography based on hydrophobicity, 
size or charge) and/or gel-based (PAGE according to their MW or pI/MW couple) separation of 
proteins, followed by a bottom-up MS-based identification (digestion of protein fractions, 
separation of peptides based on their hydrophobicity, and MS/MS peptide analysis). Based on 
this standard workflow, different redox proteomics strategies were here set up to investigate 2 
hallmarks of protein oxidation, the oxidation of cysteine residues and the carbonylation of 
proteins, as well as their impact on cellular defense processes. 
Results reminder 
Oxidation of cysteines 
Cysteine oxidation was assessed on RBCs Hb-depleted soluble extracts from 5 ECs stored for 6, 
27 and 41 days. Cysteines engaged in reversible oxidative states were reduced and labeled with 
thiol-reactive IR probes, whereas free cysteines were directly alkylated. Extracts were analyzed 
in a 2D-DIGE-like approach, and IR spot intensities were quantified by densitometry. This 
approach permitted to detect spots of interest presenting different evolution of signal intensity 
over the 3 studied storage periods. The different patterns of evolution indicate proteins 
differentially affected by the oxidation of cysteine residues. For instance, several spot intensities 
were constantly increasing, meaning that corresponding proteins were more affected by 
reversible cysteine oxidation along the RBCs storage. Others spot intensities were decreasing, 
corresponding to proteins less prone to labeling thus becoming irreversibly oxidized along the 
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storage period. This study reports for the first time that cysteine oxidation belongs to RBC 
storage lesion. In addition to highlighting its occurrence, our data suggested a targeted 
mechanism since not all proteins were affected, and affected proteins showed different 
susceptibility. 
From Coomassie-blue stained 2D gels, spots of interest were excised then proteins were 
digested, analyzed by LC-MS/MS and classified by GO annotation. Most of identified proteins 
(56 %) presented specificity towards reversible or irreversible oxidation of cysteines, highlighting 
a protein-dependent effect. The proportions of molecular functions engaged through modified 
proteins differed regarding this reversibility, meaning that the oxidation of cysteines is most 
likely to target protein populations. Among proteins exclusively suffering from irreversible 
cysteine oxidation, catalytic enzymes (hydrolase, transferase, isomerase) were more 
represented. Such proteins are thus most likely to present altered structures, and probably 
functions. Catalytic protein functions are highly involved in cellular processes, such as for 
instance the glycolysis. Metabolomic data show altered glycolysis during RBCs storage [3, 5]. If 
substrate depletion is most likely a major issue, oxidative modifications to key enzymes have to 
be taken into account. In particular, our data highlighted that PGAM4 and TPIS, two enzymes 
implicated in glycolysis, showed a first increase in reversible oxidation (i.e. oxidative stimulation) 
then a decreasing reversible oxidation (i.e. irreversible oxidation or degradation/elimination 
from the cytoplasm). Additionally, G6PD and TALDO are involved in the PPP and showed 
constant irreversible oxidation or degradation/elimination. On the contrary, AO and transporter 
activities appeared more susceptible to reversible cysteine oxidation, suggesting a storage-
related increasing stimulation by oxidative conditions, which is not surprising for the former. 
Carbonylation of proteins 
The carbonylation of proteins during the storage of RBCs was investigated quantitatively by 
western-blots and qualitatively by an AP-MS approach followed by GO annotation. To better 
assess this modification, weekly collected RBCs from 3 ECs were efficiently fractionated at the 
subcellular level. Soluble Hb, Hb-depleted cytosol, integral membrane proteins and cytoskeleton 
fractions were thus investigated for protein carbonyl quantitation through chemical 
derivatization and immunodetection of derivatized proteins. This study allowed to characterize 
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a time-dependent and compartment-dependent evolution of protein carbonylation during RBCs 
storage, with a particularly interesting membrane-related end-storage increase for both integral 
and cytoskeleton proteins, starting from 3 and 4 weeks of storage, respectively. Regarding the 
integral membrane fraction, a decrease in carbonylation was observed at the very end of the 
storage, suggesting a loss of the damaged material. Soluble fractions revealed a starting 
decreasing pattern, stabilized after 2 weeks, which let thinking of a processing of soluble 
carbonylated content in the beginning of the storage. 
The proteomic analysis of proteins affected by carbonylation implied a chemical derivatization 
with biotin in order to purify carbonylated proteins before LC-MS/MS analysis. In the Hb-
depleted soluble fraction, a qualitative change in targeted proteins was demonstrated along the 
storage. In particular, AO activity-bearing carbonylated proteins showed a higher proportion at 
day 26, further decreased at day 41, suggesting a particular occurrence of carbonylation in this 
protein population during the first half of storage, afterwards these proteins should be 
processed, making them less detectable from soluble fraction. From what is known regarding 
cellular processes of proteins in RBCs, this can mean either membrane recruitment, proteolytic 
degradation by the proteasome, or elimination through the release of microvesicles. Of interest 
are numerous carbonylated enzymes involved in glycolysis (G3PD, ENOA and PGM2, mainly 
carbonylated during the first half of storage) and in the PPP (6-PGD, RPIA, TALDO, and TKT, 
mainly carbonylated during the second half of the storage period). These results on glycolytic 
enzymes are in accordance with cysteine oxidation ones, in the sense that key proteins of RBCs 
metabolism are oxidatively altered during the storage period. Moreover, regarding enzymes out 
of the PPP, their absence in the soluble carbonylome at the end of the storage and their 
decreasing cysteine-labeling intensity at day 41 suggest high oxidative injuries during the 4 first 
weeks of storage and either a membrane recruitment or degradation/elimination at the end of 
RBCs banking. Regarding enzymes from the PPP, they appear to suffer from irreversible cysteine 
oxidation and were identified in the soluble carbonylome mainly starting from the 4 weeks limit, 
suggesting that from that storage time they cannot be degraded. Data from Zolla’s group 
suggest a recruitment of the PPP after 2 weeks of storage [5], which does not seem coherent 
with the present data, where PPP enzymes were found damaged during the second half of 
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storage.  
As for the membrane carbonylation, changes were mostly quantitative, with increasing copies 
of carbonylated proteins (only 20 different proteins) along the storage, with 55 % of identified 
proteins being common to the three storage durations. 
Inhibition of the P20S activity 
Future of oxidized proteins in living cells is quite clear. What becomes useless is degraded. 
Proteasome is the cellular machinery allowing the proteolysis of oxidized proteins among other 
denatured proteins [14]. However, it is known that oxidative injuries can lead to protein 
crosslinking. As we showed that stored RBCs are an environment prone to protein oxidation, a 
particular interest was put on the effective proteolysis activity during ECs banking. Our data 
show that the P20S-driven proteolysis is affected by a 40 % loss of its activity at day 41 in 
comparison to samples from day 6 and day 27. Here again, it seems that after around 4 weeks 
of storage, a major cellular process suffers from the conditions offered by the storage of RBCs. 
Storage-related activity modulation could be associated with the storage-related increase in 
oxidative injuries to proteins. Characterization of the soluble carbonylome revealed altered sub-
units of the proteasome complexes, as shown in Part 3, table 2 (more sub-units of the P20S 
complex were identified in the soluble carbonylome, but were not validated with our criteria, 
thus do not appear in this table). In addition, oxidized proteins tend to crosslink, and are 
recognized by P20S complexes [15]. We thus investigated the potential inhibitory effect of 
increasing quantities of exogenous oxidized proteins on the P20S activity in fresh RBCs samples. 
A dose-dependent and protein-dependent inhibitory effect was demonstrated through our 
experiments, highlighting an interesting higher induced inhibition by oxidized Hb compared to 
oxidized BSA. 
Release of microvesicles 
All along the storage period, RBCs are known to release increasing amounts of MVs [16], with an 
intense exponential release starting from 4 weeks of storage. In vivo as in stored ECs, 
heterogeneous populations of RBCs are encountered regarding the age of cells. Whether all 
cells or only old ones participate to the MV release is unknown. As a consequence, one cannot 
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state if cytoskeleton destabilization through hemichromes binding originates the release of 
MVs. Hemichromes binding to membrane [17] is likely to induce conformational changes of 
band 3, creating a surface neo-epitope [18] recognized by naturally occurring anti-band 3 auto-
antibodies [19, 20], favorizing the in vivo clearance of RBCs. Moreover, storage-released MVs 
have been found enriched in such altered band 3. As a consequence, it seems likely that 
hemichromes binding to RBCs membrane occurs before the massive MVs release. Pushing 
further, one can hypothesize a signal role of hemichromes binding towards microvesiculation, 
through the destabilization of the membrane-to-cytoskeleton association. This way to eliminate 
such aging marker makes microvesiculation of potential mechanism of defense. 
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Conclusions – an oxidative pathway model of the RBCs storage 
 
In addition to a storage lesion, oxidative modifications, and particularly the oxidation of 
cysteines is known to be involved in multiple cellular processes, through oxidation-reduction 
cycles. AO enzymes are the best example. Soluble AO were shown to be less prone to 
irreversible cysteine oxidation during storage, suggesting that their active site would be 
preserved, allowing RBCs to fight against ROS, as shown in Figure 38, step1. However, they 
present a higher carbonylation status by the first half of the storage period. This correlates with 
the double incidence (cellular processes and protein lesions) of oxidation in the case of RBCs 
storage. The global quantitative decrease in soluble carbonylated proteins should thus be 
related to a preserved AO activity up to the first 2 weeks of storage (Figure 38, step 1). Up to day 
26, AO proteins appeared to cumulate oxidative injuries through carbonylation. However, the 
proportion of this protein family is lowered from day 26 to day 41. Protein oxidation is known to 
induce recognition and degradation by 20S proteasome complexes (Figure 38, step 2), which 
would fit with the observed decrease. Increasing oxidation of AO defenses, though apparently 
not altering their active sites and beyond making them prone to proteolysis is likely to change 
them into proteasome inhibitors, as suggested by the protein oxidation dose-dependent 
inhibitory effect observed on P20S activity.  
In summary, efficient AO defenses, among other proteins, would accumulate oxidative injuries 
until around 4 weeks of storage, making them recognized by P20S complexes to either being 
degraded (Figure 38, step 2) or inhibiting the proteasomal activity (Figure 38, step 3). AO defenses 
would thus decrease so low that they would not be able to counterbalance oxidants, allowing 
overoxidation of proteins which cannot be taken over by the proteolysis machinery anymore, as 
enzymes from the PPP seem to be. Protein overoxidation is known to induce the formation of 
aggregates. Regarding Hb, its aggregated forms termed hemichromes are known to bind band 3 
on its cytoplasmic domain (Figure 38, step 4). Band 3 proteins are the loci of membrane-to-
cytoskeleton binding, and also of multiprotein complexes. In particular, proteins belonging to 
the glycolysis chain are found in band 3 complexes. The binding of hemichromes is likely to 
affect the structure of the cytoplasmic domain of band 3, thus displacing these proteins and 
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potentially inducing destabilization of cytoskeleton and altering glycolytic functions of RBCs. 
Hemichromes like Hb are capable of autoxidation, which can participate to oxidative injuries 
that we have shown to accumulate on cytoskeleton and membrane proteins (Figure 38, step 5), 
as well as on glycolysis and PPP enzymes. The hemichromes binding and further oxidation of the 
cytoskeleton and membrane environment might be a signal for high release of aging markers 
and other modified proteins by microvesiculation (Figure 38, step 6). 
Contrary to several clinical studies on blood age-related transfusion-linked adverse outcomes, 
and some research studies on RBCs storage lesions and altered metabolism, tending to show a 
14-day storage limit after which RBCs would not be suitable for transfusion, our results suggest 
that oxidative stress-linked alterations of stored RBCs rather tend to a longer limit of 4 weeks. In 
Lausanne, statistics of transfusion at the CHUV (see Part 1) showed that half ECs are transfused 
during the 2 first weeks of storage, and that around 90 % are transfused during the 4 first 
weeks. As a consequence, it seems that, in most cases, transfused RBCs are healthy enough to 
ensure the transfusion goal of increasing tissue oxygenation capacities. However, statistics had 
also shown a particular difference for transfusions of B and AB rare blood groups, particularly 
true for the AB+ blood group. These groups revealed a mean higher transfusion abundance of 
ECs stored for 6 weeks. For these particular cases, our observations thus tend to be in disfavor 
of a more than 4-week EC storage duration, and further investigations should be conducted in 
regard to the effect of storage duration on clinical adverse outcomes to transfusion recipients of 
B and AB blood groups. According to storage conditions (in particular the additive solution) and 
policies of ECs delivery, these conclusions may be modified. At the time of a patient-specific 
medicine, the storage of blood products for transfusion might become recipient-dependent as 
well. 
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Figure 38: Oxidative pathway model of RBCs storage. Step 1: RBCs antioxidant defenses prevent most oxidative damages by reducing ROS into less reactive intermediates, or 
being oxidized themselves, followed by a recycling mechanism. After a certain storage period, these defenses are exceeded by the oxidative stress and protein oxidation 
occurs at both cytosolic and membrane levels. Step 2: oxidized proteins are recognized by the 20S proteasome complexes through exposure of hydrophobic moieties. 
Antioxidant defenses are oxidized as well, and are susceptible to proteolysis, allowing for overoxidation of RBCs content. Step 3: surrounding 4 weeks of storage, 
overoxidized proteins crosslink and cannot be degraded anymore, inhibiting the proteolysis of fairly oxidized as well as other damaged proteins. Step 4: oxidized Hb 
aggregates as hemichromes and binds to membrane band 3 protein, modifying its conformation and potentially altering its association with cytoskeleton and displacing 
bound glycolytic enzymes. Step 5: hemichromes autoxidation produces ROS which oxidize cytoskeleton and membrane proteins. Step 6: exponential phase of the MVs 
release, allowing the elimination of RBCs aging markers such as altered band 3 and externalized phosphatidylserine. 
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Perspectives 
 
The age of transfused blood products, particularly of ECs, is a currently highly debated question 
in the transfusion medicine field. As introduced in Part 1, several clinical studies tend to 
correlate “old blood” transfusion with recipients adverse outcomes. But what is an “old blood”? 
Can we really define precise storage duration after which, despite suitable transfusion 
prognostics (storage hemolysis and in vivo 24-hour recovery), a blood product would be 
undoubtedly harmful for its recipient? In fact, clinical studies cannot delimit such single storage 
duration. There are several obvious reasons for that. First, an EC is not a globally defined blood 
product. Depending on where you live, the production way of this therapeutic product will 
change. From the blood collection to the delivery of an EC unit, many parameters make it 
different depending on countries. If one of these parameters should be highlighted, it would be 
the additive solution used to preserve RBCs during their non-physiological cold storage. 
Formulations of diverse AS used worldwide seem similar in term of components, but some 
subtle changes appear to significantly impact the storage of RBCs, as discussed in Part 1. The 
energy metabolism is a key point for RBCs maintenance, bringing the required energy for 
diverse cellular processes. It is currently being investigated during ECs storage by several groups, 
and it appeared to be differentially impacted, depending on the AS. It thus seems difficult to 
attribute clinical adverse outcomes to a given storage duration, while in fact all products of this 
age are not identical. Another reason making difficult the establishment of a storage limit for a 
guaranteed successful transfusion procedure is the health status of recipients. Will a same 
product similarly affect patients suffering from different unhealthy conditions? Deeping further, 
will a same product similarly affect two patients presenting the same hematologic disorder, if 
one of them is young and the other old? What if one is a man and the other a woman? Most 
clinical investigations regarding age of ECs focused on a particular situation, for instance 
patients from a given type of surgery, and individual characteristics are being taken into account 
too. But until now, it seems to be a very difficult task to undoubtedly associate blood storage 
duration to transfusion-related adverse issues.  
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Increasing ECs storage duration brings its batch of lesions to RBCs. If clinical studies tend to find 
a storage limit before which these lesions will not be hazardous for the transfusion recipients, 
issues regarding blood supply have to be considered. In the other side of the recipients, 
scientists are assessing storage lesions in order to bring comprehensive data on potential post-
transfusion complications. Moreover, new ways to store blood products, avoiding the 
occurrence of these lesions are being developed and are under investigation. New additive 
solutions, pre-transfusion procedures and special storage conditions are being investigated, and 
gave interesting results. In particular, oxygen-depleted storage environment and addition of 
antioxidants to additive solutions seem promising. Efforts should be put on such strategies, not 
necessarily aiming at prolonging storage durations based on RBCs stability during storage and 
after transfusion, but to understand what happens in stored ECs, to try preventing or correcting 
lesions, maybe to find new markers of RBCs quality, and most certainly to supply physicians and 
more importantly patients, with blood products of the highest quality.  
In this sense, my PhD thesis gave access to new comprehensive data regarding the oxidative 
character of the RBCs storage. Targeted cellular processes were highlighted, opening 
investigation routes towards further developments of RBCs storage conditions. Additionally to 
improving global knowledge in the domain of transfusion medicine and the research on RBCs 
storage lesions, my work will be at the basis of further investigations that our research team will 
conduct. The present established data concerning currently used storage conditions will serve 
as reference for ongoing studies in our institution. In particular, oxidation-related data will be of 
high importance regarding our current experiments on oxygen-depleted RBCs storage and 
investigations of global metabolism, as well as for upcoming studies on additive antioxidants. 
Moreover, the biochemical and proteomic methods developed will be useful in the scope of 
another PhD thesis assessing the oxidative effects of pathogen reduction technologies on 
platelet concentrates. 
Short-term perspective will focus on the characterization of RBCs membrane proteins 
presenting storage-induced oxidation of cysteines. In particular, it would be interesting to 
correlate membrane-bound oxidized proteins such as Hb, enzymes from the energy 
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metabolism, or cytoskeleton components with the proposed oxidative pathway model. This 
work is part of a global strategy to improve RBCs storage, where the next steps will be based on 
this research.  
 
  
 Part 5 - Conclusion and perspectives 
173 
References 
 
1. Hess, J.R., Red cell changes during storage. Transfus Apher Sci, 2010. 43(1): p. 51-9. 
2. D'Alessandro, A., et al., An update on red blood cell storage lesions, as gleaned through 
biochemistry and omics technologies. Transfusion, 2014. 
3. Roback, J.D., et al., Metabolomics of ADSOL (AS-1) red blood cell storage. Transfus 
Med Rev, 2014. 28(2): p. 41-55. 
4. Yoshida, T., et al., The effects of additive solution pH and metabolic rejuvenation on 
anaerobic storage of red cells. Transfusion, 2008. 48(10): p. 2096-105. 
5. D'Alessandro, A., et al., Time-course investigation of SAGM-stored leukocyte-filtered red 
bood cell concentrates: from metabolism to proteomics. Haematologica, 2012. 97(1): p. 
107-15. 
6. Dumaswala, U.J., et al., Protein and lipid oxidation of banked human erythrocytes: role 
of glutathione. Free Radic Biol Med, 1999. 27(9-10): p. 1041-9. 
7. Kriebardis, A.G., et al., Membrane protein carbonylation in non-leukodepleted CPDA-
preserved red blood cells. Blood Cells Mol Dis, 2006. 36(2): p. 279-82. 
8. Kriebardis, A.G., et al., Progressive oxidation of cytoskeletal proteins and accumulation 
of denatured hemoglobin in stored red cells. J Cell Mol Med, 2007. 11(1): p. 148-55. 
9. Berezina, T.L., et al., Influence of storage on red blood cell rheological properties. J 
Surg Res, 2002. 102(1): p. 6-12. 
10. Frank, S.M., et al., Decreased erythrocyte deformability after transfusion and the effects 
of erythrocyte storage duration. Anesth Analg, 2013. 116(5): p. 975-81. 
11. Hovav, T., et al., Alteration of red cell aggregability and shape during blood storage. 
Transfusion, 1999. 39(3): p. 277-81. 
12. van de Watering, L.M., Age of blood: does older blood yield poorer outcomes? Curr 
Opin Hematol, 2013. 20(6): p. 526-32. 
13. Koch, C.G., et al., Duration of red-cell storage and complications after cardiac surgery. 
N Engl J Med, 2008. 358(12): p. 1229-39. 
14. Ciechanover, A., A. Orian, and A.L. Schwartz, Ubiquitin-mediated proteolysis: 
biological regulation via destruction. Bioessays, 2000. 22(5): p. 442-51. 
15. Pacifici, R.E., Y. Kono, and K.J. Davies, Hydrophobicity as the signal for selective 
degradation of hydroxyl radical-modified hemoglobin by the multicatalytic proteinase 
complex, proteasome. J Biol Chem, 1993. 268(21): p. 15405-11. 
16. Rubin, O., et al., Microparticles in stored red blood cells: an approach using flow 
cytometry and proteomic tools. Vox Sang, 2008. 95(4): p. 288-97. 
17. Waugh, S.M. and P.S. Low, Hemichrome binding to band 3: nucleation of Heinz bodies 
on the erythrocyte membrane. Biochemistry, 1985. 24(1): p. 34-9. 
18. Kay, M.M., et al., Senescent cell antigen is immunologically related to band 3. Proc Natl 
Acad Sci U S A, 1983. 80(6): p. 1631-5. 
19. Hornig, R. and H.U. Lutz, Band 3 protein clustering on human erythrocytes promotes 
binding of naturally occurring anti-band 3 and anti-spectrin antibodies. Exp Gerontol, 
2000. 35(8): p. 1025-44. 
20. Lutz, H.U. and G. Stringaro-Wipf, Senescent red cell-bound IgG is attached to band 3 
protein. Biomed Biochim Acta, 1983. 42(11-12): p. S117-21. 
 Part 5 – Conclusion and perspectives 
174 
 
 
 
 Annex A 
175 
ANNEX A – Details on ECs used for experiments 
 
EC reference Donor sexe Donor age Blood group Study  
EC1 Female 31 A+ 1, 3, 4, 5 
EC2 Male 72 O+ 1, 3, 4, 5 
EC3 Female 20 O+ 1, 3, 4, 5 
EC4 Female 61 A+ 1, 3 
EC5 Male 55 A- 1, 3 
EC6 Female 64 A+ 2 
EC7 Male 59 B+ 2 
EC8 Female 19 A+ 2 
EC9 Female 21 O+ 6 
EC10 Female 25 B+ 6 
EC11 Female 19 O+ 6 
EC12 Female 21 A+ 6 
EC13 Male 44 A+ 6 
EC14 Female 53 O+ 6 
 
Table 1. Donor details of erythrocyte concentrates used for the study of cysteine oxidation. Study 1 stands for the detection 
of cysteine oxidation (PART 2, chapter one), study 2 for the quantitation of protein carbonylation (PART 2, chapter two), 
study 3 for the identification of proteins presenting modifications of cysteine oxidation during the storage (PART 3, chapter 
one), study 4 for the identification of carbonylated proteins along the storage period (PART 3, chapter two), study 5 for the 
characterization of P20S activity during storage and its behavior in oxidative conditions and study 6 for the determination of 
loss of carbonylated proteins in microvesicles. 
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ANNEX B – Characterization of protein extracts 
Material and methods 
Protein extracts were analyzed by SDS-PAGE. 15 μg of proteins of each extract and 3 μL 
of BenchMark Protein Ladder were loaded on precast Mini-PROTEAN TGX gels, 4-15 % (BIO-
RAD, USA). Proteins were stained with Coomassie Brilliant Blue R250 and gel was destained so 
as to obtain the optimum contrast. Extracts were prepared as described in Part 1 Chapter 2, 
from erythrocytes stored for 8 days post-collection. Moreover, membrane proteins were 
extracted under different conditions. A 1.5 mL-tube containing washed membranes was split in 
2, and centrifuged at 18000 g for 30 minutes at 4 °C. From the first half, the total membrane 
extract was obtained by solubilizing the membrane proteins with DC buffer. The second pellet 
was resuspended in DDM buffer and centrifuged as before. The supernatant (DDM membrane 
extract) was stored at 4 °C and the pellet was washed three times with DDM buffer (only the 
first wash was kept for SDS-PAGE analysis). Then, the pellet was solubilized in DC buffer. After a 
final centrifugation, the supernatant (DC membrane extract) was stored at 4 °C for further 
analyses. 
Membrane protein identification was achieved on a liquid chromatography-mass spectrometer 
apparatus (Agilent 1100 series LC/MSD trap) from Agilent Technologies (Santa Clara, CA, USA) 
after membrane protein separation on SDS-PAGE. This identification was performed to ensure 
that the two different membrane extracts obtained correspond, as thought, to the integral and 
the peripheral (cytoskeleton) membrane fractions. As for the two soluble fractions, SDS-PAGE 
separation was sufficient to characterize the depletion of one major protein (i.e. Hb). 
RBC soluble fractions 
Proteins from RBCs were fractionated in different extracts, which allowed the analysis of 
protein carbonylation within different compartments. Figure 39 shows the protein content of 
each sample extract (lanes 1 to 5). As already reported, the Hb-depletion clearly exhibits the 
gain in dynamic range [1]. The depletion removed 95 % of the Hb from the cytoplasmic extract 
(data not shown) and Hb fraction contains a dim quantity of other proteins. Hence, the 
carbonylation analyses will focus on soluble Hb and on Hb-depleted soluble extracts. 
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RBC membrane fractions 
Prior to membrane extractions, it is of importance to note that, after the washing steps, 
membranes from end-storage ECs remained redder than membranes from short-storage ones, 
indicating the presence of more insoluble Hb-based material. 
Lanes 4 and 5 (Figure 39) represent the two membrane protein extracts following the sequential 
extraction with DDM and DC buffers. The lane patterns exhibit a clear difference, which 
indicates various types of proteins solubilized. In order to point out the differences, RBC 
membranes were treated either directly with DC buffer (total membrane fraction) or with DDM 
buffer, followed by three steps of washing with the same buffer and a final extraction with DC 
buffer (see Figure 39, lanes 7 to 10 respectively). As expected, the washes (only the first one was 
shown) have the same pattern as DDM membrane extract, and the differences between DDM 
and DC extracts are highlighted. Five main differences were observed: spectrin region above 
220 kDa, band 3 around 90 kDa, proteins 4.1 and 4.2 below the band 3, and actin and stomatin 
regions at 45 and 33 kDa, respectively (see lanes 8 and 10 in Figure 39 for highlighted 
differences). 
Integral membrane proteins, e.g. band 3, protein 4.2, stomatin, were more abundant in DDM 
membrane extract. Band 3 is a transmembrane protein embedded within the lipid bilayer [2-4], 
protein 4.2 is a peripheral membrane protein connecting band 3 and Rhesus complexes [3, 5], 
and stomatin is found in lipid rafts as shown by Salzer and Prohaska [6]. They have shown that 
stomatin has a low solubility in Triton X-100 buffer because of its association with lipid raft. In 
the present study, stomatin was however extracted with the DDM buffer, a detergent similar to 
Triton X-100. This is explained by the presence of aminocaproic acid in the DDM buffer, which 
has been reported to allow the extraction of membrane-embedded complexes at high salt 
concentrations [7]. On the other hand, Crepaldi Domingues et al. have shown that stomatin is 
recovered in both soluble and insoluble fractions after Triton X-100 extraction [8]. Various 
parameters may influence the membrane protein extraction, such as the detergent-to-protein 
ratio or the existence of microdomains [8]. 
As for DC membrane extract, obtained with an ionic detergent, it contained proteins stemming 
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from the peripheral membrane cytoskeleton, such as α- and β-spectrin, protein 4.1 and actin. In 
particular, protein 4.1 is implied in the junctional or 4.1R complex [9, 10]. Unlike protein 4.2, 
protein 4.1 interacts directly with the cytoskeleton [9]. 
Hence, this sequential membrane protein extraction enables the partial separation of 
membrane proteins and cytoskeleton, beyond the cytosol/membrane sample fractionation. 
 
Figure 39 SDS-PAGE of RBC subcellular fractionation. SDS-PAGE of the different sample extracts. 15 μg of proteins were 
loaded on each lane. Left side of the MW marker: typical sample extracts used for quantitation of protein carbonylation. The 
depletion of Hb (lanes 1 to 3) and the sequential solubilization of membrane proteins (lanes 4 and 5) allowed the 
fractionation of RBC protein samples and the analysis of proteins of lower abundance. Right side of the MW marker: 
characterization of membrane extracts. The first extraction with DDM (lane 8), a non-ionic detergent, mainly extracted the 
membrane proteins whereas the last extraction with DC (lane 10), an ionic detergent, mainly extracted the cytoskeleton 
proteins. Arrows on the right point out the main differences characterizing these two extracts (see text for details). 
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ANNEX C – Depletion of oxidized hemoglobin  
 
A sample of RBCs was taken from an EC stored for one day. Cells were washed with 0.9 % NaCl 
then lysed by hypotonic shock (incubation with 2 cell volumes of 0.1 X PBS under agitation at 4 
°C during 1 hour). Membranes were pelleted and the soluble protein extract was recovered 
from the supernatant. One mL of soluble extract was loaded in the chromatographic system for 
Hb depletion, and the UV signal for protein detection was monitored and is shown in Figure 1.  
 
Figure 40. Run of hemoglobin depletion from a RBC soluble protein extract. The first peak before the beginning of the elution 
gradient is the flow through, corresponding to unbound proteins (all proteins except hemoglobin). The second peak is eluted 
with buffer B, and corresponds to the hemoglobin fraction. 
 
The eluate consisting of the Hb was collected as a single fraction. The Hb fraction was splited in 
two. One half was conserved as is, and the other half was submitted to chemical oxidation by 
incubation with one volume of 2X oxidation solution (50 mM HEPES pH 7.2, 50 mM ascorbic 
acid, 200 μM FeCl3) under agitation during 5 h at 37 °C and in the dark. Oxidized Hb was then 
dialyzed overnight at 4 °C against a solution of 50 mM HEPES pH 7.2 buffer containing 1mM 
EDTA. Hb preparations were both submitted to Hb-depletion. 
Untreated Hb sample is entirely retained in the IMAC column, as shown in Figure 2. UV signal 
only detect proteins in the eluate. As for the over-oxidized Hb sample, the majority of the 
sample went through the depletion column, and high protein content was detected in the flow 
through, as shown in Figure 3. A little part of proteins was however retained by the solid phase, 
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indicating an incomplete oxidation of the sample. Surprisingly, the flow through containing 
nearly all hemoglobin was colorless, whereas the eluate, which contained few proteins, was 
reddish. The red color of hemoglobin is due to the iron oxidation occurring through oxygen 
binding. The hard oxidative conditions to which was submitted the Hb sample may certainly 
alter the heme core of Hb, originating the loss of coloration. Moreover, the binding site of Hb to 
nickel (His-2 residue of the β globin chains, see reference [1]) is probably altered too, so that 
highly oxidized Hb does not bind the IMAC column anymore. 
 
Figure 41. Run of hemoglobin depletion from the untreated Hb fraction. All proteins are detected in the eluate. 
 
Figure 42. Run of hemoglobin depletion from the oxidized Hb fraction. The majority of proteins are detected in the flow 
through and a small part in the eluate. 
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